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Abstract 
For many centuries, malaria has remained the most common parasitic disease in sub-
Saharan Africa potentially placing 32 million pregnancies at risk each year. Malaria in pregnancy 
(MiP) in malaria endemic Africa is mostly asymptomatic or paucisymptomatic, yet associated 
with maternal anaemia and intra-uterine growth retardation resulting in low birth weight (LBW) 
which is an important risk factor for infant mortality (chapter 1).  
In Mali, several observational studies have determined the risk and consequences of 
malaria in pregnancy. However, national estimates of the burden of MiP and its potential impact 
are lacking. This thesis describes the results of a series of surveys conducted in different malaria 
transmission settings countrywide from 2005 to 2010, to quantify the burden and consequences 
of MiP in Mali (chapter 2). Results demonstrate that the risk of malaria infection at delivery was 
generally high ([average prevalence 11.6%]) and showed marked diversity between regions and 
transmission settings. Coverage of intermittent preventive treatment (IPTp) with sulfadoxine-
pyrimethamine (SP) and impregnated treated bednets (ITNs) was low (30.4% and 60.7%) and 
indicated important miss opportunities for the control of PAM. 
To prevent the disease and its consequences in pregnancy, the World Health 
Organization recommends IPTp using SP and use of an ITN. For IPTp, the recommended regimen 
consists of at least 2 doses of SP given during the second and third trimesters for HIV negative 
women and at least 3 doses for HIV-positive women not receiving cotrimoxazole. However, 
there are concerns that the 2-dose regimen, which provides at most 12 weeks of prophylaxis, 
leaves many women unprotected for as much as half of the 20-26 pregnancy weeks after 
quickening. Re-infection with the 2-dose regimen is common, especially during the transmission 
seasons and amongst women who complete their last dose early in the third trimester. A trial 
was therefore conducted to compare the standard 2-dose regimen versus 3 doses using SP, 
hypothesizing that the third dose may add significant benefit over the 2-dose regimen in 
preventing placental malaria and other birth outcomes (chapter 3). The study concluded that 
IPTp-SP with 3-doses was superior to the standard 2-dose regimen and resulted in better birth 
outcomes.  
 The results of this trial were then combined with 6 similar trials as part of a meta-
analysis assessing if 3 or more doses of IPTp-SP are more effective than the current standard 2-
dose regimen. The pooled results suggested a marked benefit of adding extra SP doses over the 
standard 2-dose regimen in both regions of high and low SP resistance as measured by the 
prevalence of dihydropteroate synthase K540E mutations (chapter 4). 
 Although studies from western Africa favour the use of IPTp-SP, SP resistance is now a 
serious threat to the longevity of IPTp with SP in parts of eastern and southern Africa where the 
quintuple dihydofolate reductase (N51I, C59L, S108N) /dhps (A437G, K540E) mutation is 
saturated in many places. In order to get a better understanding of the impact of SP resistance 
on IPTp effectiveness, this thesis also determined the in vivo response of parasites in 
asymptomatic parasitaemic pregnant women who received IPTp-SP and the effectiveness of 
IPTp-SP on birth parameters in West-Africa (chapter 5 & 6) Overall, the study concluded that SP 
resistance in Mali and Burkina Faso is low and that the IPT-SP is associated with clinically 
relevant improvements in birth outcomes in Mali. 
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Chapter 1 
 
2 
 
1. Chapter 1: General introduction 
1.1 Epidemiology and burden of malaria during pregnancy 
A long time before the discovery of the malaria parasite in 1880 by Alphonse Laveran 
(Bockarie et al., 1999), pregnant women have been burdened by malaria. However, the 
association between the two conditions was described only since the early 20th century 
(Desai et al., 2007). In the first quarter of the 21st century, malaria continues to place 
approximately 125 million pregnant women at risk each year who live in malaria endemic 
areas, of whom 32 million live in sub-Saharan Africa (Dellicour et al., 2010).  Five 
parasites species (Plasmodium falciparum, P. malariae, P. vivax, P. ovale , and P. 
knowlesi) were described to infect humans (White, 2008). However, recently infection 
with Plasmodium cynomolgi has been also found in a female patient of 39 year old from 
east coast of Peninsular Malaysia (Ta et al., 2014). Except P. vivax and P. falciparum 
which are the most commonly implicated in the occurrence of adverse pregnancy 
outcomes (Dellicour et al., 2010), the harmful effect of the other four species in 
pregnancy are not known. The burden is greatest with the latter which is unfortunately 
the most prevalent in sub-Saharan Africa (Dellicour et al., 2010). It is estimated to 
account for 25% of placental infections at the time of delivery, 26% of cases of severe 
anaemia and a 20% incidence of low birth weight (LBW) in stable transmission areas of 
Africa (Desai et al., 2007).  
1.1.1 Vulnerability of pregnant women  
The risk and consequences of the disease in pregnant women relies on a myriad of 
factors. The vulnerability of pregnant women to disease is due to their immunity 
impairment compared to non-pregnant adult women. Thus, women become more 
susceptible to malaria infection during pregnancy with a higher risk of disease and death 
in both the mother and her foetus. 
A study conducted in the Democratic Republic of Congo found more infection among 
pregnant women than non-pregnant women of child bearing age  with 37.2% and 30.4%, 
respectively (Taylor et al., 2011b).  
Compared to their counterpart non-pregnant women, pregnant women are more 
attractive to mosquitoes (Lindsay et al., 2000, Ansell et al., 2002). In the Gambian 
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population, Lindsay and colleagues demonstrated that pregnant women were more 
attractive to An. gambiae mosquitoes than their counterpart non-pregnant women 
under an untreated bednet. The same study showed that the number of mosquitoes 
entering bednets each night was 1.7-4.5 times higher in the pregnant group (p = 0.02), 
and that pregnant women also received a higher proportion of bites under the bednets 
than did non-pregnant women (70% vs 52%, p = 0.001). The authors suggested that 
physiological and behavioural changes occurring during pregnancy could be partially 
responsible. Thus, this study clearly demonstrates that pregnant women are more 
exposed to malaria parasites than other women.  
This vulnerability of malaria in pregnancy is also more important among women in their 
first and second pregnancies who have not yet developed adequate pregnancy-specific 
immune responses against the subpopulation of parasites that sequester the placenta 
(Fried and Duffy, 1998). Thus, they are more prone to the deleterious effects of malaria 
than age-matched multigravid women after exposure during previous pregnancies and 
are partially protected against the deleterious effects of these parasite strains that can 
sequester in the placenta. However this gravidity dependence depends on the level of 
acquired immunity obtained after repeated infections and thus level of malaria 
transmission.  
1.1.2 Clinical implications in high or stable transmission settings  
Though the vast majority of pregnant women infected are asymptomatic (Desai et al., 
2007), malaria can result in LBW and maternal anaemia (Guyatt and Snow, 2004), all of 
which act individually or in concert with each other to increase maternal, neonatal and 
infant mortality (Katz et al., 2013).  
1.1.2.1 Anaemia 
Compared to non-pregnant women, anaemia is more common in pregnant women for 
several reasons including the diluting effects of the increased intravascular volume 
during the second trimester, as well as the increased demand on iron and folate stores 
(Ayoya et al., 2006). Among the other important risk factors in sub-Saharan Africa that 
include HIV infection, inadequate nutrition, heamoglobinopathies and hookworm 
infestation, the contribution by malaria is substantial. Of the 5-10% of pregnant women 
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who suffer from maternal severe anaemia, malaria is believed to be the main cause in 
26% (Desai et al., 2007, Rogerson et al., 2007b). Maternal severe anaemia increases the 
mother’s risk of death especially at the time of delivery. It is estimated that in 
holoendemic malarious areas where 5% of pregnant women have haemoglobin levels <7 
g/dL, there will be 9 maternal deaths related to severe malaria anaemia per 100 000 live 
births to primigravida (Brabin et al., 2001). 
1.1.2.2 LBW 
Low birth weight (LBW) is one of the main determinants of perinatal and infant mortality 
(Katz et al., 2013, Marchant et al., 2012, Slyker et al., 2014) and has strong association 
with childhood growth, cognition, and disability (Huang et al., 2007, Guyatt and Snow, 
2004). Although LBW is multifactorial (Huang et al., 2007), the contribution of malaria as 
a cause of preterm delivery and intrauterine growth retardation is remarkable in high 
malaria endemic areas of Africa (Rogerson et al., 2007b, Guyatt and Snow, 2004). The risk 
of LBW is doubled in women with placental malaria compared to those without. This is 
more pronounced in primigravida than multigravida (Desai et al., 2007). In sub-Saharan 
Africa, 1 in 5 LBW deliveries are attributable to malaria, corresponding to 35% of 
preventable LBW deliveries in women of all gravida (Taylor et al., 2011b). In the 
Democratic Republic of Congo, among 880,415 first and second pregnancies, the number 
of births with LBW was estimated to be 169,704 annually of which 49,214 (29.0%) were 
preventable if universal coverage with intermittent preventive treatment in pregnancy 
(IPTp) and insecticide treated nets (ITN) could be achieved (Taylor et al., 2011b).  
The impact of malaria induced LBW on newborns and infants’ health is particularly 
alarming. From different reports, it contributes every year to 11.4% of neonatal deaths 
and 17 infants’ deaths per 1,000 live births in Africa (Desai et al., 2007). LBW contributes 
to at least 13% of all infant deaths each year and the overall perinatal mortality endorsed 
by malaria was reported to be 25-80/1,000 per year (van Geertruyden et al., 2004). 
Other authors reported that infant mortality is three times higher for LBW babies than 
for those of normal weight, and that neonatal mortality is nine times more with LBW 
babies than those of normal weight (Guyatt and Snow, 2004). In East Africa, more recent 
reports suggested more impact of LBW on neonatal mortality (Katz et al., 2013, Marchant 
et al., 2012). Some reports indicated that LBW is a predictor for poor neurosensory, 
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cognitive, behavioural development, school performance and academic achievement 
(Agarwal and Lim, 2003, Corbett and Drewett, 2004).  
1.1.3 Clinical implications in low, unstable endemic settings  
In these settings, women have little exposure to malaria infections and thus relatively 
little acquired adult and pregnancy-specific immunity and all ranks of pregnant women 
are therefore at risk. P. falciparum infections are more likely to result in symptoms 
including fever, headache, vomiting, abdominal and joint pains which, if not treated can 
progress rapidly to severe malaria leading to death of the mother or foetus (Desai et al., 
2007). Although the prevalence of malaria is low in these settings, the overall maternal 
deaths attributable to malaria are roughly similar to that reported for high transmission 
areas. Outside Africa, this was reported to be 0.6-12.5% and 0.5-23.0% in low and high 
transmission settings, respectively. In these settings, infection with Plasmodium vivax is 
also an important risk factor for maternal anaemia and LBW (Desai et al., 2007). 
The prevalence of low birth weight was reported to be 9.3% and 16% in low 
endemic areas of sub-Saharan Africa and outside Africa, respectively (Desai et al., 2007). 
Compared to stable transmission, the prevalence of premature delivery is more 
important and was found to be the leading cause of LBW. Though placental malaria 
infection is not a first line burden in these settings, it was associated with LBW, stillbirth, 
and preterm delivery in the few existing studies in Asia (Rijken et al., 2012) and sub-
Saharan Africa (Desai et al., 2007). 
1.1.4 Effect of malaria on infant outcomes 
As in the mother, malaria impacts seriously on her offspring at different stages of its 
growth. The importance of this deleterious effect relies also on the transmission 
intensity, gravidity of the mother and other factors such as HIV and malnutrition (Desai 
et al., 2007, Rogerson et al., 2007b). In low endemic areas where pregnant women are 
less immune against malaria, acute malaria (fever, vomiting, nausea, headache, 
abdominal pain) is associated with preterm delivery and abortion and stillbirth (Nosten et 
al., 2004). Maternal malaria in high endemic area is predominantly indirectly associated 
with infant mortality through a reduction in birth weight through intrauterine growth 
retardation and with neonatal mortality through prematurity (Steketee et al., 2001, 
Guyatt and Snow, 2004). In nine studies conducted in sub-Saharan Africa, regardless of 
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gravidity, placental malaria doubled the risk of stillbirths (van Geertruyden et al., 2004). 
Clinical trials with IPTp-SP and ITNs have also shown that successful malaria control can 
substantially curtail foetal loss (abortions and stillbirths) by as much as 33% and perinatal 
mortality by 27% (Gamble et al., 2007, Garner and Gulmezoglu, 2006). Thus, the 
contribution of malaria to perinatal death is considerable in sub-Saharan Africa, even 
though the vast majority of maternal infections in these endemic areas remain 
asymptomatic or pauci-symptomatic.  
Malaria exposure in utero may also result in modulation of the immune responses 
immune sensitisation of the developing fetus (Malhotra et al., 2009). Several studies 
have shown that the risk of anaemia and malaria in childhood was greater among infants 
born from mothers with infected placentas in Kenya (Malhotra et al., 2009), Cameroon 
(Le Hesran et al., 1997), Tanzania (Mutabingwa et al., 2005) and in Gabon (Schwarz et al., 
2008).  
Compared to non-malarious areas, foetal anaemia is more common in malaria 
endemic areas suggesting that malaria can be an important contributing factor (Brabin et 
al., 2004a, Rogawski et al., 2012, Brabin, 1992).  
In high endemic areas, a high prevalence of foetal anaemia was observed with an 
increased risk of high parasite density at delivery and placental malaria based histology 
(Brabin et al., 2004b). Another contributing factor was birth during the rainy season 
(Brabin et al., 2004a). 
Malaria may contribute to 8-14% of LBW (Steketee et al., 2001), and it has been 
hypothesized that malaria in pregnancy indirectly may have long term implications 
through poor neurosensory, cognitive, and behavioural development, as well as 
potentially poorer school performance and academic achievement (Guyatt and Snow, 
2004).  
1.2 Pathophysiology of malaria in pregnancy 
The mechanism of LBW and malaria is complex, with intrauterine growth retardation 
(IUGR) and preterm delivery (PTD) as the main pathophysiological pathways. Acute 
infection and high parasitaemia are associated with PTD whereas chronic placental 
inflammatory infiltrates are especially associated with IUGR (Foetal growth retardation) 
(Rogerson et al., 2007b). In foetal growth retardation (FGR) there is an increase in 
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inflammatory cytokines such as TNF and IL-8 whilst in PTD a reduction of these cytokines 
may occur (Rogerson et al., 2007b, Melville and Moss, 2013). Different authors reported 
that chronic parasite infection in the placental blood and the associated cellular immune 
response may result in consumption of glucose and oxygen that would have gone to the 
foetus; and that some infected placentas have evidence of thickening of the 
cytotrophoblastic membranes, which may interfere with nutrient transport (Guyatt and 
Snow, 2004). Erythrocytes infected with P. falciparum congregate in the maternal 
placental vascular space, where parasites replicate. Malaria infected placentas are 
frequently observed to carry antibodies, cytokines, and macrophages which are 
indicative of an active immune response. This immune response may stimulate early 
labour, though the precise effect of malaria-parasitized placentas on prematurity is not 
clear (Guyatt and Snow, 2004).  
Malaria during pregnancy relies mainly on the infection of placenta by P. 
falciparum which can sequester in the placenta. During P. falciparum infection, 
sequestration of infected erythrocytes (IEs) to endothelial cells in the brain or other 
organs is mediated by receptors such as CD36 and ICAM-1. However in the placenta, IEs 
sequestration occurs through adhesion to chondroitin sulphate A (CSA) and, to a lesser 
extent, to hyaluronic acid (HA), both of which are expressed by syncytiotrophoblast cells 
that line the placental intervillous spaces. CSA binding IE, unlike other IE, adsorb IgM, 
which may also promote sequestration (Brabin et al., 2004b, Rogerson et al., 2007b). As 
women have little or no immunological exposure to these parasites subpopulations prior 
to their first pregnancy, this makes primigravida women particularly vulnerable to the 
placental infection and its adverse consequences (Fried and Duffy, 1998). Specific 
immunity conferring protection against these parasite subpopulations in subsequent 
pregnancies occurs through the development of anti-adhesion antibodies and / or 
variant-specific agglutinations antibodies (Fried and Duffy, 1998, Scherf et al., 2001). 
Plasmodium falciparum erythrocyte membrane protein and CSA: implication in the 
immunity of malaria during pregnancy  
The immunological basis of this gravidity dependence consists of the unique ability of P. 
falciparum to insert proteins, functioning as adhesins, into the membrane of the infected 
erythrocytes (IEs) including those infecting the placenta. These proteins called PfEMP1 
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proteins support P. falciparum parasites to sequester in the host microvasculature, 
thereby avoiding clearance by the spleen system (Tembo and Montgomery, 2010, Fried 
and Duffy, 1996).  
In pregnant women where a distinct subpopulation of P. falciparum parasites is 
sequestered in the placenta, the VAR2CSA protein, which is a member of the PfEMP1 
family and present in the intervillous space of the placental syncytiotrophoblast, has 
been implicated to be responsible for the binding of IEs to the placental tissue (Fried and 
Duffy, 1998). Acquired protective immunity to placental malaria is developed over 
successive pregnancies and is correlated with the buildup of anti-VAR2CSA antibodies 
capable of blocking the VAR2CSA-chondroitin sulfate A interaction. Studies demonstrated 
that primigravida at the beginning of their first pregnancy do not yet possess these 
protective antibodies that inhibit CSA-specific IE adhesion, whereas many multigravida 
who have been exposed to malaria in previous pregnancies have high levels of such 
antibodies (Fried et al., 1998). VAR2CSA has therefore been the focus of the 
development of a vaccine for malaria in pregnancy. Available evidence indicates that a 
vaccine based on VAR2CSA that can inhibit IE adhesion to CSA in the placental intervillous 
space and opsonize VAR2CSA-positive IEs for phagocytosis would markedly reduce 
mortality and morbidity from malaria in pregnancy (Hviid, 2011).  
1.3 Diagnosis of malaria during pregnancy 
As malaria is a devastating disease during pregnancy, its diagnosis is important. Current 
diagnostic tools available for clinical practice are based on clinical symptoms, microscopy 
and rapid diagnostic test (RDTs). Other diagnostic methods based on DNA detection are 
more of research interest. 
In malaria endemic countries, malaria symptoms in pregnant women (fever, headache, 
joint pain, vomiting, abdominal pain, etc) can result from other infectious diseases or 
even pregnancy itself. This renders the diagnosis difficult and can drive to wrong 
therapeutic decision as many women may receive unnecessary antimalarial treatment in 
the absence of infection. In Mali, during the rainy season, in a semi urban area, 60% of 
sick pregnant women with negative blood smear microscopy received unnecessary 
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quinine (Kassoum Kayentao, personal communication). A similar observation was made 
in Mozambique (Bardaji et al., 2008).  
Light microscopy of stained thick or thin blood smear is viewed as the gold standard for 
the diagnosis of malaria in pregnant women for case-management. The sensitivity of this 
method in expert hands is about 10 infected erythrocytes per µl blood. It also allows for 
assessment of parasites species, which is best done on the thin film. Although this 
method is the most widely available because of cost, it requires well trained and 
experienced technicians.  
RDTs are based on the detection of malaria parasite soluble antigens that include 
Plasmodium falciparum histidine-rich protein 2 (HRP2) and plasmodial aldolase and 
plasmodial lactate dehydrogenase (pLDH). The better quality RDTs have the advantage 
over microscopy of being able to reliably detect relatively low-density infections in the 
peripheral blood of pregnant women with similar levels of sensitivity that can be 
achieved with expert microscopy (Kattenberg et al., 2012) . In addition RDTs may be able 
of detecting placental malaria in peripheral blood (Uneke, 2008, Kattenberg et al., 2012). 
However, the widespread use of RTDs is not without its challenges. They tend to be 
expensive ($0.7 to 1 USD per test), have to be stored at room temperature and their 
accuracy varies widely between brands and in untrained hands are subject to high rates 
of false positives, and false negatives results (Faye et al., 2013, Mouatcho and Goldring, 
2013, McMorrow et al., 2011). 
PCR methods are generally considerably more sensitive than microscopy or RDTs 
(Mockenhaupt et al., 2006, Mens et al., 2010, Kattenberg et al., 2011). These methods 
based on parasite DNA detection have the advantage of being able to detect sub 
microscopic malaria infection (‘absence’ of detectable parasites by microscopy). 
However, PCR does not detect all cases in which parasites are identified by microscopy or 
placental histology. This is more frequent with P. vivax than with P. falciparum (Barker et 
al., 1992). Also, although this method can process more than a thousand samples per day 
by a single technician, high volume PCR is an unrealistic alternative for routine malaria 
diagnosis in pregnant women for point of care.The clinical meaning of sub-microscopic 
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infections is not yet clear, with an association detected with adverse birth outcome in 
some but not all studies (Fried et al., 2012).  
The gold standard for malaria diagnosis in the placenta is placental histology. It has 
the advantage over the previous methods of showing signs of active infection (presence 
of infected erythrocytes in the intervillous space), chronic or past infection (malaria 
pigment); or both (Uneke, 2008). The main value is for research, not for point of care 
because of its high cost, requirement for skilled labour, and because the diagnosis is only 
made after delivery, when it is typically too late to have clinical implications.  
1.4 Control of malaria during pregnancy 
To tackle the adverse consequences of malaria during pregnancy, the World Health 
Organization (WHO) recommends a three-pronged approach consisting of intermittent 
preventive therapy (IPTp) with sulfadoxine–pyrimethamine (SP), insecticide treated nets 
(ITNs) for prevention, and case management of malaria and anaemia (WHO/AFRO, 2004). 
The deployment of these interventions relies on many factors including the level of 
malaria transmission, HIV status, and SP-resistance.  
1.4.1 Prevention  
1.4.1.1 Intermittent preventive treatment using SP 
IPTp is defined as the provision of a curative treatment dose of an effective antimalarial 
drug at predefined intervals during pregnancy as an integrated part of routine antenatal 
care. Using SP, IPTp has been introduced as an alternative to weekly CQ 
chemoprophylaxis which had been the mainstay for malaria prevention during pregnancy 
since the 1950s (Briand et al., 2007). The safety and efficacy of this strategy has been 
tested during many randomised controlled and quasi-randomised trials conducted in 
eastern, southern and western Africa (Kayentao et al., 2013, Ter Kuile et al., 2007). Its 
introduction started in East Africa in mid 1990s before reaching West Africa in the early 
2000s (Van Eijk et al., 2011, van Eijk et al., 2013). IPTp during pregnancy provides 
intermittent clearance or suppression of existing asymptomatic infections from the 
placenta (the treatment effect) and because SP is slowly eliminated it may prevent new 
infections from occurring for several weeks by maintenance of suppressive drug levels 
(the post-treatment prophylactic effect) (White, 2005). For malaria endemic areas, WHO 
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recommends that IPTp-SP is given at each scheduled ANC visit, starting as early as 
possible in the second trimester until delivery, provided that the doses are given at least 
one month apart (WHO, 2013).  
In areas where HIV prevalence is more than 10%, three doses were recommended in all 
women; no IPTp-SP is required for HIV infected pregnant women on co-trimoxazole 
prophylaxis for the prevention of opportunistic infections (WHO/AFRO, 2004). The 
effectiveness of this strategy has been challenged by an alarming rate of SP resistance in 
eastern and southern Africa (Naidoo and Roper, 2011) and the low coverage of 2 doses 
(Van Eijk et al., 2011). As previously reported (van Eijk et al., 2008, Peters et al., 2007, 
Ouma et al., 2006), SP is considered safe after quickening. SP can be given together with 
folate at a daily dosage of <1 mg (Mbaye et al., 2006a). 
1.4.1.2  Insecticide treated nets 
In addition to the IPTp strategy, ITN use is also recommended as part of the ANC package 
to be provided during pregnancy. Its benefit on birth outcomes had been proven in 
clinical trials (Gamble et al., 2007). In addition, its use has been associated with a 
reduction in childhood morbidity from malaria (ter Kuile et al., 2003). Thus, this tool used 
throughout pregnancy and the postpartum period has been promoted to combat 
pregnancy associated malaria.  Similar to IPTp-SP, ITN coverage was also found to be 
modest despite the wide deployment of international efforts. A review analysis reported 
coverage between 0.4% (Guinea) and 60.3% (Rwanda) in pregnant women (Van Eijk et 
al., 2011). This coverage for many sub-Saharan African countries has improved with the 
recent support from international donors (van Eijk et al., 2013). 
1.4.1.3 Indoor residual spraying (IRS) 
In addition to ITNs, indoor residual spraying (IRS) has become an increasingly important 
component of vector control of malaria. Both strategies alone or in combination have 
shown to have significant impact on malaria indices (Zhou et al., 2013). IRS is now 
supported by the Global Fund to fight HIV/AIDS, Tuberculosis and Malaria, along with 
other donors and many countries are embarking on this strategy. However, there is a 
concern that IRS can potentially affect the coverage of ITNs in pregnant women because 
of resource competition (Van Eijk et al., 2011). Another concern of this strategy is malaria 
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vector resistance to common insecticides, especially in areas that use similar insecticide 
classes for both IRS and ITNs (Tangena et al., 2013, Protopopoff et al., 2013)  
1.4.2 Case management 
1.4.2.1 Malaria 
For symptomatic malaria in pregnancy, the emphasis is on prompt and effective case 
management of the malaria infection and any concomitant anaemia. This is especially 
important in low transmission areas where women have little acquired immunity, and 
where acute uncomplicated malaria in a pregnant woman can rapidly change to severe 
disease and to death. Because of safety concerns, antimalarial treatments used rely on 
gestational age, the stage of the disease and the Plasmodium species (WHO, 2010). An 
exception is the treatment of severe malaria in pregnancy when the primary objective is 
to save the mother’s life. 
First trimester 
Quinine, chloroquine, clindamycin and proguanil can be used without safety concern at 
recommended doses. For P. falciparum uncomplicated malaria, quinine plus clindamycin 
for 7 days (or quinine monotherapy if clindamycin is not available) is the recommended 
treatment. If this treatment fails, clindamycin plus artesunate for 7 days is indicated. For 
complicated malaria, a parenteral antimalarial should be given to pregnant women in full 
doses without delay. In the first trimester, the risk of hypoglycaemia is lower and the 
uncertainties over the safety of the artemisinin derivates are greater. However, weighing 
these risks against the evidence that artesunate reduces the risk of death from severe 
malaria, both artesunate and quinine can be considered as an option until more evidence 
becomes available (WHO, 2010).  
Second and third trimester 
For the treatment of severe malaria in the 2nd and 3rd trimester, parenteral 
artesunate is preferred over quinine, because quinine is associated with recurrent 
hypoglycaemia. Artemisinin-combination therapy (ACT) can be recommended for 
uncomplicated malaria, and if these are not available, an artesunate plus clindamycin 
given for 7 days or quinine plus clindamycin given for 7 days can be considered as 
alternatives. All ACTs are recommended in the 2nd and 3rd trimester, although by 2009, 
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there was relatively little experience with dihydroartemisinin + piperaquine (DHA+PPQ) 
as first line treatment (WHO, 2010), with the exception of parts of Indonesia where 
DHA+PPQ has been used as drug of choice in the 2nd and 3rd trimester since 2005 
(Poespoprodjo et al., 2011)  
For P. vivax treatment, chloroquine is the drug of choice in areas where the 
parasites are sensitive to the drug. ACT is recommended in areas where P. vivax is 
resistant to chloroquine (Nosten et al., 2007). 
1.4.2.2 Anaemia 
The management of anaemia is part of the routine antenatal clinic package administered 
to pregnant women at booking. This includes iron and folate supplementation. As iron 
deficiency is common in pregnant women, weekly iron supplementation is required 
throughout the pregnancy period. The standard antenatal dose to prevent recurrence of 
anaemia is 30-60 mg of elementary iron –plus 0.4 mg of folic acid daily (WHO, 2013). If a 
woman is diagnosed with anaemia, WHO recommends treatment with 120 mg elemental 
iron daily, given in two separate doses of 60 mg and 0.4 mg folic acid supplementation 
until her haemoglobin concentration rises to normal. Folic acid at a dose of 5 mg is not 
recommended with SP-IPTp (WHO, 2013). 
1.5 Challenges to Intermittent preventive treatment using Sulfadoxine-
pyrimethamine to prevent malaria in pregnancy 
IPTp-SP is the mainstay for malaria prevention in pregnant women in sub- Saharan Africa. 
However, although a very convenient and widely deployed strategy, recently it has faced 
multiple challenges including an alarming increase in SP resistance, especially in eastern 
and southern Africa (Harrington et al., 2011). Other challenges include the modest 
coverage of IPTp 2 and 3 doses of SP (van Eijk et al., 2013).  In addition, there is no 
suitable replacement to SP for IPTp in terms of its costs, tolerance, ease of administration 
and safety profile. 
1.5.1 Resistance to SP and alternative drugs to SP 
1.5.1.1 Resistance to SP 
SP is an antifolate drug that blocks two key enzymes in the folic acid biosynthetic 
pathway. Folic acid is needed for the biosynthesis of purines and pyrimidine and hence 
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DNA synthesis and cell multiplication. Pyrimethamine is a synthetic diaminopyridine that 
binds to and inhibits the bifunctional enzyme dihydrofolate reductase-thymidylate 
synthase of plasmodia. This enzyme interrupts nuclear division which results in 
subsequent death of the cell (Oyibo and Agomo, 2011). Sulfadoxine has a structure 
analogue of p-aminobenzoic acid (PABA). It is a long-acting sulphonamide that 
competitively inhibits dihydropteroate synthase (DHPS), an enzyme that is necessary for 
the conversion of PABA to folic acid. This enzyme is also a component of the folate 
metabolic pathway and is upstream of DHFR (the enzyme that is targeted by 
pyrimethamine).  
Although the fixed combination of pyrimethamine and sulfadoxine offers a two-
step synergistic blockage of plasmodial division, the mechanism which it exerts in IPTp is 
not clearly understood. However, there is a suggestion of a treatment effect by providing 
intermittent clearance or suppression of existing asymptomatic infections, and a 
prophylactic effect by preventing new infections from occurring for several weeks 
because of the maintenance of its suppressive drug levels (Ter Kuile et al., 2007, White, 
2005). The long half-life elimination of the drug contributes to this prophylactic effect. 
The mean elimination half-life of sulfadoxine and pyrimethamine is 169 h (range: 100-
213 h) and 111 h (range: 54-148 h), respectively (Oyibo and Agomo, 2011). This has been 
suggested to vary during pregnancy, but evidence is not in favour of dose adjustment of 
the combined drug (Nyunt, 2009). Such a long half-life elimination of SP is also 
contributing to the risk that parasites resulting from re-infections are exposed to sub-
therapeutic drug concentrations, potentially leading to selection of mutant resistant 
forms (Watkins and Mosobo, 1993). Resistance to sulfadoxine-pyrimethamine occurs 
from mutations at specific codons in the dihydrofolate reductase (dhfr) and 
dihydropteroate synthase (dhps) genes of the parasite. With increasing drug resistance, 
the minimum inhibitory concentration at which parasite growth is inhibited, increases 
and the time window for drug concentrations to fall below these levels shortens. This 
results in a progressive shortening of the duration of the suppressive prophylactic effect 
post-treatment. Parasites with triple dhfr mutations have an approximate 1000-fold 
reduction in susceptibility to pyrimethamine, which translates into a reduction in the 
duration of post-treatment prophylaxis of 1 month, compromising the efficacy of the 2-
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dose regimen, which can have a 3-month interval between doses (Ter Kuile et al., 2007, 
White, 2005). This has been the case in southern and eastern Africa where SP resistance 
is increasing to alarming levels (Naidoo and Roper, 2013) to mar the effectiveness of the 
IPTp strategy (Harrington et al., 2011, Harrington et al., 2009, Naidoo and Roper, 2011). 
However, in the same areas, other reports suggest that IPTp-SP remains efficacious, even 
in areas with high SP resistance (Kayentao et al., 2013, Ter Kuile et al., 2007).In western 
Africa, SP resistance is not yet a major public health problem and trials (Diakite et al., 
2011, Valea et al., 2010) and observational studies (Gies et al., 2009, Sirima et al., 2006, 
Vanga-Bosson et al., 2011) demonstrated good sustenance in improving birth outcomes. 
Good efficacy results in pregnant women and infant were also reported by other authors 
(Coulibaly et al., 2006, Dicko et al., 2010, Tekete et al., 2009). 
This marked variability of SP resistance and the varying impact on birth 
parameters in African regions, appeal for critical monitoring of SP resistance and its 
impact on IPTp effectiveness. Such a monitoring tool is being developed by the Malaria in 
Pregnancy Consortium in collaboration with the World Health Organization.  
1.5.1.2 Alternative drugs to SP for IPTp 
In the meantime, priority research is underway to look for alternative drugs to SP for 
IPTp or alternative strategies to IPTp for the control of malaria in pregnancy. Proposed 
alternatives are discussed below.  
Mefloquine (MQ): 
Mefloquine (MQ) is a potential candidate to replace SP for IPTp because of its long half-
life, possible single dose administration, and efficacy profile against P. falciparum, 
although conflicting results on its safety exist related to risk of stillbirths associated with 
melfoquine in some of the earlier studies in pregnancy (Briand et al., 2007, Nosten et al., 
2007). More recently in Benin, IPTp with MQ showed similar pregnancy outcomes as 
IPTp-SP, while being more effective in reducing placental and clinical malaria, and 
maternal anaemia. However, its tolerability profile has led to reservations for this drug 
for IPTp (Briand et al., 2009, Chico and Chandramohan, 2011b), potentially compromising 
its large scale use. Members of the Malaria in Pregnancy Consortium are conducting a 
large scale study to further explore the efficacy, safety, and tolerability of single and split 
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dose MQ for IPTp (ClinicalTrials.gov identifier NCT00811421). Its combination with 
artesunate (AS) is also being evaluated in several case-management (treatment) studies 
in Africa and Asia (Takem and D'Alessandro, 2013)  
Dihydro-Artemisinin (DHA)-Piperaquine  (PPQ): 
This combination is used for malaria treatment in pregnant women in the western Pacific 
and is now under investigation as treatment option and as IPTp in studies in Africa and 
Asia (NCT00852423, NCT01054248, and MCTO131113). The combination may have an 
important role to play as IPTp thanks to its good tolerability and the long terminal 
elimination half-life of piperaquine (PPQ) (14 days (range of 10 to 18) in children, and 23 
days (range of 19 to 28 days) in adults (Dorsey et al., 2007, Zongo et al., 2007) may 
ensure 4 to 6 weeks post-treatment prophylaxis, while the active rapid antimalarial 
compound of dihydro-artemisinin (DHA) helps to ensure radical cure of any existing 
infections among IPTp recipients. Pharmacokinetic studies with DHA-PPQ in pregnancy 
have also recently been completed and suggests that the same dose can be used in 
pregnant women as in adults (Tarning et al., 2012) Though preliminary findings on the 
cure rates and pharmacokinetics are reassuring, the published data on its safety and 
tolerability in pregnant women remains limited (Davis et al., 2010), although significant 
operational experience exists in Indonesia where DHA-PPQ has been the national first 
line therapy in the 2nd and 3rd trimester since 2010, and in Papua-Indonesia since 2005. 
The combination is under investigation as IPTp in trials in Indonesia and Kenya conducted 
by members of the Malaria in Pregnancy Consortium (ClinicalTRials.gov identifier 
NCT01669941 and NCT01231113).  
Safety of DHA-PPQ: A trial with monthly and 2-monthly IPT with DHA-PPQ conducted in 
non-pregnant Thai adults showed that 9 full 3-day treatment courses with DHA-PPQ has 
a good tolerability, safety, and effectivity profile (Lwin et al., 2012). The study also 
suggested that for effective prevention of malaria, DHA-PPQ should be given monthly in 
order to achieve steady state concentrations above the minimum inhibitory 
concentrations and sustained prophylactic levels (Lwin et al., 2012). 
PPQ is well tolerated. Side effects in adults include transient drops in haemoglobin by day 
7 (seen with all artemisinins), headache, weakness and fever. The main safety concerns 
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with PPQ relate to its dose-dependent QTc prolongation. QTc prolongation has been 
confirmed in clinical trials, but these were mild and similar to many other anti-malarials 
(Mytton et al., 2007), and there is no indication from clinical data signalling that it is 
associated with clinically significant arrhythmias (Keating, 2012). This is consistent with 
recent in vitro models which confirmed that despite mild QTc prolongation the potential 
cardiac proarrhythmic risk with PPQ is low and similar to that observed with lumefantrine 
(the long-acting component in Coartem), and lower than for chloroquine. This study 
concluded that DHA-PPQ does not appear to induce potential torsadogenic effects in 
vitro which could result in life threatening abnormality of heart rhythm (Keating, 2012).  
To minimise QTc prolongation the manufacturer of DHA-PPQ advises patients to take the 
first day’s dose approximately three hours after meals as fatty food can increase the 
absorption of PPQ. However, the trial providing DHA-PPQ every 2 months or monthly did 
not find any relationship between drug levels and whether DHA-PPQ was provided with a 
small amount of fat (200-ml carton of chocolate milk containing 6.4g of fat to be taken 
with each dose) or without (Lwin et al., 2012), There was no difference at any time point 
in PPQ  concentrations between the group that received DHA-PPQ with fat and the group 
that received it without fat (Lwin et al., 2012), consistent with observations by others 
that this amount of fat does not increase exposure to PPQ (Annerberg et al., 2011). More 
recently a detailed study in healthy volunteers showed that much higher concentration 
of fat provided by a full high-fat meal (obtained from McDonalds) containing 54g of fat 
approximately doubles the oral bioavailability of PPQ relative to the fasting state in 
health volunteers. Importantly, this method of PPQ administration did not produce 
significant metabolic or cardiovascular effects, the side effects, postural blood pressure 
changes, electrocardiographic corrected QT interval, serum glucose, and other 
biochemical and haematological indices were similar in the fasting and fed states over 28 
days of follow-up (Sim et al., 2005). 
Thus, overall it appears that DHA-PPQ is well tolerated and can be given with small 
amount of food, although drug levels were also effective when given to fasting patients 
(Mytton et al., 2007). 
 
Chapter 1 
 
18 
 
Safety of DHA-PPQ in pregnancy 
Studies in Indonesia found DHP to be very effective in the treatment of malaria in 
pregnancy (Poespoprodjo, 2010). In 2006, it was made first-line policy for the treatment 
of 2nd and 3rd trimester malaria in southern Papua, and in 2010 this became national 
policy for malaria endemic areas. Between Thailand and Papua, Indonesia, over 1200 
pregnancies exposed to DHP have now been carefully documented and DHP was found 
to be well tolerated and effective. Formal reprotoxicology studies have not raised 
concern (Tarning et al., 2012) 
Azithromycin-chloroquine 
Azithromycin (AZI) is a macrolide antibiotic structurally related to erythromycin that also 
has antimalarial activities. With a good safety profile, this drug has been used extensively 
in pregnant women for the treatment of sexually transmitted infection (STIs) (Gray et al., 
2001) and  also for malaria in pregnancy in combination with SP (as IPTp) or artesunate 
(as treatment) (Kalilani et al., 2007, Luntamo et al., 2010). Its combination as fixed-dose 
with chloroquine (CQ) in pregnant women has the advantage of providing opportunities 
to reduce both malaria and bacterial infections in pregnant women in any trimester 
(Chico and Chandramohan, 2011a). However, if dose adjustment is not needed for AZI, 
CQ dosing needs to be given for three days. AZI-CQ was under investigation for IPTp in a 
multicentre, multi-country, phase III, open-label, randomized trial initiated in 2010 by 
Pfizer Inc. and the Medicines for Malaria Venture (MMV) in Benin, Kenya, Malawi, 
Tanzania and Uganda  (Chandra S Richa, 2013). However, the trial has been stopped 
prematurely.  
1.5.2 Alternative to IPTp strategy: 
Intermittent Screening and Treatment strategy 
Explorations are underway to evaluate a new test-and-treat strategy that consists of 
screening using an RDT and treatment of malaria infection using an effective ACT at 
scheduled antenatal clinic visits (Intermittent Screening and Treatment, IST). This 
strategy has been tested in Ghana (Tagbor et al., 2010) and is now under investigation 
under the auspices of the Malaria in Pregnancy Consortium in four West African 
countries including Mali, Burkina-Faso, Ghana, and the Gambia (ClinicalTrials.gov 
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Identifier: NCT01084213). Based on data reported in the Kumasi study, this strategy can 
be a promising alternative to IPTp with SP, especially for areas with high SP resistance 
such as eastern and southern Africa (Kayentao et al., 2013, Naidoo and Roper, 2011, Ter 
Kuile et al., 2007), and potentially in areas with very low malaria endemicity such as 
Zanzibar (Shakely D, 2013), the Gambia (Ceesay et al., 2012), and northern Mali (Doumbo 
O., 1991). The translation of such a strategy into programmatic conditions in antenatal 
clinics can be complex and its implementation will have significant logistical challenges. 
The success of this strategy as a viable alternative to IPTp-SP relies also on the use of 
RDTs and their sensitivity to detect low-level, chronic placental infections, and their 
costs. Thus, whether this strategy is operationally feasible and will be a cost effective 
alternative to IPT-SP where SP resistance is high, or in areas where malaria is declining 
remains to be determined. 
1.5.3 Low coverage of IPTp-SP  
To promote and protect both the mother and her offspring health, IPT-SP has been the 
mainstay for malaria prevention in pregnant women after the decline of CQ 
chemoprophylaxis. Because of its effectiveness in improving birth parameters (Kayentao 
et al., 2013, Ter Kuile et al., 2007), a global effort is needed to increase its uptake.  
Although IPTp-SP is the most convenient and most widely deployed strategy, its 
coverage was found to be modest in the majority of the sub-Saharan African countries 
(van Eijk et al., 2013). In 2010 Roll Back Malaria (RBM) aimed to insure universal coverage 
for IPTp-SP (RBM, 2008). However, a comprehensive review suggested that by 2010 only 
one country (Zambia) had reached the Abuja target of 2-dose coverage of 60% in 2005, 
despite a very high proportion of women making use of ANCs (median of 90%), which 
constitute an important distribution point of this intervention. Surprisingly, this coverage 
was lower in high intensity malaria transmission where it is most needed (Van Eijk et al., 
2011).  
In Mali, the last demographic health survey (DHS) carried out in 2012-2013 
reported a coverage of 2-dose IPTp of 19.9% (DHS, 2012-2013); it was 4% in 2006 (DHS, 
2006). This improvement is mainly the result of international programme efforts seen in 
Mali and this could be similar in many sub-Saharan African countries. Despite these 
Chapter 1 
 
20 
 
efforts, the most recent review of IPTp uptake suggested stagnation or even decrease in 
coverage of IPTp in some countries since the last survey (van Eijk et al., 2013). 
Thus, missed opportunities of IPTp-SP uptake were suggested; and important factors 
include: late ANC attendance, SP stockouts, unclear message on IPTp (timing, drug 
interactions with SP, empty stomach, etc…), lack of training, and nurse 
underachievement (Van Eijk et al., 2011, Webster et al., 2013a). Problems with IPTp have 
been reported at all levels including among health workers, IPT-SP recipients, the 
community environment, and in the government (Hill et al., 2013).  
1.6 HIV and malaria during pregnancy 
In sub-Saharan Africa, malaria and HIV are the most prevalent infections (WHO, 2005) 
which can act individually or in concert with each other to become a significant and 
complex public health interest (Guyatt et al., 2004). It is estimated that 13.5 million of 
the world’s HIV infected women live in sub-Saharan Africa (Desai et al., 2007) where also 
32 million pregnant women are exposed to the risk of malaria (Dellicour et al., 2010). 
Immunological suppression caused by HIV infection reduces the immune response to 
parasitaemia and therefore leads to an increased prevalence of asymptomatic and 
symptomatic attacks of malaria in pregnant women. The overall malaria prevalence in 
pregnancy that could be attributed to HIV is estimated to be 5.5% and 18.8% in areas 
with HIV prevalence of 10% and 40%, respectively (ter Kuile et al., 2004). The two 
diseases act independently to lead to moderate to severe anaemia in pregnancy, 
stillbirth, preterm delivery, low birth weight and foetal growth restriction (ter Kuile et al., 
2004, Muhangi et al., 2007). However, they can also act synergistically as HIV increases 
the degree to which malaria is associated with maternal severe anaemia and LBW by 
increasing malaria parasite densities (Desai et al., 2007). As described, the burden of 
malaria in pregnancy is more prevalent in women in their first or second pregnancy than 
those with multiple pregnancies in malaria stable transmission areas. However, because 
of compromised malaria immunity caused by HIV infection, this gravidity specific pattern 
is suppressed, and the trend of the malaria burden among HIV infected women is similar 
among all gravidae (Desai et al., 2007).  
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Plasmodium falciparum infection stimulates HIV-1 replication through the production of 
cytokines (IL-6 and TNF-alpha) by activated lymphocytes (Oyibo, 2009). It has been 
shown to increase the potential reservoir for HIV in the placenta by increasing the 
number of chemokine receptor 5 (+) macrophages (Tkachuk et al., 2001) . Placental HIV-1 
viral load is increased in women with placental malaria, especially those with high 
parasite densities (Rogerson et al., 2003, Oyibo, 2009).  
The control of malaria in pregnancy changes with HIV infection. IPTp-SP is not 
recommended if women are receiving daily co-trimoxazole, whereas 3-dose IPTp is 
recommended for all pregnant women not receiving co-trimoxazole (WHO/AFRO, 2004). 
1.7 Description of study sites  
Mali is a large landlocked country in West Africa divided in 8 administrative regions with 
a wide range of malaria transmission patterns as described earlier (Doumbo O., 1991). 
The infant mortality is estimated to be 99 per 1000 live births and the under-five 
mortality rate is 176 per 1000 live births (UNICEF, 2011). Malaria accounts for 38.4% of 
clinic visits with 1,633,423 cases and 2,331 fatalities reported in 2009.  
Malaria transmission is highly seasonal, spans usually from June to December with the 
peak in September-October and varies importantly by regions. Transmission patterns in 
Mali were classified ‘a priori’ into 5 strata based on the prevalence of prevalence of 
parasitemia in children aged 2-9 years old (Doumbo O., 1991): 1) in the South and South-
West of the country, malaria transmission is holo-endemic with a peak infection 
prevalence of 70 to 80%and with an annual rainfall total of >1,000 mm and a relatively 
long rainy season lasting ~6 months and an equally long transmission season; 2) the 
savannah areas extending between the North and South have an annual rainfall total of 
~500 to 1000 mm and a season spanning 3-4 months (Maiga et al., 2010). Malaria 
transmission in these areas is meso-to hyperendemic with peak infection prevalence of 
50-70%; 3) the arid Sahelian areas such as in the Timbuktu region in northern Mali have 
little rain (<300 mm per year) and very short seasons (2-3 months). Malaria transmission 
is hypo-endemic or epidemic with a peak infection prevalence not exceeding ~ 5%. 
Nevertheless, even though the annual rainfall is very low in these arid areas, focal 
transmission can be maintained throughout the year near permanent water reservoirs 
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such as ponds and oases (Koita et al., 2012); 4) the bimodal transmission areas: In 
addition to the characteristics for savannah regions, these areas have virtually year-
round transmission due to the combination of seasonal rainfall (from June to October) 
and irrigation projects for the rest of the year (Sogoba et al., 2007, Ceesay et al., 2012); 5) 
lastly, in the urban transmission areas such as Bamako malaria transmission is low with 
peak infection prevalence of ~5-10%.  
Our studies were conducted in 9 study sites which have been stratified a priori 
(Doumbo et al, 1991) into high (Bougouni, Kita, and Fana), moderate (San, Djenne, Koro, 
Sangha), and low (Bamako, Timbuktu) transmission settings (Figure 2. 1 & Table 2. 1 in 
chapter 2). In addition, the site of Bla in moderate transmission area has served for the 
conduct of the study discussed in chapter 3. 
1.7.1 High malaria transmission areas: 
Bougouni: Located (Latitude 11.41, Longitude -7.48) in the South of Mali, 180 kilometres 
south of Bamako. In Bougouni malaria transmission occurs mainly during the rainy 
season (May-June to October) with the peak in October. The study described in chapter 2 
was conducted from September 2006 to March 2007 in the 3 community health centers 
and the reference health center of the town of Bougouni. This site was identified for the 
pilot implementation of IPTp at community level by “Save the Children” described in 
chapter 6. The population of the urban community of Bougouni was estimated to be 
59,679 in 2009 with 2,984 pregnant women. The number of assisted deliveries recorded 
in the four health structures was estimated to be 1,021 in 2007.  
Kita:  The study described in chapter 2 and 6 was conducted from July 2009 to 
January 2010 in the reference health center and the two community health centers of 
the town of Kita (Latitude 13.05, Longitude -9.48). Located 182 kilometers west of 
Bamako, this site started the IPTp-SP strategy in 2004 with the support of UNICEF. The 
population of the commune of Kita is estimated to be 48,947 in 2009 with 2,448 
pregnant women. In 2009, the number of assisted deliveries was estimated to be 1,358 
in the three health centers where the study took place.  
Fana:  Located (Latitude 12.77, Longitude -6.95) 130 kilometres east of Bamako, 
Fana is a semi urban area where malaria transmission is intense, with similar rainfall as 
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the above sites. The chapter 2 study was conducted from November 2005 to February 
2006 in the reference health centre which had received more than 1,500 ANC visits and 
869 deliveries in 2006. The frequency of the Pfcrt K76T mutants in Plasmodium 
falciparum infections in peripheral blood was 68.8% (11/16) and 100% (16/16) in the 
placenta (p = 0.004). The frequency in peripheral blood of the DHFR N51I mutation was 
12.5% (2/16) and 18.8% (3/16) in the placenta (p=0.12). The frequencies of the DHPS 
A437G mutants were similar in both sites 25% (4/16). No DHPS K540E and DHFR 164L 
mutations were found (Doumbo, 2013). 
1.7.2 Moderate malaria transmission areas: # 
Here the surveys described in chapter 2 and 6 were conducted from September 2006 to 
March 2007 in the health districts of Koro, Djenne, and San.  
Since 2003, the sites of Koro (Latitude 13.94, Longitude -3.02) and Djenne 
(Latitude 13.9, longitude -4.55) were part of a UNICEF funded  pilot implementation 
program of IPTp as part of their project on “Child and Mother hood Survivor Project”. 
Both Koro and Djenne belong to the Mopti region. The town of Djenne becomes an 
island during the rainy season resulting from the annual flood produced by Bani river. In 
2009, the population and number of pregnant women was estimated to be ~62,681 
inhabitants and 3,135 pregnant women in Koro and 32,944 and 1,650 in Djenne, 
respectively. In both sites, malaria transmission lasts from June to October with the peak 
in September.  
The site of San (Latitude 13.3, Longitude -4.9) also benefitted from the support 
from UNICEF’s IPTp pilot program since late 2004. In the town of San, two surveys had 
been conducted, the first from September 2006 to March 2007 and the second from July 
2009 to January 2010. This area has similar characteristics of rainfall and malaria 
transmission pattern as Koro and Djenne. In 2009, the commune of San had 68,078 
inhabitants and 3,404 pregnant women. The number of ANC visits, and assisted 
deliveries in the town of San was 2,019 and 1,042 in 2009. This site belongs to Segou 
region as well as the following site.  
The site of Bla is located (Latitude 12.95, Longitude -5.75) 320 kilometres east of 
Bamako in the Segou region. The district has had the support from UNICEF since 2001, 
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but IPTp implementation only started in 2004. The trial comparing 3 versus 2 doses of SP 
described in chapter 3 was conducted from April 2006 to March 2008 in the two main 
health facilities in Bla (Diakite et al., 2011), which  serve a population of approximately 
39,000 inhabitants.  
Sangha (Latitude 14.66, Longitude-3.31) is a rural commune, 800 kilometers 
north-east of Bamako in the district of Bandiagara, in Mopti region. The commune is 
known as a centre for traditional religion with many temples and shrines, and as a base 
for visitors to the local Dogon villages. The commune of Sangha had a population of 
32,513 inhabitants in 2009 with an estimated 1,626 pregnant women. Malaria 
transmission occurs during the rainy season which lasts from July to October with annual 
rainfall of ~700 mm3. The prevalence of malaria disease in the general population was 
14% in 2008 and entomologic inoculation rate (EIR) measured in Bandiagara was 1.1 
infected bites per person year (Yaro A.S., 2003). IPTp-SP implementation started in 2004 
with the support of UNICEF. The study described in chapter 2 was conducted from June 
2006 to February 2007 in the community health center.  
1.7.3 Low or epidemic malaria transmission areas: 
In Bamako (Latitude 12.65, Longitude -8.00), two surveys were conducted, the first in 
January 2005 in the community health centre of Banconi having 11,084 antenatal visits 
and 3,506 deliveries in 2011, and the second from March to November 2009 in the 
community health centre of Sabalibougou which recorded 3,498 ANC visits and 1,109 
deliveries in 2009. The community health centre covered a population of 72,995 in 2008. 
Although Bamako is characterized by heavy rainfall (more than 1,000 mm per year), 
malaria transmission is low because of its urbanisation (Doumbo O., 1991, Pond, 2013). 
Malaria transmission spans from June to December with a peak in October 
corresponding to the end of the rainy season.  
In the Timbuktu region, data were collected from January to March 2005 in the 
reference health centre of Timbuktu (Latitude 16.77, Longitude -3.00) and Niafunke 
(Latitude 15.93, Longitude -3.99) which is located 200 kilometres west of Timbuktu by 
the left side of the river Niger. Timbuktu is part of the Sahara, with an average 
temperature of 38oC (varying from 25oC to 45oC) in the hot dry season (March, April, and 
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May) and annual rainfall of ~300 mm (Koita et al., 2012). Malaria transmission is thought 
to be very low or epidemic (Doumbo O., 1991, Koita et al., 2012). Infections with P.vivax 
have been reported in this area (Bernabeu et al., 2012). Although Timbuktu is indicated 
to be a semi-arid region (Doumbo O., 1991) as are the other regions in northern Mali, the 
recent arrival of large irrigation projects permitting rice culture during the dry season has 
created a massive body of water formed by rice paddies. This can maintain mosquito 
population abundance after the rainy season to levels needed to sustain malaria 
transmission during the dry season.  
1.8 Thesis objectives  
1.8.1 Overall objective 
The general objective of the thesis was to quantify the burden of malaria in pregnancy 
and uptake of IPTp and ITNs in pregnancy in Mali, to assess the efficacy and safety of two 
versus three or more doses of sufadoxine-pyrimethamine in Africa, and to monitor 
sulfadoxine-pyrimethamine resistance and its potential impact on IPTp-SP effectiveness 
on birth parameters in Mali.  
1.8.2 Specific objectives 
This thesis specifically sets out:  
1. To quantify the burden and consequences of malaria in pregnant women in different 
sites and regions belonging to different malaria transmission entities in Mali (chapter 
2)  
2. To determine the coverage and use of malaria prevention strategies for malaria in 
pregnancy in different sites and regions in Mali (chapter 2)  
3. To compare the 2-dose IPTp regimen versus 3 doses using SP in preventing placental 
malaria and other birth outcomes in Mali (chapter 3)  
4. To determine whether 3 or monthly doses IPTp with SP is more effective for the 
prevention of malaria in pregnancy than the 2-dose regimen in Africa and to assess if 
this is modified by the gravidity, HIV status, or the degree of SP-resistance (chapter 
4) 
5. To determine the efficacy of SP in providing radical cure and preventing new 
infection when provided to asymptomatic parasitaemic pregnant women as part of 
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their first course of IPTp in Mali and Burkina Faso, using a 42-day in vivo follow-up 
(chapter 5) 
6. To describe the level of SP resistance as assessed by molecular markers (chapter 5) 
7. To assess IPTp-SP effectiveness on birth parameters in 5 health districts of Mali and 
determine how this is correlated with molecular levels of SP resistance in those same 
areas (chapter 6) 
1.9 Thesis outlines and chapters 
This thesis consists of seven chapters including 3 published papers (chapters 3, 4, and 
chapter 5). The publications are attached in the annex of this thesis. 
1.9.1 Chapter 1: General introduction on malaria in pregnancy.  
This chapter, as described above provides a background on the epidemiology and burden 
of malaria in pregnancy, a description of study sites where data were collected, and an 
overview of the overall aim and the specific objectives of the thesis.  
1.9.2 Chapter 2: Mapping the risk of malaria during pregnancy in different 
transmission settings in Mali.  
In Mali, several individual observational studies have determined the risk and 
consequences of malaria in individual pregnant women in areas of high (Bouvier et al., 
1997a, Bouvier et al., 1997b) and moderate (Kayentao et al., 2007, Dicko et al., 2003) 
malaria transmission. However, national estimates of the burden of malaria in pregnancy 
and its potential impact are lacking. This chapter describes the results of 11 surveys 
conducted in 9 sites across different malaria transmission settings of the country from 
2005 to 2010. Data generated was used to quantify the burden and consequences of 
malaria in pregnancy by site, region, transmission settings, and at national level through 
extrapolation.  
1.9.3 Chapter 3: Randomised controlled trial of the efficacy and safety of 2 
versus 3 doses of IPTp-SP for the prevention of malaria during 
pregnancy in Mali. 
In Mali where resistance to SP is very low (Dicko et al., 2010, Tekete et al., 2009), surveys 
conducted in 2006-2007 involving 1,696 pregnant women of all parities, showed that 
placental infection was very common among women who had received the full two-dose 
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regimen of IPTp (23%; Kayentao et al, unpublished). This is consistent with the finding 
from an earlier trial showing a significant association between IPTp-SP and the risk of 
placental infections during the transmission season, especially in women who completed 
the second dose of IPTp-SP early in the third trimester (Kayentao et al., 2005). This 
suggested that two doses may provide insufficient protection against reinfections later in 
the third trimester, a period of rapid in utero foetal growth. We therefore conducted a 
trial comparing the 2-dose IPTp regimen versus three doses using SP, hypothesizing that 
the third dose may add significant benefit over the 2-dose regimen in preventing 
placental malaria (primary end point) and other birth outcomes (Diakite et al., 2011).  
1.9.4 Chapter 4: A systematic review and meta-analysis of IPTp using 2 versus 
3 or more doses of SP on low birth weight in Africa 
The results of the above trial (chapter 3) were then pooled with all other similar trials as 
part of a meta-analysis assessing if three or more doses of IPTp-SP are more effective 
than the  2-dose regimen and to examine whether this is moderated by SP resistance, 
HIV status, gravidity or bednet. This meta-analysis was able to identify 6 other clinical 
trials. The pooled results suggested a marked benefit of adding extra SP doses over the 2-
dose regimen in both regions of high and low prevalence of dhps K540E mutations 
(Kayentao et al., 2013). Results gained had guided the World Health Organization to 
revise IPTp-SP policy (WHO, 2013).  
1.9.5 Chapter 5: Parasite clearance following treatment with sulfadoxine-
pyrimethamine for intermittent preventive treatment in Burkina-Faso 
and Mali: 42-day in vivo follow-up study. 
This chapter describes the results of a 42-day in-vivo study to determine the 
parasitological response to a standard single dose of SP when provided as part of the first 
course of IPTp in asymptomatic parasitaemic pregnant women in one site in Burkina Faso 
and two sites in Mali. The study was designed to get a better understanding of the 
efficacy of SP in clearing parasites and the duration of post-treatment prophylaxis to 
prevent new infections. The study also contains a molecular module to determine the 
level of SP resistance among the local parasite populations. Monitoring SP resistance was 
previously mostly based on in-vivo treatment studies in symptomatic children; however, 
extrapolation from children to asymptomatic pregnant women is difficult because 
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pregnant women are immunologically different from children. They remain typically 
asymptomatic when infected and have lower parasites densities than sick children and as 
a result have typically better treatment responses to antimalarials, including SP (Kalanda 
et al., 2006). The chapter concludes that SP is very effective in clearing existing infections 
in Mali and Burkina-Faso. 
1.9.6 Chapter 6: Effectiveness of intermittent preventive therapy for the 
control of malaria in pregnancy in five health districts of Mali 
As in chapter 5, this chapter is also part of the studies aimed at obtaining a better 
understanding of the impact of SP resistance on the effectiveness of IPTp-SP. Chapter 6 
describes the result of observational studies conducted in delivery units and the 
association between the number of doses of SP received by women and clinical 
parameters. IPTp is shown to be strongly associated with reduced risk of low birth weight 
and maternal anaemia. Results generated will be added to the existing database on the 
effectiveness and resistance of IPTp-SP in West–Africa.  
1.9.7 Chapter 7: General discussion and conclusion 
The final chapter is a synthesised discussion of the main findings in chapter 2 to 6. It 
highlights new knowledge gained and provides their implication in the control of malaria 
in pregnancy in Africa. On-going research and future research needs are discussed. 
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2 Mapping the risk of malaria during pregnancy in different 
transmission settings in Mali 
2.1 Introduction 
Pregnancy associated malaria (PAM) is an overwhelming public health problem in sub-
Saharan Africa where 32 million pregnant women are estimated to occur each year 
(Dellicour et al., 2010). The epidemiology and clinical presentation of PAM depend on the 
prevailing intensity of malaria transmission (Bardaji et al., 2008, Newman et al., 2003a, 
Nosten et al., 2004). Disease control strategies in this vulnerable group have focused on a 
three-pronged approach: intermittent preventive treatment (IPTp) using sulfadoxine-
pyrimethamine (SP) in the second and third trimester, use of insecticide treated nets 
(ITNs) provided at antenatal booking, and effective case management of malarial illness 
and anaemia (WHO/AFRO, 2004). Deployment of these control strategies is determined 
by the characteristics of the transmission settings. Effective case management is the 
primary strategy in areas with low or unstable transmission such as Asia, Latin America 
and parts of the horn of Africa where most malaria infections eventually result in clinical 
malaria because of low levels of acquired antimalarial immunity, whilst in higher or 
stable transmission areas high levels of acquired immunity in adults means most P. 
falciparum infections remain asymptomatic, yet can have harmful consequences for 
mother and newborn. In these settings, both case management and prevention 
strategies are used (Bardaji et al., 2008, Menendez et al., 2007, Newman et al., 2003b, 
Nosten et al., 2004, WHO/AFRO, 2004). 
Mali is a landlocked country divided in 8 administrative regions with a wide range 
of malaria transmission patterns as described earlier (Doumbo O., 1991). Malaria is 
highly seasonal with most transmission occurring in May-June to October with important 
differences in intensity and duration of the seasons between the North and the South. 
The South is characterized by longer rainy seasons and >=1,000 mm of annual rainfall and 
has a malaria infection prevalence during the peak of the transmission season ranging 
from 70 to 80% , whereas in the North the seasons are much shorter (2 to 3 months) with 
an annual rainfall of <300 mm and a peak parasite prevalence below 5% (Doumbo O., 
1991, Koita et al., 2012). In addition, some parts of the country have virtually year-round 
transmission due to irrigation for rice cultivation which helps maintains transmission 
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outside the rainy seasons (Ceesay et al., 2012, Doumbo O., 1991, Sogoba et al., 2007). 
The risk and consequences of malaria in pregnancy is likely to vary importantly by 
administrative region in Mali, yet the control strategy is similar throughout the country.  
Using different designs, several individual studies have assessed the burden of PAM 
in different parts of Mali (Bouvier et al., 1997a, Bouvier et al., 1997b, Diakite et al., 2011, 
Diallo et al., 2007, Dicko et al., 2003, Kayentao et al., 2005, Kayentao et al., 2007, Maiga 
et al., 2010). However, national estimates of the absolute burden of PAM are lacking and 
routine surveillance data of malaria in pregnancy are not available in Mali. National 
health information systems data suggest that malaria represent 36.5% of consultations in 
health centres in Mali in 2009, and is the leading cause of mortality and morbidity in 
children under five and anaemia in pregnant women (Ministère de la Santé, 2009). To 
allow for efficient allocation of limited resources for the control of malaria in pregnancy, 
there is a need for estimating the burden of PAM by transmission strata, as suggested by 
the WHO (WHO, 2000b).  
In this chapter we report the burden of malaria in pregnancy in different regions of 
Mali using data collected from 11 surveys conducted between January 2005 and January 
2010. The results of the analysis of the effectiveness of IPTp are reported elsewhere 
(chapter 6). Here we report the results with regards to peripheral and placental malaria 
and their associations with birth outcome. The survey data are then used to estimate the 
national burden of malaria in pregnancy and the potential added benefits from upscaling 
ITNs and IPTp use (Gamble et al., 2007, Ter Kuile et al., 2007). 
2.2 Methods 
2.2.1 Study sites and surveys 
A total of 11 surveys in 9 sites were conducted between January 2005 and 2010 (Figure 
2.1 & Table 2. 1). All the surveys were cross-sectional, used similar methods and had 
similar objectives to assess the burden of malaria in pregnancy and the effectiveness of 
IPT and ITNs on birth parameters among women who presented for delivery. The only 
exception was that during the last 2 surveys conducted from July 2009 to January 2010 in 
the districts of San and Kita, information on placental and maternal malaria using PCR 
was available. A detailed description of the study sites is available in chapter 1.  
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Table 2. 1: Socio-demographic characteristics  
Transmission Low Moderate High  
Sites 
Timbuktu 
(N=213) 
Bamako-1 
(N=201) 
Bamako-2 
(N=379) 
Koro 
(N=424) 
Djenne 
(N=424) 
Sangha 
(N=202) 
San-1 
(N=424) 
San-2 
(N=471) 
Bougouni 
(N=424) 
Fana 
(N=200) 
Kita 
(N=624) 
All 
3,986 
Regions North* Bamako Bamako Mopti Mopti Mopti Segou Segou Sikasso Koulikoro Kayes  
Latitude  16.77 12.65 12.65 13.94 13.9 14.66 13.3 13.3 11.41 12.77 13.05  
Longitude  -3.0 -8.00 -8.00 -3.02 -3.55 -3.31 -4.9 -4.9 -7.48 -6.95 -9.48  
Km from Bamako 907 0 0 722 567 800 423 423 180 127 182  
Study period Jan05-
Mar05 
Jan05-
Mar05 
Mar-09 
Nov 09 
Sep06-
Mar07 
Sep06-
Mar07 
Jun-06 
Feb 07 
Sep06- 
Mar07 
Jul09- 
Jan10 
Sep06- 
Mar07 
Nov05- 
Feb06 
Jul09- 
Jan10 
 
 
Peak transmission
&
 Sep-Oct Oct-Nov Oct-Nov Sept-Oct Sept-Oct Sept-Oct Sept-Oct Sept-Oct Oct-Nov Oct-Nov Oct-Nov  
Observed % Mal† 17/163 
(10.4) 
4/134  
(3.0) 
0/109  
(0.0) 
63/179 
(35.2) 
16/154 
(10.4) 
7/23  
(30.4) 
41/147 
(27.9) 
14/127 
(11.0) 
29/111 
(26.1) 
19/102 
(18.6) 
19/155 
(12.3) 
229/1,404 
(16.3) 
Delivery during rainy 
season‡, n (%) 
0 (0.0) 0 (0.0) 270  
(71.2) 
186  
(43.9) 
168  
(39.6) 
155  
(77.1) 
377  
(88.9) 
405  
(86.0) 
272  
(64.2) 
15  
(7.5) 
561  
(90.3) 
2409   
(60.4) 
Completed primary 
school, n (%) 
52  
(24.4) 
46  
(22.9) 
64  
(16.9) 
100  
(23.6) 
71  
(16.8) 
3  
(1.5) 
83  
(19.6) 
105  
(22.8) 
129  
(31.1) 
40  
(20.0) 
198  
(31.8) 
824  
(21.4) 
Age in years              
  Median  (range) 23 
(15-44) 
24  
(15-45) 
23  
(15-45) 
25 
(15-45) 
25 
(15-45) 
25  
(15-45) 
25 
(15-42) 
25 
(15-48) 
23  
(15-46) 
23  
(15-44) 
23 
(14-50) 
24  
(15-42) 
  <=20 years, n (%) 80 (37.6) 71 (35.3) 161 (42.5) 141 (33.3) 116 (27.4) 30 (19) 122 (28.8) 131 (27.9) 169 (39.9) 77 (38.5) 230 (37.0) 1,347 (34.2) 
Married  184  
(86.4) 
192  
(95.5) 
349  
(93.3) 
361  
(85.1) 
400  
(94.3) 
190  
(94.1) 
383  
(90.5) 
436  
(93.4) 
384  
(90.6) 
167  
(83.5) 
527  
(85.0) 
3573  
(89.8) 
Gravidity             
  Median (range) 3 (1-11) 3 (1-13) 3 (1-13) 2 (1-10) 3 (1-12) 4 (1-12) 2 (1-9) 2 (1-12) 2(1-11) 3 (1-14) 2 (1-11) 2 (1-10) 
  G1 66 (31.0) 41 (20.4) 104 (27.4) 117 (27.8) 93 (22.1) 33 (16.3) 100 (23.6) 96 (20.2) 99 (23.5) 43 (21.5) 160 (25.8) 952 (24.0) 
  G2 38 (17.8) 42 (20.9) 88 (23.2) 59 (14.0) 56 (13.3) 37 (18.3) 85 (20.1) 85 (18.1) 88 (20.9) 39 (19.5) 107 (17.2) 724 (18.2) 
  G3 26 (12.2) 29 (14.4) 62 (16.4) 55 (13.1) 56 (13.3) 24 (11.9) 61 (14.0) 69 (14.7) 59 (14.0) 19 (9.5) 95 (15.3) 555 (14.0) 
  G4+ 83 (39.0) 89 (44.3) 125 (33) 190 (45.1) 215 (51.2) 108 (53.5) 177 (41.8) 219 (46.7) 176 (41.7) 99 (49.5) 259 (41.7) 1740 (43.8) 
Notes: N, sample size; ANC, antenatal clinic; G1, first pregnancy ; G2, second pregnancy; G3, third pregnancy; G4+,  four or more pregnancies ;  
*The north of Mali includes the regions of Timbuktu, Gao and Kidal
 
&
Peak malaria transmission, based on annual rainfall data 
†Malaria transmission intensity based on the prevalence of malaria at delivery in women not receiving SP 
‡Rainy season defined as the time in months between first and last drops of rain in a given year  
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Figure 2.1: Map of Malaria prevalence in Mali with the different study sites 
Open circles depict the location of the 9 survey sites.  
Source: This map is a product of the MAP project ( 
http://www.map.ox.ac.uk/client_media/pdf/Pf_mean_2010/Pf_mean_2010_MLI.pdf )  
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2.2.2 Study Procedures  
In all the surveys, women of all gravida were screened in the delivery unit of the 
participating health centre. Before enrolment, women were asked to provide informed 
consent after the study procedures were explained in their local language (Bambara) and 
if their age was >=15 years old.  
At enrolment, a questionnaire focused on socio-demographic characteristics, 
history of fever, and use of insecticides treated nets (ITNs), chemoprophylaxis, and 
intermittent preventive therapy (IPTp). The number of doses of IPTp during pregnancy 
reported by the woman was verified using antenatal clinic (ANC) cards and records. 
Details of the number of SP doses was not assessed for the first three surveys in 
Timbuktu, Bamako and Fana, but any use of IPTp was recorded as >=1 or none. The 
axillary temperature was measured in degrees Celsius using an digital thermometer and a 
capillary blood sample taken by finger stick for haemoglobin levels (not in the first three 
surveys) and malaria thin and thick smears (all surveys). Placental (maternal side) and 
umbilical cord blood (infant) smears were also taken. In all but 4 surveys (Timbuktu, 
Bamako [2] and Sangha) dried blood spots were collected for polymerase chain reaction 
(PCR) for molecular markers of drug resistance (6 surveys) and for detection of malaria 
(last two surveys). Within 24 hours of delivery, singleton neonates were weighed using 
identical digital scales. Gestational age was assessed using a standardized Ballard 
examination (Ballard et al., 1979).  
Thick blood smears were stained with Giemsa and examined for malaria parasites. 
Parasites were counted for against 300 leukocytes, and parasites densities expressed 
using an assumed leukocytes count of 7,500 /mm3. Smears were considered negative if 
no parasites were detected in 100 high power fields. An expert microscopist from the 
Malaria Research and Training Center (MRTC) read 10% random sample of positive and 
negative slides for quality control. When >=20% of discrepancy in the results was found 
between the field microscopists and the expert microscopist when comparing positive vs 
negative results, all the slides were read again. HemoCue® (Hemoglobin AB, Ångelholm, 
Sweden) was used to assess haemoglobin levels.  
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2.2.3 Definitions 
LBW was defined as birth weight of <2500 grams in live born singleton births, and 
prematurity as a gestational age of <37 weeks assessed by Ballard examination. Small for 
gestational age (SGA) was determined as <10th percentile in birth weight for attained 
gestational age (Landis et al., 2009). Anaemia was defined as haemoglobin (Hb) levels of 
<11 g/dL, and severe anaemia as Hb <8 g/dL. The composite LBW-preterm was defined as 
a new born with either LBW or preterm birth. Women were classified as young if they 
were ≤20 years old. ITN use was defined as the use of an insecticide treated net the night 
before the survey as reported by women at delivery. 
For the purpose of our analysis we stratified the 9 study sites a priori into high 
(Bougouni, Kita, and Fana), moderate (San, Djenne, Koro, Sangha), and low (Bamako, 
Timbuktu) transmission settings (Figure 2.1 & Table 2. 1) according to Doumbo et al. 
(Doumbo O., 1991), (chapter 1). In addition, we used observed malaria transmission 
intensity, which was defined based on the Plasmodium falciparum prevalence  in the 
peripheral blood at delivery in women not receiving IPTp, and  classified as low if 
prevalence was <20% and high if ≥20%.  
Proportion stillbirths and live births of all births 
Figure 2. 2 : Calculation of malaria in pregnancy estimates in Mali  
Estimates of population size by region Census 2009: 
http://instat.gov.ml/voir_actu.aspx?lactu=44 
Estimates number of live births in Mali: 622,000 
World population Prospects: the 2012 Revision 
Population Database: http://esa.un.org/wpp/ 
Births 2005-2010 
Dellicour 2010, Table S1, 2007 estimates 
http://www.plosmedicine.org/article/info:doi/10.13
71/journal.pmed.1000221 
Total stillbirths and live births in Mali: 637,150 
Total stillbirths and live births per region: Distribution 
proportional to population size per region 
Total fertility rate 6.80 
World population Prospects: the 2012 Revision 
Population Database: http://esa.un.org/wpp/ 
Total fertility rate 2005-2010: 6.8 
Estimate proportion primigravidae and 
secundigravidae (G1/2) and multigravidae (G3+): 
G1/2: ([100/TFR]*2), MG: 100-G1/2: 
G1/2:  29.4%, G3+:  70.6% 
Prevalence of outcomes (placental malaria, low 
birth weight, anaemia) by gravidity group per region 
per season 
Mali studies Kayentao et al for all regions conducted 
in 2005-2010 
-Under malaria prevention coverage as reported 
-Rainy season based on rain data for each site for year 
of study 
Total prevalence of outcomes in pregnancy in Mali 
estimated for 2005-2010 under malaria prevention 
coverage as reported for the different regions 
Number of outcomes prevented by documented 
IPTp or ITN use 
Number of outcomes that still can be prevented if 
100% coverage 
Efficacy data G1/2 in percentage 
 
IPTp Source ITN Source 
Placental 
malaria 52 Ter Kuile 2007 22 Gamble 2007 
Low birth 
weight 29 Ter Kuile 2007 23 Gamble 2007 
Anaemia 7 Ter Kuile 2007* 6 Gamble 2006* *Efficacy anaemia by IPTp recalculated from Ter Kuile 2007 using data which only compared IPTp vs. no IPTp (Ter Kuile 
et al., 2007); efficacy anaemia by ITNs recalculated from Gamble 2006 using data from Browne 1996 and Njagi (Njagi 
et al., 2003), comparing ITNs vs. no ITNs (Gamble et al., 2006) 
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Figure 2.2:  Calculation of malaria in pregnancy estimates in Mali  
Estimates of population size by region Census 2009: 
http://instat.gov.ml/voir_actu.aspx?lactu=44 
Estimates number of live births in Mali: 622,000 World population Prospects: the 2012 
Revision Population Database: 
http://esa.un.org/wpp/ 
Births 2005-2010 
Dellicour 2010, Table S1, 2007 estimates 
http://www.plosmedicine.org/article/info:do
i/10.1371/journal.pmed.1000221 Total stillbirths and live births in Mali: 637,150 
Total stillbirths and live births per region: 
Distribution proportional to population size per 
region 
Total fertility rate 6.80 World population Prospects: the 2012 
Revision Population Database: 
http://esa.un.org/wpp/ 
Total fertility rate 2005-2010: 6.8 Estimate proportion primigravidae and 
secundigravidae (G1/2) and multigravidae (G3+): 
G1/2: ([100/TFR]*2), MG: 100-G1/2: 
G1/2:  29.4%, G3+:  70.6% 
Prevalence of outcomes (placental malaria, low birth 
weight, anaemia) by gravidity group per region per 
season 
Mali studies Kayentao et al for all regions 
conducted in 2005-2010 
-Under malaria prevention coverage as 
reported 
-Rainy season based on rain data for each 
site for year of study 
 
Total prevalence of outcomes in pregnancy in Mali 
estimated for 2005-2010 under malaria prevention 
coverage as reported for the different regions 
Number of outcomes prevented by documented 
IPTp or ITN use 
Number of outcomes that still can be prevented if 
100% coverage 
Efficacy data G1/2 in percentage 
 
IPTp Source ITN Source 
Placental 
malaria 52 
Ter Kuile 
2007 22 Gamble 2007 
Low 
birth 
weight 29 
Ter Kuile 
2007 23 Gamble 2007 
Anaemia 7 
Ter Kuile 
2007* 6 Gamble 2006* 
 
Notes: *Efficacy anaemia by IPTp recalculated from ter Kuile 2007 using data which only compared IPTp vs. no 
IPTp; efficacy anaemia by ITNs recalculated from Gamble 2006 using data from Browne 1996 and Njagi (Njagi 
et al., 2003), comparing ITNs vs. no ITNs (Gamble et al., 2006). 
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Table 2.2:Malaria prevention measures used during pregnancy reported at delivery  
Transmission Low Moderate High All 
Sites 
Timbuktu 
(N=213) 
Bamako-1 
(N=201) 
Bamako-2 
(N=379) 
Koro 
(N=424) 
Djenne 
(N=424) 
Sangha 
(N=201) 
San-1 
(N=424) 
San-2 
(N=471) 
Bougouni 
(N=424) 
Fana 
(N=200) 
Kita 
(N=624) 
 
3986 
Bednet use, n 
(%) 
104 (48.8) 126 (62.7)  338(79.7) 416(98.1)  371 (87.5) 454(96.39) 239 (56.4) 150 (75.0) 566(91.0) 2764 (92.5) 
ITN last night, 
n (%)  
36 (16.9) 39 (19.4) 306 (81.4) 249 (58.7) 288 (67.9) 109 (63.0) 260 (61.3) 444 (94.5) 152 (35.9) 123 (61.5) 549 (88.3) 2555 (64.7) 
IPTp-SP doses, 
n (%) 
            
  0 165 (78.2) 134 (67.7) 109 (28.8) 180(42.5) 154(36.3) 23 (11.4) 147(34.7) 127(27.1) 111 (26.2) 102 (79.7) 155(25.5) 1307 (34.5) 
  >=1 46 (21.8) 64 (32.3) 270 (71.2) 244 (57.5) 270 (63.7) 179 (88.6) 277 (65.3) 342 (72.9) 313 (73.8) 26 (20.3) 454 (74.5) 2485 (65.5) 
  1   111 (29.3) 147(34.7) 119(28.1) - 186(43.9) 175(37.3) 187(44.1)  132(21.6) 1057 (33.5) 
  2   159 (42.0) 97(22.9) 151(35.6) - 91(21.5) 157(33.5) 126 (29.7)  322(53.0) 1103 (35.0) 
  >=3    0 0 - 0 10 (2.1) 0  0 10 (2.1) 
Notes: N, sample size; n, number of events; ITN, insecticide treated nets; IPTp, intermittent preventive treatment; SP, sulfadoxine-pyrimethamine.  
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2.2.4 Rainfall data  
Monthly rainfall data were provided by The Malian Metrological Agency of the Ministry 
of Equipment and Transports. This was available for the entire year of all study periods 
for all the sites. Daily rainfall data were not available.  
2.2.5 Statistical approach  
Data entry was done using access 2000 (Microsoft Office) and data analysis was done 
using Stata 12.0 (StataCorp LP, Texas) and Microsoft Excel 2010 (Microsoft Office). The 
prevalence of maternal anaemia, maternal and placental parasitemia, as well as that of 
LBW, small for gestational age (SGA), preterm delivery, and the composite LBW-preterm 
was determined per site, region, and transmission settings. Possible risk factors for these 
outcomes were determined using univariate and multivariate analysis. Crude and 
adjusted prevalence ratios (aPR) were estimated based on generalized linear models 
(GLM) using log binomial regression. For non-convergence models, the “binreg” option 
was used (Cummings, 2009). All predictor variables with a p-value <0.2 in the univariate 
analysis were included in the multivariable models. However, a priori transmission 
setting was forced into all models because of its epidemiological importance. Other 
variables considered for inclusion as possible confounders included: age (≤20 versus >20 
years), season of delivery (dry versus rainy), gravida group (G1-G2 versus G3+) and ITN 
(use versus none use). IPTp use was entered as 2 or more doses of IPTp versus women 
only one course of IPT, or no IPT. Data from the survey of Bamako 2005 was excluded 
from the analysis of LBW and mean birth weight because this site experienced a 
calibration issue with their weighing scale which was detected close to the end of the 
survey. Forest plots and meta-regression was used to determine the association between 
malaria transmission intensity (defined as the observed prevalence of malaria in the 
peripheral blood of women at delivery) and the risk of LBW. 
2.2.6 Extrapolation to annual national numbers of pregnancies affected and 
impact of prevention strategies  
To obtain estimates of the total number of pregnancies affected annually in Mali, and the 
potential impact of upscaling the coverage of IPTp and ITNs the results of the survey data 
were extrapolated to national levels using near identical methods as described previously 
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to quantify the burden and consequence of malaria in pregnancy in the Democratic 
Republic of the Congo (Taylor et al., 2011b).  
Estimates for the annual number of live and stillbirths were obtained from the United 
Nations world population database (World-Population-Prospect, 2012) and Dellicour et 
al. (Dellicour et al., 2010). The national fertility rate (The World Population Prospects 
2012 database) (World-Population-Prospect, 2012) was used to obtain the number of 
births by gravidity. The risk of malaria was assumed to be restricted to the transmission 
season, which was estimated to last 6, 4 or 3 months in areas with high, moderate and 
low transmission respectively, except for Bamako which has low transmission, but a 6 
months transmission season.  
The prevalence of outcomes (malaria, LBW, anaemia) and coverage of prevention 
strategies (ITNs and IPTp) in the survey were calculated by gravidity group (G1-G2 and 
G3+), per region (6 region strata where the three northern regions with similar 
characteristics [Timbuktu, Gao and Kidal] were pooled into the single region of Timbuktu) 
and eventually per transmission strata (a priori set as high, moderate, low) (Table 2. 1). 
For the site of Timbuktu rainy season burden data was not available. We 
estimated the risk ratio of rainy to dry season for placental malaria among primi-and 
secundigravida for all other sites; the pooled risk was 1.7; 95% CI, 1.2-2.6, I-squared 51%, 
and used this to estimate the rainy season prevalence of placental malaria in Timbuktu. 
For multigravida, we extrapolated the measured prevalence for the dry season to the 
rainy season because it was perceived as high for the area. 
The observed prevalence estimates for placental malaria, LBW, and anaemia in our 
surveys, combined with the absolute number of pregnancies at risk were then used to 
estimate the total number of births resulting in placental malaria, LBW, and anaemia in 
each region, transmission strata and nationally.  
The potential impact of successful malaria control in pregnancy was estimated by 
using the summary protective efficacy (PE) of ITNs and IPTp-SP obtained from previous 
meta-analyses of randomized controlled trials comparing IPTp-SP against placebo or 
passive case detection (case-management). The published protective efficacy  estimates 
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for ITNs and IPTp-SP among first and second pregnancies are 23% and 29% for LBW, 52% 
and 22% for placental malaria and 7% and 6% for anaemia at delivery (Hb<10 or 11 g/dL), 
respectively (Figure 2.2). 
The reduction in the risk of each outcome (event) from IPTp or ITNs under the 
observed coverage of 2-dose IPTp or ITNs in G1-G2 (first and second pregnancies) in the 
11 surveys was then calculated as 1/(1-(coverage% * PE%)), where the coverage% is the 
observed coverage of 2-dose IPTp or ITNs in the specific region and PE% is the % 
protective efficacy observed in trials. The number of events prevented under the 
observed coverage of the intervention was then calculated as the number of events if 
there was no IPTp or ITN (0% coverage), minus the observed number of events. The 
potential number of events that could be prevented if all women used IPTp was 
calculated as the number of events under 0% coverage times the protective efficacy 
estimated from trials; the potential number that could be prevented by increasing the 
coverage from the observed value to universal coverage was estimated by deducting the 
observed events from this figure (Taylor et al., 2011b).  
For example, for the effect of 2-dose IPTp on LBW in primi,- and secundigravida in the 
Kayes region, the coverage of 2-dose IPTp was 55.3% in G1-G2. The estimated % 
reduction in the LBW with 55.3% 2-dose of IPTp coverage was calculated as 0.553 * 29% 
= 16.0%, where 29% is the PE value obtained from the meta-analysis for the effect of 2-
dose IPTp on LBW. To calculate the annual number of LBW events that would have 
occurred in the absence of a 2-dose IPTp strategy, the estimated LBW events based on 
the observed risk of LBW and the observed coverage of 2-dose IPTp or ITNs was divided 
by a factor of 1-(coverage % x PE%), where coverage% is the observed coverage of the 
intervention in the region, and PE% is the value obtained from the meta-analysis of trials. 
For example in Kayes, the average risk of LBW was 20.25% in G1-G2, and the annual 
number of births was 25,776, giving 5,220 LBW events per year; the events that would 
have occurred without any IPTp strategy was: 5,220 / (1-(55.3% x 29.0%)) = 6,217. Thus 
the 55.3% coverage prevented 6,217-5,220 = 997 LBW events annually. The additional 
number of LBW that could be prevented by increasing the coverage to 100% (universal 
coverage) was calculated as the number of LBW events that would potentially be 
Chapter 2 
 
41 
 
prevented with 100% coverage of 2-dose IPTp (29% of 6,217 = 1,803) minus the number 
of events prevented under the current coverage : 1,803-997=806.  
2.3 Ethical statement 
The institutional review boards (IRB) of the Faculty of Medicine, Pharmacy, and Dentistry 
of Mali (FMPOS) (all surveys), the Centers of Diseases Control and Prevention (CDC) 
(middle 4 of 5 surveys), and the Liverpool School or Tropical Medicine (LSTM) (last 2 
surveys) approved the study protocols. 
2.4 Results 
Characteristics: From 2005 to 2010, 11 surveys were conducted in 9 sites involving a 
total of 3,982 deliveries of which 793 (19.9%), 1,945 (48.8%), and 1,248 (31.3%) occurred 
in the low, moderate, and high malaria transmission areas, respectively (Table 2. 1). The 
median (range) duration of each survey was 7 (1-12) months and most of the deliveries 
occurred during the rainy season (60.4 %). The median (range) ITN use was 61.5% (16.9-
94.5) varying from 16.9% in Timbuktu in 2005 to 94.5% in San in 2009 (Table 2.2). Among 
the 7 surveys which collected information on the number of IPTp-SP doses received, the 
median (range) coverage of >=2 doses was 35.4% (21.5-53.2) and highest in Kita (2009) 
(53.2%) and lowest in San (2006) (21.5%) and Koro (2006) (23%) (Table 2.2). Of the 
singleton deliveries, 5.8% resulted in stillbirths ranging from 12.5% and 8.9% in Djenne 
and Koro to 1.5% and 1.1% in Sangha and Bamako-2009. More than half of the women 
were anaemic (56.5 %) and 10.8% had moderate-severe anaemia.  
Malaria: Overall, malaria parasitemia in the peripheral and placental blood was found in 
15.2% and 13.2% of women, respectively. The highest for both was observed in Koro, a 
moderate transmission area, and the lowest in Bamako, a low transmission area (Table 
2.3 & Figure 2.3). Risk factors for both maternal and placental parasitemia (Table 2.4) by 
both univariate and multivariate analysis, were living in areas defined (a priori) as 
moderate transmission areas, being primi-or secundigravidae, and delivering during the 
rainy season, not using an ITN, and being single or divorced (not married). Young women 
were more likely to have maternal and placental parasitemia in univariate analysis, but 
not in multivariate analysis. The receipt of two doses of IPTp-SP was associated with a 
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32% and 33% reduction of both maternal peripheral and placental parasitemia (Table 2.4), 
respectively in univariate analysis and 22% and 21% in multivariate analysis, respectively.  
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Figure 2.3: Number (left graphs) and prevalence (right graphs) of outcomes per region  among 
all gravida (Top graphs) and primi-, secundigravida (bottom graphs) 
  
  
Notes: PL, placental malaria infection; LBW, low birth weight.  
# indicates absolute number;  % indicates prevalence of outcomes 
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Table 2.3: Clinical and biological outcomes  
Transmission Low Moderate High All 
Sites Timbuktu Bamako-1 Bamako-2 Koro Djenne Sangha San-1 San-2 Bougouni Fana Kita  
Birth Outcome             
  Live born, n (%) 195 (93.3) 189 (96.4) 359 (98.4) 357 (86.2) 356 (87.0) 193 (98.5) 399 (95.5) 450 (95.5) 407 (96.9) 174 (91.6) 578 (92.9) 3657 (93.5) 
  Miscarriage, n (%) 4 (1.9) 3 (1.5) 2 (0.5) 20 (4.8) 2 (0.5) 0 (0) 2 (0.5) 2 (0.4) 1 (0.2) 3 (1.6) 5 (0.8) 44 (1.1) 
  Stillbirth, n (%) 10 (4.8) 4 (2.0) 4 (1.1) 37 (8.9) 51 (12.5) 3 (1.5) 17 (4.1) 19 (4.0) 12 (2.9) 13 (6.8) 39 (6.3) 209 (5.8) 
Birth weight             
  Grams, Mean (SD) 3004  
(536) 
2919  
(500) 
2957  
(517) 
3183  
(562) 
3151  
(499) 
2820  
(405) 
3089  
(518) 
3042  
(445) 
3130 
 (519) 
2913  
(487) 
3027  
(518) 
3044  
(514) 
  LBW, n (%) 23 (12.2) 41 (21.7)* 41 (11.4) 27 (7.7) 23 (6.5) 34 (17.6) 29 (7.3) 40 (9.2) 28 (6.9) 21 (12.1) 58 (10.4) 365 (10.1) 
Gestational age             
  SGA 61 (33.3) 35 (19.0) ** 68 (19.5) 96 (9.7) 114 (60.0) 125 (31.4) 152 (35.4) 121 (30.0) 40 (23.4) 183 (33.0) 995 (31.0) 
  Weeks, Mean (SD) 41 (3) 37 (3) ** 39 (1) 40 (1) 38 (1) 41 (1) 40 (1) 40 (1) 39 (3) 39 (1) 39 (2) 
  Preterm (<37wks), n (%) 17 (9.3) 65 (35.3) 11 (2.9) 10 (2.9) 9 (2.6) 8 (4.2) 8 (2.0) 1 (0.2) 7 (1.7) 19 (11.1) 12 (2.2) 167 (4.6) 
  Preterm-LBW 31 (16.9) 82 (44,6) 43 (11.9) 27 (7.8) 24 (6.9) 37 (19.3) 32 (8.0) 40 (9.3) 26 (6.5) 29 (17.0) 59 (10.6) 430 (12.0) 
Haemoglobin, g/dL             
  Mean (SD) - - - 10.6(2.2) 10.4(2.1) - 10.6(2.0) 10.5(1.85) 10.7(2.0) - 10.6(2.0) 10.5 (2.0) 
  Hb<11, n (%) - - - 239(56.4) 239 (56.4) - 286 (67.5 266(58.3) 210(49.5) - 218(50.8) 1458 (56.5) 
  Hb<8, n (%) - - - 46 (10.9) 54(12.7) - 55 (13.0) 36(7.9) 45(10.6) - 42(9.8) 278 (10.8) 
Placental Malaria, n (%) 24 (11.3) 4 (2.0) 6 (1.6) 126 (31.0) 49 (11.7) 20 (10.1) 99 (23.4) 31 (6.7) 88 (20.8) 20 (10.0) 57 (9.4) 524 (13.3) 
Maternal Malaria, n (%) 19 (9.1) 5 (2.5) 9 (2.4) 126 (29.8) 48(11.5) 23 (11.5) 117(27.6) 44(9.5) 121(28.6) 32 (16.1) 59 (9.6) 603 (15.3) 
Notes: SD, standard deviation; LBW, low birth weight; SGA, small for gestational age; g/dL, grams per decilitre; Hb, haemoglobin;   
*In Bamako-1, the high prevalence of LBW resulted from a calibration problem of the weighing scale (resulting in a systematic underestimation of the true weight of the baby). This 
was only discovered towards the end the survey 
**Gestational age was not correctly recorded for Bamako 2009 and Ballard measurement was not used. 
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Table 2.4:Bivariate and multivariate log binomial regression models of the risk of maternal (upper) 
 and placental (lower) parasitemia 
Maternal Malaria 
  No. of 
women 
% with 
malaria 
PR (95% CI) P-value APR (95% CI) P-
value 
Transmission Low 789 4.2 0.24 (0.17-0.34) <0.001 0.17 (0.09-0.33) <0.001 
 Moderate 1,929 18.6 1.10 (0.93-1.27) 0.294 1.27 (1.08-1.49) 0.004 
 High 1,235 17,1 1  1  
Marital 
status 
Married 3,545 14.2 1  1  
 Not married  402 24.4 1.72 (1.42-2.08) <0.001 1.27 (1.03-1.56) 0.022 
Age >20 2,568 13.4 1  1  
 <=20 1,341 18.9 1.41 (1.21-1.63) <0.001 0.85 (0.69-1.03) 0.100 
Season Rainy 2,880 18.2 2.58 (2.05-3.25) <0.001 2.60 (1.90-3.56) <0.001 
 Dry 1,073 7.1 1    
Gravidity G1-G2 1,667 20.4 1.78 (1.53-2.06) <0.001 1.87 (1.54-2.30) <0.001 
 G3+ 2,286 11.5 1    
ITN use Yes 2,534 13.1 0.69 (0.59-0.80) <0.001 0.59 (0.51-0.69) <0.001 
 No 1,416 19.1 1    
IPTp doses* 0 982 18.5 1    
 1 1,052 18.8 1.02 (0.85-1.22) 0.868 1.00 (0.84-1.18) 0.961 
 2 1,108 12.9 0.68 (0.57-0.85) <0.001 0.78 (0.64-0.95) 0.015 
Placental malaria 
  No. of 
women 
% with 
malaria 
PR (95% CI) P-value APR (95% CI) P-
value 
Transmission Low 789 4.3 0.33 (0.23-0.48) <0.001 0.15 (0.07-0.33) <0.001 
 Moderate 1,911 17.0 1.31 (1.1-1.56) 0.003 1.49 (1.24-1.80) <0.001 
 High 1,225 13.0 1    
Marital 
status 
Married 3,523 12.2 1    
 Not married  396 22.5 1.85 (1.51-2.27) <0.001 1.32 (1.06-1.65) 0.013 
Age >20 2,553 11.5 1    
 <=20 1,328 16.8 1.46 (1.25-1.72) <0.001 0.90 (0.72-1.12) 0.348 
Season Rainy 2,858 15.7 2.39 (1.88-3.04) <0.001 2.66(1.89-3.75) <0.001 
 Dry 1,067 6.6 1    
Gravidity G1-G2 1,648 17.8 1.80 (1.53-2.12) <0.001 1.83 (1.46-2.30) <0.001 
 G3+ 2,277 9.9 1    
ITN use Yes 2,516 11.5 0.70 (0.60-0.82) <0.001 0.62 (0.53-0.74) <0.001 
 No 1,406 16.4 1    
IPTp doses* 0 957 16.9 1    
 1 1,049 15.4 0.91 (0.75-1.11) 0.367 0.92 (0.76-1.11) 0.365 
 2 1,104 11.4 0.67 (0.54-0.84) <0.001 0.79 (0.63-0.97) 0.027 
Notes: No, sample size; PR, prevalence ratio; APR, adjusted prevalence ratio; G1-2, 1st or 2nd pregnancy ;  
G3+, >= 3rd pregnancy; IPTp-SP, intermittent preventive treatment with sulfadoxine-pyrimethamine 
*Not assessed by dose in 4 surveys (Bamako 2005, Timbuktu, Sangha, and Fana). 
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Table 2.5: Bivariate and multivariate log binomial regression models of the risk of low birth weight* (upper) 
and the composite of low birth weight or preterm birth (lower)*  
Low Birth Weight 
  No. of 
women 
% with 
LBW* 
PR (95% CI) P-value APR (95% CI) P-
value 
Transmission Low 550 11.8 1.26 (0.94-1.68) 0.122 1.26 (0.89-1.79) 0.196 
 Moderate 1,731 8.8 0.94 (0.74-1.19) 0.612 0.87 (0.67-1.13) 0.303 
 High 1,139 9.4 1    
Marital status Married 3,058 8.7 1    
 Not married  355 16.3 1.87 (1.44-2.43) <0.001 1.38 (1.00-1.90) 0.049 
Age >20 2,217 7.2 1    
 <=20 1,159 13.8 1.91 (1.55-2.35) <0.001 1.59 (1.13-2.24) 0.009 
Season Rainy 2,651 9.2 0.87 (0.69-1.11) 0.267   
 Dry 769 10.5 1    
Gravidity G1-G2 1,444 13.0 1.85 (1.50-2.28) <0.001 1.22 (0.85-1.74) 0.275 
 G3+ 1,973 7.0 1    
ITN use Yes 2,292 9.2 0.91 (0.73-1.13) 0.389   
 No 1,121 10.1 1    
IPTp doses** 0 817 12.6 1    
 1 989 7.1 0.56 (0.42-0.75) <0.001 0.59 (0.45-0.80) <0.001 
 2 1,053 7.0 0.56 (0.42-0.74) <0.001 0.60 (0.45-0.80) 0.001 
Placental 
Malaria  
Positive 463 12.1 1.32 (1.00-1.73) 0.044 1.28 (0.94-1.73) 0.118 
Negative  2,926 9.2 1    
Low birth weight or preterm* 
  No. of 
women 
% with 
LBW/PT 
PR (95% CI) P-value APR (95% CI) P-
value 
Transmission Low 546 13.9 1.35 (1.03-1.76) 0.031 1.21(0.84-1.73) 0.301 
 Moderate 1,719 9.4 0.91 (0.73-1.14) 0.423 0.88 (0.68-1.15) 0.362 
 High 1,132 10.3 1    
Marital status Married 3,040 9.5 1    
 Not married  350 18.9 1.98 (1.56-2.53) <0.001 1.42 (1.04-1.94) 0.028 
Age >20 2,202 8.1 1    
 <=20 1,151 14.9 1.85 (1.52-2.25) <0.001 1.42 (1.01-1.99) 0.040 
Season Rainy 2,637 9.8 0.76 (0.61-0.94) 0.012 0.99 (0.71-1.38) 0.964 
 Dry 760 12.9 1    
Gravidity G1-G2 1,431 7.6 1.90 (1.55-2.32) <0.001 1.34 (0.95-1.89) 0.096 
 G3+ 1,963 14.4 1    
ITN use Yes 2,278 9.6 0.78 (0.65-0.98) 0.029 1.16 (0.90-1.51) 0.254 
 No 1,112 12.1 1    
IPTp doses** 0 811 13.3 1    
 1 982 7.3 0.55 (0.42-0.73) <0.001 0.58 (0.44-0.78) <0.001 
 2 1,050 7.2 0.54 (0.11-0.16) <0.001 0.58 (0.43-0.77) <0.001 
Placental Positive 461 12.8 1.26 (0.97-1.64) 0.083 1.27 (0.93-1.72) 0.131 
malaria Negative  2,906 10.2 1    
Notes: No, sample size; LBW, low birth weight; PT, preterm, PR, prevalence ratio; APR, adjusted prevalence ratio; 
G1-2, 1st or 2nd pregnancy ; G3+, >=3rd pregnancy; IPTp-SP, intermittent preventive treatment with sulfadoxine-
pyrimethamine; *Bamako 2005 survey was excluded due to calibration problem of the weighing scale (tempted 
to lower baby’s weight); **Not assessed by dose in 4 surveys (Bamako 2005, Timbuktu, Sangha, and Fana).   
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LBW, SGA, preterm delivery, and LBW-preterm birth: Among the livebirths, the 
prevalence of LBW was 10.1% and highest in Bamako-2005 (21.7%) and lowest in Djenne 
(6.5%).  The prevalence of small for gestational age (SGA) was 31.0% overall with the 
highest in Sangha (60.0%) and the lowest in Bamako 2005 (19.0%). The overall 
prevalence of preterm delivery (PTD) and the composite LBW-preterm was 4.6% and 
12.3%, respectively. Risk factors for LBW in multi-variate models included not being 
married and young age (Table 2.5). Use of IPTp was strongly associated with a lower risk 
of LBWs in both univariate and multivariate analysis. Placental malaria was associated 
with an increased risk of LBW in univariate, but not in multivariate analysis. Transmission 
setting was not associated with the risk of LBW (Table 2.5). The same associations were 
found for the composite of LBW-preterm births (Table 2.5).  
Using a meta-analysis approach, the prevalence of LBW assessed in women not receiving 
SP was similar across levels of transmission intensity, defined a priori as low, moderate, 
and high or based on the observed prevalence of maternal peripheral malaria (<20% 
versus >=20%) in women not receiving SP (Figure 2.4 & Figure 2.5). The same pattern was 
seen when stratified by gravidity.  
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Figure 2.4: Prevalence of low birth weight by transmission intensity defined a priori as low, moderate and high 
 
 
Notes: LBW, low birth weight 
Prevalence of low birth weight in all gravida (Top graph) and primi-secundigravida (Bottom graph) by transmission 
intensity defined a priori as low, moderate, and high 
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Figure 2.5: Prevalence of LBW by observed transmission intensity defined as <20% and >= 20% in 
women without SP  
 
 
Notes: LBW, low birth weight;  
Prevalence of low birth weight in all gravida (Top graph) and primi-secundigravida (Bottom graph) 
by observed transmission intensity defined as <20% or >=20% in women without SP.  
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When adjusted for surveys, marital status, age of women and gravidity, placental malaria 
was associated with an increased risk of LBW, SGA, the composite LBW or SGA or PTD, any 
anaemia and moderate to severe anaemia (Table 2.6); and a decrease in mean haemoglobin 
(Table 2.7). Women with placental infection were more likely to deliver preterm babies, 
although statistical significance was not reached. Overall, there was a decrease in mean birth 
weight among women with placental infection, but significant level was reached only for 
primi,-secundigravida (Table 2.7). 
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Table 2.6:Association between placental malaria and the risk of LBW, small for gestational age, preterm delivery, and their composite, maternal anaemia by gravidity in 
univariate and multivariate analysis 
 LBW* SGA** Preterm 
 PR P-
value 
aPR P-
value 
PR P-
value 
aPR P-
value 
PR P-
value 
aPR P-
value 
All 1.32 (1.01-1.73) 0.044 1.46(1.10-1.94) 0.009 1.16 (1.02-1.33) 0.027 1.25 (1.09-1.44) 0.001 0.86 (0.54-1.38) 0.541 1.29 (0.81-2.05) 0.277 
G1-G2 1.48 (1.09-2.01) 0.011 1.74(1.27-2.42) 0.001 1.14 (0.97-1.33) 0.120 1.32 (1.11-1.57) 0.002 0.99 (0.58-1.70) 0.976 1.32 (0.78-2.26) 0.308 
G3+ 0.67 (0.36-1.26) 0.219 0.77 (0.41-1.45) 0.412 1.00 (0.79-1.29) 0.954 1.09 (0.86-1.39) 0.486 0.49 (0.18-1.32) 0.159 0.96 (0.34-2.68) 0.934 
 LBW or SGA or PTD Any anaemia (Hb<11 g/dL) Moderate to severe anaemia (Hb<8 g/dL) 
 PR P-
value 
aPR P-
value 
PR P-
value 
aPR P-
value 
PR P-
value 
aPR P-
value 
All 1.25 (1.10-1.42) 0.001 1.27 (1.12-1.45) <0.001 1.33 (1.24-1.43) <0.001 1.31 (1.22-1.41) <0.001 2.01 (1.58-2.56) <0.001 1.91 (1.48-2.46) <0.001 
G1-G2 1.29 (1.11-1.50) 0.001 1.27 (1.01-1.50) 0.003 1.32 (1.20-1.46) <0.001 1.31 (1.19-1.44) <0.001 2.07 (1.49-2.86) <0.001 1.76 (1.25-2.46) <0.001 
G3+ 1.03 (0.81-1.31) 0.800 1.06 (0.84-1.34) 0.627 1.29 (1.16-1.45) <0.001 1.30 (1.16-1.47) <0.001 1.81 (1.25-2.65) 0.002 2.05 (1.46-2.89) <0.001 
Notes: LBW, low birth weight; SGA, small for gestational age; PR, prevalence ratio; aPR, adjusted prevalence ratio (adjustment a priori for survey, marital status, age (>20 
versus <=20 years old) and gravidity; Hb, haemoglobin; G1-G2, first and second pregnancies; G3+, third or more pregnancy. 
*Bamako 2005 was excluded from this analysis. 
**Bamako  2009 was excluded from this analysis. 
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Table 2.7: Difference in mean birth weight and mean haemoglobin among women with placental malaria versus no placental malaria 
by gravidity in univariate and multivariate analysis 
 Mean difference in birth weight* Mean difference in haemoglobin 
 Univariate P-value Multivariate** P-value Univariate P-value Multivariate** P-value 
All  -28 (-78,  22) 0.270 -37 (-87, 13) 0.141 -0.83 (-1, -63) <0.001 -0.76 (-0.97, -0.54) <0.001 
G1-G2 -35 (-102, 32) 0.306 -86 (-155, -19) 0.013 -0.93 (-1, -0.64) <0.001 -0.82 (-1.11, -0.53) <0.001 
G3+ 49 (-24, 123) 0.187 20 (-54, 94) 0.593 -0.63 (-0.93, -0.33) <0.001 -0.64 (-0.94, -0.34) <0.001 
Notes: G1-G2, first and second pregnancies; G3+, third or more pregnancy.  
Mean differences represent the mean value among women with placental malaria minus the mean value among women without 
placental malaria.   
*Bamako 2005 was excluded from this analysis. 
** Multivariate analysis adjusted a priori for survey, marital status, age and gravidity.  
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Seasonal trends: Some of the surveys that were conducted during the rains and that 
continued for several months afterwards showed that the prevalence of maternal and 
placental malaria typically peaked towards the end of the rainy season or within 1 month 
after the rains had subsided (Figure 2.6). A similar trend was not apparent for LBW except for 
the sites of San 2009 and Kita, but overall difference in the prevalence of LBW by month 
were much smaller. For North Mali data was collected only during the dry season and the 
relationship to rainfall could not be assessed. 
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Figure 2.6: Rainfall data and prevalence of outcomes determined during the surveys for each site. 
Low transmission settings 
 
Bamako, 2009  
 
 
Timbuktu & Gao & Kidal, Timbuktu 2005  
Moderate transmission settings 
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High transmission settings 
 
Sikasso, Bougouni 2006-2007  
 
Koulikoro, Fana 2005-2006 
 
Kayes, Kita 2009  
 
Notes: LBW, Low birth weight; PI, placental malaria infection; MI, maternal malaria infection; Rainfall in the 
left Y-axis is in millimeters; prevalence of outcomes in the right Y-axis.  
A three-month moving average was used to estimate the prevalence of LBW, maternal and placental 
malaria. Malaria transmission is depicted by the average monthly rainfall in the study locations during the 
study period.  
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Extrapolation of the prevalence of placental malaria parasitemia, low birth weight, and 
anaemia to the total population: 
In 2009, an estimated 637,150 births occurred in Mali (Table 2.8). Based on the average 
prevalence of placental malaria of 11.6% (95% confidence interval [CI], 11.5-11.7) observed 
across the 11 surveys in this study, 73,775 (95% CI, 73,274-74,276) births may be affected by 
placental malaria infection every year in Mali. The corresponding figures for primi,- and 
secundigravidae were 36,248/187,397 (19.3%) were affected by placental malaria. Universal 
coverage with 2-dose IPTp-SP among this gravidity group has the potential to reduce 
placental malaria by 52% from 36,248 birth annually under the current coverage (30.4%) to 
20,510 births annually and universal coverage of ITNs alone from 36,277 with 56.1% 
coverage to 32,077 births with universal ITN coverage among primi,- and secundigravidae 
(Table 2.9).  
Among first or second pregnancy, 25,243 of the 187,397 births or 13.5% ended in 
LBW births. Increasing the coverage of 2-dose IPTp-SP from the observed 30.4% to universal 
coverage (100%) has the potential of reducing LBW events among primi,- and secundigravida 
by an additional 21.6% or 5,459 LBW events from 25,243 to 19,784 births in Mali. The 
corresponding figures for universal coverage with ITNs were an additional 10.6% or 2,665 
LBW events prevented from 25,243 to 22,578 births (Table 2.9).  
Overall (in moderate and high malaria endemic areas, except Koulikoro), 213, 235 of 
the 394,843 births or 54.0% ended in anaemia (Table 2.8). This corresponding figure in first or 
second pregnancy was 63,951 of the 116,130 births or 55.1%. For universal coverage of IPTp, 
there is a potential of reducing anaemia among primi,-secundigravida by an additional 4.6% 
or 2,965 anaemia cases from 63,951 to 60,986 births. The corresponding figures for universal 
coverage with ITNs were 2.5% or 1,576 anaemia cases prevented from 63,951 to 62,375 
(Table 2.9). 
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Table 2.8: Births with placental malaria , low birth weight or anaemia in all gravida 
Transmission 
settings 
  /Regions 
Study sites IPTp 
cover 
age, % 
ITN  
cover 
age,% 
Annual 
number of 
births* 
Annual 
estimate of 
PM,  
No (%)** 
Annual  
estimate of 
LBW,  
No (%) ** 
Annual  
estimate of 
anaemia,  
No (%)** 
Low  29.9 41.9 136,169 8,761 (6.4) 17,037 (12.5) - 
  Bamako Banconi & Sabalibougou 42.0 59.8 79,401 1,191 (1.5) 10,265 (12.9) - 
  Timbuktu   Timbuktu /Gao/Kidal  13.1 16.9 56,769 7,570 (13.3) 6,771 (11.9) - 
Moderate  30.8 71.6 191,954 25,930 (13.5) 16,003 (8.3) 112,062 (58.4) 
  Segou San 28.8 80.0 102,537 10,338 (10.1) 7,641(7.5) 65,056 (63.4) 
  Mopti Koro & Sangha‡ 32.4 60.1 68,453 13,367 (19.5) 7,010 (10.2) 35,227 (51.5) 
  Mopti Djenne Djenne 35.4 67.9 20,965 2,225(10.6) 1,352 (6.4) 11,779 (56.2) 
High  30.4 62.2 309,027 39,084 (12.6) 27,985 (9.1) 101,292 (32.8) 
  Kayes Kita 53.0 97.3 87,639 6,212 (7.1) 9,348 (10.7) 36,003 (41.1) 
  Koulikoro Fana† 12.2 61.5 106,138 15,086 (14.2) 12,495 (11.8) - 
  Sikasso Bougouni 29.9 36.0 115,250 17,786 (15.4) 6,141(5.3) 65,290 (56.7) 
Total  30.4 60.7 637,150 73,775 (11.6) 61,025 (9.6) 213,355 (54.0) 
Notes: IPTp, intermittent preventive treatment; ITN, insecticide treated net;  No, number ; PM, placental malaria; LBW, low birth weight;  
* Annual estimate of life and stillbirths ( see flow chart and method section). 
**Point prevalence provided by the different surveys under the reported coverage of IPTp and ITNs.  
†  Haemoglonin level were not assessed during the Koulikoro survey 
‡ Anaemia based on data from  Koro only, no haemoglobin data from survey in Sangha. 
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Table 2.9: Births with placental malaria, low birth weight, and anaemia among first or second pregnancy 
Transmission 
settings  /Regions 
 Annual 
births* 
IPTp 
cover 
age, % 
ITN 
cover 
age, % 
Annual 
estimate of 
PM, No (%)**  
No of 
PM if 
100 % 
IPTp 
No of 
PM if 
100 % 
ITN 
Annual 
estimate of 
LBW, No (%) 
** 
No of 
LBW if 
100 % 
IPTp 
No of 
LBW if 
100 % 
ITN 
Annual 
estimate of 
anaemia, No 
(%)** 
No of 
anaemia 
if 100 
IPTp 
No of 
anaemia 
if 100 %  
ITN 
Low 40,050 27.1 42.2 1,922 (4.8) 1,034 1,612 4,396 (11.0) 3,374 3,731    
  Bamako 23,353 38.5 60.0 602 (2.6) 361 541 2,264 (9.7) 1,810 2,022    
  Timbuktuctou/ 
  Gao/Kidal 
16,697 11.1 17.3 1,320 (7.9) 673 1,071 2,131 (12.8) 1,564 1,709    
Moderate 56,457 30.3 62.6 12,340 (21.9) 7,030 11,127 7,010 (12.4) 5,453 6,298 28,952 (51.3) 27,443 28,227 
  Segou 30,158 29.0 74.8 5,928 (19.7) 3,350 5,535 3,588 (11.9) 2,781 3,337 14,118 (46.8) 13,401 13,894 
  Mopti (Koro) † 20,133 30.9 47.2 5,510 (27.4) 3,151 4,796 3,043 (15.1) 2,373 2,628 10,611 (52.7) 10,015 10,232 
  Mopti (Djenne) 6,166 34.9 53.0 902 (14.6) 529 796 379 (6.1) 299 332 4,223 (68.5) 4,026 4,100 
High 90,890 31.8 58.2 21,985 (24.2) 12,446 19,338 13,838 (15.2) 10,958 12,549 34,999 (38.5) 33,543 34,148 
  Kayes 25,776 55.3 96.6 3,217 (12.5) 2,167 3,186 5,220 (20.3) 4,414 5,167 15,316 (59.4) 14,818 15,283 
  Koulikoro‡ 31,217 12.2 54.9 8,384 (26.9) 4,297 7,438 4,336 (13.9) 3,191 3,821    
  Sikasso 33,897 32.1 32.1 10,384 (30.6) 5,982 8,714 4,283 (12.6) 3,561 3,561 19,683 (58.1) 18,725 18,865 
Total 187,397 30.4 56.1 36,248 (19.3) 20,510 32,077 25,243 (13.5) 19,784 22,578 63,951 (55.1) 60,986 62,375 
Notes: IPTp, intermittent preventive treatment in pregnancy ; ITN, insecticide treated net ; PM, placental malaria; LBW, low birth weight; No, number 
* Annual estimate of life and stillbirths ( see flow chart and method section). 
**Figures in parentheses for each region represent the observed prevalence from surveys. Figures in parentheses under the aggregated data for low, moderate, 
high and total are the annual number of LBW for that strata divided by the annual number of births at risk in that strata x 100. 
† Haemoglonin level were not assessed during the Koulikoro survey. 
‡ Anaemia based on data from Koro only, Haemoglonin level were not assessed during the Sangha survey. 
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2.5 Discussion  
Our results suggested that approximately 11.6% of the 637,150 births that occurred in Mali 
in 2009 may have had placental infection detectable by microscopy, and 9.6% resulted in 
LBW births, 25,243 of which were in primi and secundigravidae. Except in Bamako itself, the 
risk of placental malaria in 9 surveys conducted in other parts of Mali was considerable in 
women not receiving IPTp, ranging from 7.1% in Kayes, to 19.5% in Mopti (Koro & Sangha) 
(Figure 2.3). Placental malaria was associated with a higher risk of LBW (aPR, 1.46; 95% CI, 
1.10-1.94), either due to preterm birth (aPR, 1.29; 95% CI, 0.81-2.05) or SGA (aPR, 1.25; 95% 
CI,  1.09-1.44) or the composite of the three outcomes (aPR 1.27; 95% CI, 1.12-1.45), or 
severe maternal anaemia (aPR, 1.91; 95% CI, 1.48-2.46) (Table 2.6). Interestingly, ITN 
ownership (93%) and use the night before the survey (65%) was among the highest reported 
for sub-Saharan Africa (van Eijk et al., 2013). This was consistent with the coverage reported 
in the recent demographic health survey conducted in 2012 (75.2%) (DHS, 2012-2013) as 
compared with that of 2006 with only 29% (DHS, 2006). However the coverage of 2-dose 
IPTp with SP was only 35%, well below the recent successive Roll Back Malaria (RBM) targets 
of 80% by 2010 and 100% by 2015, and even well below the Abudja target of 60% set in 
2005 (van Eijk et al., 2013). The 2-dose IPTp regimen was strongly associated with lower risks 
of malaria and the composite of LBW or preterm birth when compared to women who did 
not receive any IPTp.  
The relative low uptake of IPTp, suggests significant missed opportunities to further 
reduce the impact of malaria on newborn health. Our model suggested that increasing IPTp 
coverage to the audacious RBM target of universal coverage could result in a further 5,459 
decrease in the number of LBW events among first and second pregnancies, a 22% boost in 
the overall reduction of LBW compared relative to that achieved at the current 35% level of 
coverage. The low uptake however is remarkable as it occurred despite significant financial 
and operational support from UNICEF and Save the Children and in areas where ITN 
distributions have been much more successful. A more recent study in Mali specifically 
designed to identify the main barriers to IPTp uptake showed a high percentage of women 
made at least two ANC visits (75%), with a significant proportion of women initiating ANC 
attendance in their first or second trimester (88%), but poor adherence to policy guidelines 
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of antenatal staff resulting in many missed opportunities to deliver SP during scheduled 
antennal visits in the 2nd and 3rd trimester (Hill, 2013). Furthermore, it is also showed that 
only 0% to 24.5% of women receiving SP received it as directly observed therapy. Both ANC 
attendance patterns among women and factors affecting the delivery of care at ANC 
contribute to the low effectiveness reported and pointing to the need to improve the quality 
of IPTp provision (Webster et al., 2013a) . 
Interestingly, a similar high prevalence of placental infection (13.3 %) among women 
not protected by IPTp was observed in Timbuktu in the north of Mali. The high risk of 
placental malaria was unexpected because the survey had missed the rainy season and was 
conducted during a 3 month period towards the end of the dry season starting 5 months 
after the rains had ceased (Figure 2.6). Furthermore, this is a semi-arid region with an annual 
rainfall averaging ~300 mm per year that until recently had predominately low or even 
epidemic malaria transmission (Doumbo O., 1991). The most likely explanation of this high 
prevalence in the dry season is the recent shift in ecological conditions in northern Mali 
resulting from the introduction of large scale irrigation projects, which have turned parts of 
the Sahara desert into paddy fields for rice farming, sustaining malaria transmission 
throughout the year (Koita et al., 2012). In addition, parasites acquired during the rainy 
season may sequester in the placenta and persist for several months into the dry season, 
especially among women not using IPTp-SP. This is also suggested by the observation from 
some of the other surveys included in this study, such as in Mopti, Sangha (2006-2007) that 
started during the transmission season but continued in the dry season. These finding are 
also consistent with observational cohort studies using weekly follow-up in areas with low 
transmission from the Thai-Burmese border (McGready et al., 2004).  
Ecological analysis showed similar prevalence of LBW across transmission settings 
(Figure 2.3) and no clear association was found  between the risk of LBW among primi,- and 
secundigravida or all gravida and transmission intensity, as measured by the prevalence of 
maternal peripheral malaria among women who did not receive IPTp-SP using meta-analysis 
approach (Figure 2.4 & Figure 2.5). The prevalence of malaria at delivery in all other surveys, 
including in Timbuktu, exceeded 10%, thus the variation in malaria transmission intensity 
may have been too small to allow for a meaningful analysis of the trend between LBW and 
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malaria transmission intensity. Furthermore, LBW is multifactorial (Guyatt and Snow, 2004) 
and other determinants not assessed will have contributed to LBW.  
By contrast to previous studies in Timbuktu or other parts in the North of Mali 
(Doumbo O., 1991, Bernabeu et al., 2012, Koita et al., 2012), we did not find P. vivax malaria. 
This does not exclude the presence of P. vivax, and malaria control strategies should 
probably take the presence of P. vivax into account in this region.  
The study has several limitations that need to be considered. First, although the 
surveys where designed to occur during the peak transmission season some were conducted 
toward the tail end of the transmission season or even in dry season, such as in Timbuktu 
and Koulikoro. Ideally, surveys planned to capture the burden of malaria in pregnancy should 
be designed to capture data throughout the year, especially in areas with highly seasonal 
transmission such as in Mali where the start and duration of the seasons differ by 
geographical region and from year to year. Second, the surveys were conducted across a 
period of five years and the earlier surveys conducted over 8 years ago may no longer reflect 
the current coverage or the prevailing disease burden as recent reports suggest  markedly 
decrease in malaria prevalence in sub-Saharan Africa (O'Meara et al., 2010, Pond, 2013). 
Third, even though all regions were represented and the 9 sites represented the wide range 
of transmission settings in Mali, the study was not designed as a national random cluster 
survey and sites were chosen based on ongoing program activities by the Malaria Research 
and Training Center and may thus not be representative of Mali as a whole and overestimate 
coverage of ITNs and IPTp. Furthermore, some of the traditional agricultural irrigation areas 
were not included, such as Niono, Markala, Macina, Selingue, where malaria transmission is 
bimodal. Fourth, the study was clinic based and thus only included women who had access 
delivery units, where 45% of births in Mali occur at home in the community (DHS, 2012-
2013). Lastly, data captured at delivery does not exclude earlier infections during pregnancy 
that may have been cleared. We also used microscopy for the diagnosis of malaria, which is 
known to be less sensitive to capture infection than PCR and placental histology (Fried et al., 
2012, Singer et al., 2004, Taylor et al., 2010). Thus, the true prevalence of malaria detectable 
at delivery and impact on birth outcome may be considerably higher.  
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2.6 Conclusion 
Despite these limitations, this is the first comprehensive study of the burden of PAM 
throughout Mali and the results suggest that malaria in pregnancy is a major problem 
affecting over 600,000 births annually. Furthermore large scale rice irrigation projects in the 
semi-arid regions in northern Mali places women at risk throughout the year. Prospective 
burden surveys should thus aim to capture data throughout the year, ideally using sensitive 
diagnostic tests to detect malaria infection. The high ownership of ITNs is an important 
achievement; however, major further improvements can be achieved by scaling up the use 
of IPTp with SP to reduce the risk of severe maternal anaemia and birthweight. 
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3 Superiority of three over two doses of intermittent preventive 
treatment with sulfadoxine-pyrimethamine for the prevention of 
malaria during pregnancy in Mali: a randomized controlled trial  
3.1 Introduction and background 
Intermittent preventive therapy in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) is 
effective in reducing the risk of placental malaria, low birth weight (LBW) and severe 
maternal anaemia (Ter Kuile et al., 2007, WHO/AFRO, 2004) and together with insecticide 
treated nets, the main strategy for the control of malaria in pregnancy in Africa (WHO/AFRO, 
2004). IPTp consists of the administration of full curative doses of an efficacious antimalarial 
drug given presumptively in the 2nd and 3rd trimester at least one month apart. It provides 
intermittent clearance or suppression of existing asymptomatic infections from the placenta 
(‘treatment effect’) and ‘post-treatment’ prophylaxis by preventing new infections through 
the maintenance of suppressive drug-level for up to 6 weeks in areas with low parasite 
resistance (White, 2005, WHO/AFRO, 2004).  
Presently, SP is the only antimalarial recommended for IPTp (WHO, 2013). At the time of 
study, the World Health Organization (WHO) recommended at least 2 curative doses of SP in 
HIV negative women, and 3 doses for HIV-positive women, not protected by cotrimoxazole 
(Ter Kuile et al., 2007, WHO/AFRO, 2004, World Health Organization, 2004, World Health 
Organization, 2006). Although SP resistance has increased to high levels in some areas of 
southern and eastern Africa, resistance in most of western Africa is still low. Furthermore SP 
has now been reserved for use as IPT and the reduced drug pressure may prolong the 
longevity of this very valuable drug in areas with low to moderate resistance (Ter Kuile et al., 
2007, World Health Organization, 2006). IPTp with SP is thus likely to remain the main stay 
of malaria control in pregnancy for several years in these regions.  
In Mali, the two-dose strategy was adopted by the National Malaria Control Program 
(NMCP) in 2003. Mali has highly seasonal malaria transmission, moderate levels of ITNs use 
and low levels of SP resistance (Diallo et al., 2006, Thera et al., 2005). Recent survey from 
2005-2007 involving 1,696 pregnant women of all parities showed that placental infection 
was very common among women who had received the full two-dose regimen of IPTp (23%; 
Kayentao et al., unpublished data), consistent with findings from an earlier trial showing that 
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2 dose IPTp-SP, although much more effective than chloroquine prophylaxis, was associated 
with high risk of placental infections during the transmission season, especially in women 
who completed the second dose of IPTp-SP early in the third trimester (Kayentao et al., 
2005). This suggests that two doses may provide insufficient protection against reinfections 
later in the third trimester, a period of rapid in-utero growth.  
Three trials have shown that additional doses of SP add significant benefit over the two dose 
regimen among HIV-infected primi,- and secundigravidae (Ter Kuile et al., 2007). In HIV-
negative women, the beneficial effect of 3 or more doses is less clear. We conducted an 
open-label, individually randomized controlled trial comparing the efficacy and safety of the 
2-dose regimen of IPTp-SP with three doses of SP in the prevention of placental malaria, 
maternal anaemia and low birth weight in Mali.  
3.2 Methods 
This was an open-label, individually randomized, controlled trial comparing the efficacy and 
safety of the  2-dose regimen of IPTp-SP with three doses of SP in the prevention of placental 
malaria, maternal anaemia and low birth weight in Mali. The study was conducted from April 
2006 to March 2008 in two health facilities in Bla District, located 320 kilometers east of 
Bamako in Ségou Region, Mali, an area with highly seasonal malaria transmission. The two 
health facilities serve a population of approximately 39,000. Women of all gravidity 
scheduled to receive their first dose of IPTp-SP were eligible if they were aged 14-45 years, 
were between 16-26 weeks gestation (by fundal height) and had no history of antimalarial or 
cotrimoxazole use in the previous month. Women with a serious illness requiring admission, 
with severe anaemia (Hb<7 g/dL), with known HIV infection, or who were planning to deliver 
elsewhere were excluded.  
3.2.1 Randomization, masking and treatment allocation 
Women were randomly assigned to one of the two study groups by the study clinicians.  
Allocation concealment was achieved by keeping 20 allocation slips with pre-assigned study 
allocations (10 per arm) into opaque containers. Sequential participants were asked to draw 
one allocation slip from the container without possibility of replacement. The randomization 
sequence was stratified by clinic and used permuted balanced block randomization (block-
size of 20). Study drugs were provided by the study clinicians. All nurses, midwifes in the 
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delivery units, and all laboratory staff were unaware of the treatment allocation during the 
trial.  
3.2.2 Endpoints  
The primary endpoint was placental malaria infection (asexual stage parasites, any species). 
Secondary efficacy endpoints included maternal malaria determined by peripheral smear; 
mean haemoglobin, maternal anaemia (Hb <11 g/dL) and moderate-to-severe anaemia 
(Hb<8.0 g/dL); mean birthweight and low birth weight (<2500 g); mean gestational age and 
preterm delivery (gestational age <37 weeks); and low placental weight (<500 g). Safety 
endpoints included severe maternal skin reactions (e.g. Stevens-Johnson syndrome and toxic 
epidermal necrolysis), congenital malformations assessed at birth and 30 days, and neonatal 
icterus and vomiting by day 7 and day 30 of life.  
3.2.3 Procedures 
A questionnaire was administered at enrolment to collect information on socio-
demographic characteristics, maternal height, bed net use, obstetric and clinical histories, 
and drug use during the pregnancy. A blood sample was obtained by fingerpick for malaria 
smears, and haemoglobin concentrations (Hemocue® 201; Anglholm, Sweden).  
Women were asked to return to the clinic for monthly follow-up or in-between for any 
unscheduled sick-visits. If women did not return for their scheduled visit they were visited at 
home. During each visit, women were asked about signs and symptoms and examined for 
skin rashes. If a woman had documented fever (T>=37.5 oC), the axillary temperature was 
measured and a malaria blood smear taken.  
Within 2 hours after delivery a finger prick sample was taken for haemoglobin 
concentration and malaria parasitemia. Placental blood was collected by incision from the 
maternal side of the placenta for malaria blood smears. The newborns were examined by 
the study physicians for congenital malformations, and the gestational age was assessed 
using the Ballard score. Infants were weighed using a digital scale. Mothers and neonates 
were visited at home by the study staff a week and a month after delivery to examine the 
newborn. The study was monitored monthly by independent internal clinical monitors on 
behalf of the Malaria Research and Training Centre in Bamako. 
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3.2.4 Interventions 
Each treatment dose consisted of 1,500 mg of sulfadoxine and 75 mg of pyrimethamine 
(total of 3 tablets). Women in the 3-dose group received the first dose between 16-24 weeks 
gestation, the second dose between 20-32 weeks, and the third dose no later than the 36 
weeks gestation. Women in the 2-dose group also received the first dose between 16 and 24 
weeks and the second dose between 25 to 36 weeks. Doses were administered at least one 
month apart. All drugs were administered directly by the study physicians and women were 
observed for 30 minutes following dosing. If women vomited within 30 minutes the full 
treatment dose was repeated. Study participants were asked to avoid self-medication of 
antimalarials other than the study medication until completion of follow-up at 6 weeks post-
partum. All women received ferrous sulphate (200 mg containing 60 mg of iron) and folic 
acid (0.4 mg) daily starting two weeks after each SP dosing as recommended by the Malian 
Ministry of Health. If malaria occurred during follow-up visits, oral quinine was given 600 mg 
three times daily over 7 days.  
3.2.5 Laboratory assessment 
Thick blood smears were stained with 4% Giemsa for 20 minutes. Parasite densities were 
determined by counting the number of asexual parasites per 300 WBCs assuming a WBC 
count of 7,500/uL. A smear was determined to be negative if no parasites were identified 
after review of 100 high-power fields. Slides were read by an experienced microscopist 
blinded to the treatment allocation. Quality control was done on ten percent of slides which 
were read by an expert reader blinded to initial results and to treatment allocation.   
3.2.6 Sample size and data analysis 
The study was designed to detect a 7.5% reduction in the prevalence of placental malaria 
from 15% in the 2-dose group. A sample size of 304 women in each treatment arm was 
required (alpha 0.05, power 80%); this was increased to 406 to account for 5% non-
compliance and 20% loss-to-follow-up. 
Data were double entered and validated using Epi-Info (version 6.04b; CDC) and analyses 
conducted using Stata (version 12) and SPSS (version 17). The efficacy analysis was on an 
intention-to-treat basis. The safety analysis for adverse skin reactions was performed on a 
modified intention-to-treat basis and included only women who took at least one dose of 
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study drug. The analysis of safety endpoints measured at or after delivery was done on a 
per-protocol basis. The impact of the treatment on dichotomous endpoints at delivery was 
compared using robust stepwise backwards elimination Poisson regression to obtain 
adjusted prevalence ratios (APR). We also conducted exploratory analyses of potential effect 
modification by season, by gravidity and by ITN use. 
3.3 Ethical approval 
The study was approved by the ethical committee of the Faculty of Medicine, Pharmacy and 
Dentistry of the University of Bamako. Consent procedures were in the local language 
(Bambara). All women participating in the study gave written informed consent after being 
informed about the study and procedures.  
3.4 Results 
3.4.1 Study population characteristics at enrollment  
A total of 814 pregnant women were enrolled from 21 April 2006 to 19 February 2008; 413 
in the 3-dose arm and 401 in the 2-dose arm (Figure 3.1). The baseline characteristics were 
similar across the two treatment arms (Table 3.1). Thirty-one of the 814 women (3.8%) were 
lost before delivery because of travel (6 [0.7%]), consent withdrawal (14[1.7%]), and non-
compliance with the follow-up schedule (11 [1.4%]). The percentage lost-to-follow-up was 
2.6% (11) in the 3-dose arm and 4.9% (20) in the 2-dose arm (P=0.09). The remaining 783 
(96.2%) women were followed successfully until delivery and contributed to the intention-
to-treat analysis; 16 (4.0%) of the 400 women in the 3-dose group did not receive their third 
dose and 3 (0.8%) of 383 in the 2-dose group received only one dose and were excluded 
from the per-protocol analysis (Figure 3.1).  
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Figure 3.1: Trial Profile 
Figure note: Thirty-one of the 814 enrolled women (3.8%) were lost before delivery because of travel 
(6 [0.7%]), consent withdrawal (13[1.6%]), or non-compliance with the follow-up schedule (12 
[1.5%]). The percentage lost-to-follow-up was 3.1% (13) in the 3-dose arm and 4.5% (18) in the 2-
dose arm (P=0.31). The remaining 783 (96.2%) women were followed successfully until delivery and 
contributed to the intention-to-treat analysis; 16 (4.0%) of the 400 women in the 3-dose group did 
not receive their third dose and 3 (0.8%) of 383 in the 2-dose group received only one dose and were 
excluded from the per-protocol analysis. 
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Table 3.1 : Baseline characteristics on enrollment by IPTp group 
    
Characteristics 2-dose SP 
(n=401) 
3-dose SP 
(n=413) 
All women 
(n=814) 
Age in years    
mean (SD) 24.5 (6.1) 24.5 (6.0) 24.5 (6.1) 
Range 14-43 15-45 14-45 
Age<20 years, % 26.2 22.4 24.3 
Height <150 cm, % 2.0 1.5 1.7 
Weight <50 Kgs, % 7.9 6.3 7.1 
Gestational age in weeks    
mean (SD) 21.6 (2.6) 20.8 (2.6) 21.18 (2.6) 
Range  16-26 16-26 16-26 
Married, % 95.3 95.4 95.3 
Gravidity    
Median, range 3 (1-14) 3(1-13) 3(1-14) 
Primi and secundi-gravidae, No. (%) 42.1 41.5 41.8 
Attended ANC this pregnancy prior to 
enrollment, No. (%)  
128 (32.0) 129 (31.2) 257 (31.7) 
Axillary temperature ≥37.5o, %  27.7 22.0 24.8 
Sleep under bed net, No. (%) 226 (56.4) 225 (54.5) 451(55.4) 
Sleep under ITN, No. (%) 72 (18.0) 88 (21.3) 160 (19.8) 
Sleep under ITN last night, No. (%) 59 (14.7) 77 (18.4) 136 (16.7) 
Haemoglobin in g/dL    
mean (SD) 10.1 (1.5) 10.2 (1.5) 10.2 (1.5) 
Moderate anaemia (<11 g/dL), % 72.3 67.3 69.78 
Severe anaemia (<8 g/dL), % 4.2 2.2 3.2 
Positive peripheral malaria smear,  % 25.7 27.6 26.7 
Clinical malaria, % 12.0 9.2 10.6 
Parasite density /uL, geometric mean (95 CI) a 1,128 
(765, 1663) 
1843 
(1351, 2514) 
1,464 
(1145, 1872) 
Notes: Data are no. (%) or enrolled women, unless otherwise indicated. SP, Sulfadoxine-pyrimethamine; SD, 
Standard deviation; ANC, Antenatal Clinic; CI, Confidence Interval.  
Clinical malaria defined as positive peripheral smear in the presence of documented fever (≥37.5 oC) or history of 
fever within the last 24 hours. 
aAmong malaria positive women only 
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3.4.2 Efficacy of regimens  
Overall, 4.8% (20 of 413) and 7.2% (29 of 401) of women in the 3-dose and 2-dose group, 
respectively, had at least 1 episode of clinical malaria (confirmed by microscopic 
examination) and were treated with quinine (APR, 0.79; 95% confidence interval [CI], 0.56–
1.12). At delivery, the prevalence of placental malaria in the 3-dose group was half that in 
the 2-dose group (8.0% vs 16.7%; APR, 0.48; 95% CI, 0.32–0.71) (Table 3.2). Interaction 
models indicated that the beneficial effect was evident in all gravidae groups and in ITN 
users and nonusers (Table 3.2). In the 2-dose group, women enrolled before 24 weeks 
gestation were more likely to have placental malaria than were those enrolled later (APR, 
1.21; 95% CI, 1.06–1.37). This was not apparent in the 3-dose group (APR, 1.07; 95% CI, 
0.88–1.32). The risks of LBW and preterm birth were also halved, but the prevalence of 
moderate and severe anaemia was similar in the 2 treatment arms (Figure 3.2 & Table 3.2). 
The impact on LBW was similar across gravidae groups and ITN users and nonusers, but the 
impact on mean birth weight was greater in primi- and secundigravidae (who experienced an 
increase in mean birth weight of 99 g) than in multigravidae (who experienced an increase of 
50 g) and was greater in non-ITN users (who experienced an increase of 97 g) than in ITN 
users (who experienced a decrease of 27 g) (Table 3.2). The observed differences between 
the 2 treatment arms were greatest during and shortly after the malaria season (Figure 3.3). 
There were no differences between treatment groups with respect to foetal loss (Table 3.2). 
The frequency of single-nucleotide polymorphisms (SNPs) was determined in a small number 
of positive samples at delivery. The frequency of the dhfr/dhps quadruple mutant genotype 
was 85.7% (6 of 7 samples) and 55.6% (5 of 9 samples) in the 2-dose and 3-dose arms, 
respectively, at delivery (P =0 .31), and no quintuple mutation was observed. 
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Table 3.2: Primary and secondary outcomes at delivery IPTp group 
  Number of subject (%)     
Characteristics  2-dose 
SP 
3-dose 
SP 
Unadjusted 
absolute risk 
difference, % 
(95% CI) 
Unadjusted difference 
in mean 
or 
Prevalence Ratio 
(95% CI) 
Adjusted 
difference in mean 
or 
Prevalence Ratio 
(95% CI) 
aP-value 
Primary outcome        
Placental blood smear   
   No. positive (%)  
All gravidae 64/383 
(16.7) 
32/398 (8.0) 8.7  
(4.2, 13.3) 
0.48 
(0.32, 0.72) 
0.48 b 
(0.32, 0.71) 
<0.001 
       By gravidae group Primi-secundi 32/159 (20.1) 16/165 (9.7) 10.4 (2.7, 18.1) 0.48 (0.28, 0.84) 0.47 b, c (0.27, 0.82) 0.007 
           Multigravidae 32/284 (14.3) 16/233 (6.8) 7.4 (1.8, 13.0) 0.48 (0.27,0.85) 0.48 b, c (0.27, 0.85) 0.012 
       By ITN use ITN-user 14/72 (19.4) 5/85 (5.9) 13.6 (3.1, 24.0) 0.30 (0.11, 0.80) 0.30 b, d (0.12, 0.80) 0.016   
 Non ITN-user 50/311 (16.1) 27/313 (8.6) 7.5 (2.3, 12.6) 0.53 (0.36,0.83) 0.53 b, d (0.34, 0.82) 0.005 
Secondary outcome        
Positive peripheral smear   
    No. positive (%) 
All gravidae 77/383 
(20.1) 
43/400 
(10.8) 
9.4 (4.3, 14.4) 0.53 (0.37, 0.75) 0.54 b (0.38, 0.77) 0.001 
Haemoglobin 
concentration 
All gravidae       
   Mean (SD), g /dL  10.9 (1.5) 11.1 (1.5)  0.14 (-0.08, 0.35) 0.02 e (-.01, 0.1) 0.260 
   Hb<11 g/dL,  No. (%) All gravidae 188/383 (49.1) 172/400 
(43.0) 
6.1 (-0.8, 13.1) 0.88 (0.75, 1.01) 0.89 e(0.76, 1.04) 0.144 
   Hb<8 g/dL, No. (%)  All gravidae 8/383 (2.1) 13/400 (3.3) -1.2 (-7.5, 1.6 %) 1.7 (0.7, 4.1) 1.8 e(0.8, 4.1) 0.172 
Birth weightf         
        
   LBW, No. (%) All gravidae 48/360 (13.3) 25/378 (6.6) 6.7 (2.4, 11.0) 0.49 (0.31, 0.78) 0.50 f (0.32, 0.79 0.003 
       By gravidae group Primi-secundi 32/151 (21.2) 15/151 (9.9) 11.3 (3.2, 19.3) 0.47  (0.24, 0.83) 0.46 c, f (0.26, 0.82) 0.008 
           Multigravidae 16/209 (7.7) 10/227 (4.4) 3.3 (-1.2, 7.7)  0.57 (0.26, 1.24) 0.57 c, f (0.27, 1.23) 0.152 
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       By ITN use ITN-user 8/68 (11.8) 5/80 (6.3) 5.5 (-3.8, 14.8) 0.53 (0.18, 1.55) 0.53 d, f (0.19,1.46) 0.219 
 Non ITN-user 40/292 (13.7) 20/298 (6.7) 6.9 (2.1, 11.8) 0.48 (0.29, 0.82) 0.50 d,f (0.30, 0.82) 0.006 
   Mean  (SD), grams  2892 (464) 2964(428)  72.3 (7.8, 136.8) 70.37f(8.53, 132.2) 0.026 
       By gravidae group Primi-secundi 2762 (427) 2853 (457)  91.1 (-9.2, 191.3) 98.50 c, f(1.15, 195.9) 0.047   
           Multigravidae 2986 (468) 3038 (292)  52.4 (-28.7, 133.5) 49.9 c, f (-30.8, 130.6) 0.219 
       By ITN use ITN-user 2937 (515) 2911 (331)  -26.1 (-112.7, 164.9) -27.9 d,f (-164.3, 108.5 0.686 
 Non ITN-user 2882 (452) 2979 (450)  97.1 (24.1, 170.1) 89.6 d,f (19.2, 159.9) 0.013 
Gestational age All gravidae       
   Preterm, No. (%)  32/359 (8.9) 12/376 (3.2) 5.5 (2.3, 9.2) 0.35 (0.18, 0.68) 0.37 f (0.19, 0.71) 0.003 
   Mean (SD), weeks All gravidae 38.6 (1.6) 38.8 (1.5)  0.2 (-0.03, 0.4) 0.1 f (-0.03, 0.4) 0.101 
Placental weightf        
      Placental weight <500 g, 
       No. (%) 
All gravidae 113/359(31.5) 90/375 
(24.0) 
7.5 (1.01, 13.4) 0.76 (0.60, 0.97) 0.76 f (0.60, 0.97) 0.024 
      Mean (SD), grams All gravidae 530 (114) 535 (316)  -4.5 (-28.6, 37.6) 4.86 f (-38.0, 28.3) 0.774 
Pregnancy lossg , No. (%) All gravidae 16/383 (4.2) 20/400 (5.0) -0.8 (-3.7, 2.1) 1.2 (0.6, 2.3) 1.12 g (0.59, 2.12) 0.723 
Perinatal deathsh,  No. (%) All gravidae 8/383 (2.71) 10/400 (2.5) -0.4 (-2.5, 1.7) 0.84 (0.20, 2.40) 0.78 h (0.12, 2.16) 0.342 
Neonatal deaths, No. (%) All gravidae 6/360 (1.7) 6/376 (1.6) 0.1 (-1.7, 1.9) 0.95 (0.31, 2.9) 0.88 h (0.29, 2.63) 0.817 
Notes:  ANC, antenatal clinic; CI, confidence interval; ITN, insecticide treated net; LBW, low birth weight; SD, standard deviation. 
a  Bivariate endpoints: Poisson regression with robust variance, continuous endpoints: multiple linear regression 
b djusted for gravidity (where applicable), season of delivery, age, malaria at enrolment 
c P value for difference of treatment effect by gravidity strata (interaction term): placental malaria, 0.96; LBW, 0.68; mean birth weight, 0.52. 
d P value for difference of treatment effect by ITN use (interaction term): placental malaria, 0.32; LBW, 0.79; mean birth weight, 0.15. 
eAdjusted for gravidity, season of delivery and  haemoglobin at enrolment 
f adjusted for gravidity, season of delivery and maternal weight at enrolment 
g  Spontaneous abortion or stillbirth (adjusted for gravidity and season) 
h Pregnancy loss or early neonatal death in the first week of life (adjusted for gravidity and season) 
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 Figure 3.2 : Treatment effect on low birth weight and preterm delivery.  
Note: LBW, low birth weight (<2500 g); NBW, normal birth weight (>=2500 g); preterm delivery, 
<37 weeks gestation; term delivery, >=37 weeks gestation. 
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Figure 3.3: The treatment effect of 3,-versus 2-dose IPTp on placental malaria (upper graph) and LBW 
(lower graph) by malaria transmission season 
Figure note: Three-month moving averages of the prevalence ratios (PR) obtained from Poisson regression 
models adjusted for gravidity and baseline parasitemia (placental malaria) and maternal weight (LBW). The 
error bars represent the 95 confidence intervals. The top horizontal line (
 __ .. __
) depicts a prevalence ratio 
of 1 indicating ‘no difference’ between treatment groups. Point estimates below this line indicate a 
beneficial effect in favor of the 3-dose group. The effect is statistically significant if the upper error bar 
does not cross the PR value of 1. The lower horizontal line (
_ _ _ 
) at PR values of 0.48 and 0.50 indicates the 
average adjusted prevalence ratio observed over the duration of the study. Data reflects the average 
estimates per month of the 2 year period of the study. Malaria transmission is depicted by the average 
monthly rainfall in the two study locations during the study period. Significant beneficial treatment effect 
on placental malaria was observed during the 7 month period starting in June, i.e. one month after the first 
rainfall and ending one month into the dry season (December) (APR  0.43, 95% CI 0.27-0.69, P=0.001). A 
smaller non-significant reduction was observed in the dry season from January to May (APR 0.68, 95% CI 
0.33-1.40, P=0.29) (P-value interaction term 0.33). The corresponding values for LBW were: APR 0.37, 95% 
CI 0.20-0.68, P = 0.001 and APR 0.81, 95% CI 0.39-1.68, P=0.58) (P-value interaction term 0.035). 
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3.4.3 Adverse events in mothers, neonates and infants 
No severe skin rashes were observed during the study. One mother died from post-
partum hemorrhage in the two-dose group. There were 4 (0.6%) congenital 
abnormalities detected (3 poly-dactily and 1 club-foot)  at the time of birth: 3 in the 2-
dose group and 1 in the 3-dose group. There were no differences in the prevalence of 
jaundice, history of fever or history of vomiting in the neonates at day 7 or day 30 (Table 
3. 3).  
 
Table 3.3: Adverse events among newborns by study group 
                                                       Proportion (%) of newborns  
 2 -dose SP 
 
3-dose SP 
 
Absolute risk 
difference (95% CI) 
Prevalence 
Ratio 
(95%CI) 
 
Adverse events n/N (%) n/N (%)   P-value 
Icterus       
           Day 7,   9/365 (2.5) 10/375 (2.7) -0.2%(-2.4, 2.1) 1.1(0.4, 2.6) 0.9 
           Day 30 0 0    
Congenital birth 
abnormalities 
 
3/359) a 
 
1/362 b 
   
Fever           Day7 
                    Day 30 
10/365 (2.7) 
9/361(2.5) 
17/375 (4.5) 
11/375(2.9) 
-1.8%(-4.4, 0.8) 
-0.4%(-2.7, 1.9) 
1.6(0.76, 3.6) 
1.2(0.49, 2.8) 
0.19 
0.71 
Vomiting     Day 7 
                    Day30 
7/365 (1.9) 
5/361 (1.4) 
7/375 (1.9) 
9/375 (2.4) 
0%(-1.2, 2) 
-1%(-2.9, 0.9) 
1.0 (0.36, 
2.9) 
1.7(0.6, 5.1) 
0.95 
0.32 
a Poly-dactily; bclub-foot 
Notes: CI, confidence interval; data are percentage, unless otherwise indicated. 
P-values presented here compared percentage of adverse events between treatment arms on day 0 and day 
30 separately.  
Chapter 3 
 
77 
 
3.5 Discussion and conclusion 
Three doses of IPTp with SP was considerably more effective in reducing maternal and 
placental malaria, low birth weight and premature delivery than the 2-dose regimen in 
this area with low SP resistance and highly seasonal malaria. The extra dose of SP was 
well tolerated. Size at birth and prematurity are important risk factors for infant 
morbidity and mortality, and both are associated with permanent deficits in childhood 
growth and neuro-cognitive development and performance in later life 
(Medicine/National and Sciences, 1990, WHO, 1995, Teberg et al., 1988, McCormick, 
1985, Williams et al., 1982). Our findings thus have important public health implications. 
The reduction in placental malaria is not surprising, because the 3-dose group received 
their last dose, on average, 1 month closer to term, clearing existing infections and 
reducing the susceptibility to new infections at term by providing an extra period of post-
treatment prophylaxis of 4–6 weeks. The latter half of the third trimester is a period of 
considerable foetal growth, when at least 25% of the total foetal weight gain occurs in 
healthy pregnancies. 
This explains the large impact of the third dose on birth weight, despite the fact that the 
control group had received the 2-dose regimen, which itself was highly effective in a 
previous trial in Mali (Kayentao et al., 2005). The observed difference in mean birth 
weight of 66 g is comparable to that reported in meta-analyses of previous trials of ITNs 
(55 g) and of 2-dose IPTp (79 g) (Gamble et al., 2007, Ter Kuile et al., 2007). Our data add 
to the growing body of evidence showing that more than 2 doses of SP are required to 
provide adequate protection to pregnant women through the third trimester. This is the 
first trial that compares the 2-dose regimen with more frequent dosing schedules in 
western Africa. However, in eastern and southern Africa, there have been 4 previous 
trials comparing 2-dose IPTp-SP with more-frequent dosing, conducted over a 15-year 
period in areas representing a wide range of SP resistance; 4 of these involved HIV-
infected women (who were not taking cotrimoxazole) (Filler et al., 2006, Hamer et al., 
2007, Luntamo et al., 2010, Parise et al., 1998) and 3 of which involved HIV-negative 
women (Filler et al., 2006, Luntamo et al., 2010, Parise et al., 1998), 2 of which studies 
restricted recruitment to primi- and secundigravidae only (Filler et al., 2006, Parise et al., 
1998). We pooled the results from our study with those of the 2 other trials involving HIV 
negative women that reported results for primi- and secundigravidae separate from the 
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multigravidae in a meta-analysis. These data show remarkably consistent findings across 
the studies, with no evidence of heterogeneity (I2=50% for the effect on mean birth 
weight and 20% for LBW) (Kayentao et al., 2011). The other 3 trials all showed that a 
positive impact on mean birth weight was associated with more-frequent dosing, with 
increases in mean birth weight ranging from 57 g to 80 g, compared with 91 g among 
primi and secundigravidae in our current study (summary estimate across the 3 trials, 80 
g; 95% 15–145 g; P = 0.02). The summary estimate for LBW gives an APR (95% CI) of 0.64 
(0.43–0.95) (P =0.03), including the 0.47 estimate among the primi- and secundigravidae 
in our current trial. Thus, it is unlikely that the large beneficial impact observed in our 
study is a chance finding. The evidence from the other trials conducted in eastern and 
southern Africa (Filler et al., 2006, Luntamo et al., 2010, Parise et al., 1998) suggests that 
the benefits of more-frequent dosing may also apply in areas with higher, albeit 
moderate, levels of SP resistance. With increasing drug resistance, the minimum 
inhibitory concentration at which parasite growth is inhibited increases, and the time 
window for effective drug concentrations that fall below these levels decreases. This 
results in a progressive shortening of the duration of the suppressive prophylactic effect 
after treatment (White, 2005). Parasites with triple DHFR mutations have a 1000-fold 
reduction in susceptibility to pyrimethamine, which translates into a reduction in the 
duration of post-treatment prophylaxis of 1 month, compromising the efficacy of the 2-
dose regimen and requiring more-frequent dosing (Ter Kuile et al., 2007, White, 2005). 
This study was conducted in an area with low SP resistance and in the same region as our 
ongoing studies of malaria in pregnancy. In this area, the prevalence of dhfr/dhps 
quadruple mutant genotype among asymptomatic parasitemic pregnant women 
attending the clinic for antenatal care was only 28% prior to 2009. At this level of 
molecular resistance, the in vivo response to SP is excellent; weekly follow-up showed 
that only 3.2% of 268 women were parasitemic again by day 42 (Coulibaly et al., 2014) . It 
is likely that repeated dosing with SP as part of IPTp in women may select for a 
subpopulation of clones and strains with a less sensitive phenotype. Although the 
number of successfully genotyped samples from parasitemic women in the current study 
was small (16 samples), there was no suggestion that adding the third dose increased the 
level of selection. The previous trials comparing IPTp versus placebo or case management 
found that women protected by ITNs did not benefit from IPTp to the same degree as 
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women not using ITNs (Mbaye et al., 2006b, Menendez et al., 2008, Menendez et al., 
2007).  
In the current study, there was no conclusive indication that ITN use modified the effect 
of IPTp; the 15% of women who used ITNs benefited equally from the third dose, 
compared with women who were not protected by ITNs in terms of reductions in malaria 
and LBW. However, the third dose appeared to be more effective in increasing mean 
birth weight in the non-ITN users than in the ITN users (P for difference in treatment 
effect between ITN users and nonusers, .12). Similarly, previous trials have shown IPTp-
SP (and other interventions, such as ITNs) to be more effective in first pregnancies 
(Gamble et al., 2007, Mbaye et al., 2006b, Ter Kuile et al., 2007), yet in this setting, with 
highly seasonal transmission, gravidity was not found to be a significant effect modifier, 
and similar reductions in placenta malaria and LBW were observed in the first 2 
pregnancies, compared with multigravidae, although the greatest effect on mean birth 
weight was observed in the first 2 pregnancies. In contrast to the large impact on LBW 
and preterm delivery (Figure 3.2), the impact on anaemia (haemoglobin level <11 g/dL) 
was modest and non-significant (APR, 0.89; P =0.14); however, the point estimate is 
consistent with the summary estimate from the previous trials of 2-dose IPTp and ITNs, 
which also found an  average risk reduction of 10% (Gamble et al., 2007, Ter Kuile et al., 
2007).  
Our study is limited by the lack of use of a placebo and provision of study drugs by 
clinicians hired by the study. The study was partially masked, in that none of the 
laboratory staff or delivery unit staff were aware of the study assignment, but the lack of 
use of a placebo makes any study more vulnerable to bias. Both groups otherwise 
received the same antenatal care, and there was no difference in the number of 
scheduled visits between the arms. The policy implications of this study imply that more 
frequent dosing would now be appropriate for the control of malaria in pregnancy and its 
sequellae in areas with low SP resistance in western Africa. Despite the support from 
many initiatives in sub-Saharan Africa, coverage with 2 doses of SP remains very low, and 
many women attending ANC receive a single dose of SP only (Van Eijk et al., 2011). The 
experience has been that single-dosing is a common result of unsuccessfully trying to 
implement a 2-dose regimen; extending to 3 doses of IPTp-SP may thus be more effective 
in an operational context, because it counters the risk under dosing mothers (Gill et al., 
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2007). The other benefit of more-frequent dosing is this allows for a better integration 
with existing services as part of focused antenatal care, which consists of 4 scheduled 
visits, including 3 in the second and third trimester. 
These results suggest that malaria in the last few weeks of pregnancy is a major 
cause of LBW and that the addition of a third dose of SP to the 2-dose IPTp regimen used 
in most countries in western Africa may have a substantial beneficial impact on public 
health in the Sahel countries in sub- Saharan Africa, most of which currently have low 
levels of SP resistance. 
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4 Intermittent preventive therapy for malaria during pregnancy 
using 2 vs 3 or more doses of sulfadoxine-pyrimethamine and 
risk of low birth weight in Africa: systematic review and meta-
analysis  
4.1 Introduction and background 
In areas of stable malaria transmission in sub-Saharan Africa, Plasmodium falciparum 
infection in pregnant women is associated with maternal anaemia and low birth weight 
(LBW) (<2500 g) (Desai et al., 2007, Steketee et al., 2001, World Health Organization, 
2004), especially among primigravida and secundigravida and human immunodeficiency 
virus (HIV)–infected women (Desai et al., 2007). The World Health Organization (WHO) 
recommended intermittent preventive therapy during pregnancy, consisting of at least 2 
full treatment doses of sulfadoxine-pyrimethamine for HIV-negative women and at least 
3 doses for HIV-positive women not receiving cotrimoxazole, administered presumptively 
in the second and third trimesters at least 1 month apart (WHO/AFRO, 2004, World 
Health Organization, 2006). Each dose suppresses or clears any existing asymptomatic 
infections from the placenta and provides up to 6 weeks of post-treatment prophylaxis 
(White, 2005, WHO/AFRO, 2004). Although the 2-dose regimen provides at most 12 
weeks of prophylaxis (Ter Kuile et al., 2007, White, 2005), it has been shown to be 
effective in reducing LBW (Diakite et al., 2011, Kayentao et al., 2005, Mbaye et al., 2006b, 
Njagi et al., 2003, Parise et al., 1998, Shulman, 1999, Ter Kuile et al., 2007) and was 
adopted by 31 of 37 endemic countries in Africa with a policy for intermittent preventive 
therapy during pregnancy; the remaining countries use a 3-dose or monthly regimen 
(Van Eijk et al., 2011). Nevertheless, reinfections are common with the 2-dose regimen, 
especially among women who complete their last dose early in the third trimester 
(Diakite et al., 2011, Kayentao et al., 2005). A previous meta-analysis of 3 trials confirmed 
that additional doses of sulfadoxine-pyrimethamine may add benefit over 2 doses among 
HIV-infected primigravida plus secundigravida (G1-G2 women), but there was insufficient 
evidence on HIV-negative women or intermittent preventive therapy during pregnancy 
when used in combination with insecticide-treated nets (Ter Kuile et al., 2007). 
Furthermore, increasing sulfadoxine-pyrimethamine resistance, which results in a 
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progressive decrease of the duration of the prophylactic effect (White, 2005), may also 
require more frequent dosing (Ter Kuile et al., 2007).  
The objective of this analysis was to evaluate whether 3 or more doses of 
intermittent preventive therapy during pregnancy with sulfadoxine-pyrimethamine are 
associated with higher birth weight or a lower risk of LBW than the  2-dose regimen and 
to examine whether this is moderated by sulfadoxine-pyrimethamine resistance, HIV 
status, gravidity, or use of insecticide-treated nets. 
4.2 Methods 
4.2.1 Eligibility criteria 
Study inclusion criteria, outcomes, and methods for the analysis were prespecified in the 
protocol. Studies had to be quasi-randomized or randomized controlled trials conducted 
with pregnant women living in sub-Saharan Africa, which compared the 2-dose regimen 
with sulfadoxine-pyrimethamine with a regimen of intermittent preventive therapy 
during pregnancy consisting of 3 doses or monthly dosing. Studies or study groups that 
combined sulfadoxine-pyrimethamine with other antimalarial drugs, such as artemisinin 
derivatives or azithromycin, or other interventions, such as screening for malaria, were 
excluded. Use of mosquito nets was not an exclusion criterion. Trial inclusion was 
unrestricted by gravida group, HIV status, and type of outcomes reported. 
4.2.2 Study selection 
Studies were identified by searching PubMed, SCOPUS, ISI Web of Knowledge, EMBASE, 
LILACS, Cochrane CENTRAL, the Malaria in Pregnancy Library (van Eijk et al., 2012), 
WHO's International Clinical Trials Registry Platform, and the Cochrane Central Register 
of Controlled Trials from their inception to December 11, 2012, without language 
restrictions; scanning reference lists of articles; and consultation with experts in the field 
(see search criteria and PubMed Search string bellow and (Figure 4.1) .  
For trial selection, 2 authors (K.K. and A.M.v.E.) independently screened and assessed 
trials for eligibility and final inclusion in the analysis in a standardized manner. 
Disagreement between reviewers was resolved through consensus after discussion and 
consultation with the senior author (F.O.t.K.). 
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Search Criteria 
We searched PubMed, SCOPUS, ISI web for knowledge, Cochrane CENTRAL, and the 
Malaria in Pregnancy Library (van Eijk et al., 2012), and WHO’s International Clinical 
Trials Registry Platform and the Cochrane Central Register of Controlled Trials 
PubMed Search String 
The search terms were ‘(Malaria AND pregnan* AND intermittent AND (prevent* OR 
prophyla* OR presumpt* OR chemoprevent* OR chemoprophyla* OR IPT*) AND 
(sulfadoxine OR sulphadoxine OR pyrimethamine OR SP)’ with the results unrestricted by 
language, publication date or publication status. 
PubMed Search String 
PubMed Mesh 
String 
Search name  
1 Malaria Malaria 
2 Pregnancy Pregnan* 
3 Intermittent Intermittent 
4 Preventions or preventive Prevent* 
5 Prophylaxix Prophyla* 
6 Presumptive Presumpt* 
7 Chemo preventive Chemoprevent* 
8 Chemoprophylaxis Chemoprophylaxis* 
9 IPT IPT* 
10 Sulfadoxine Sulfadoxine 
11 Sulphadoxine Sulphadoxine 
12 Pyrimethamine Pyrimethamine 
13 SP SP 
14 1 &2  
15 14 & 3  
16 4 or 5 or 6 or 7 or 8 or 9  
17 15 & 16  
18 10 or 11 or 12 or 13  
19 18 or 18  
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Figure 4.1: PRISMA flow diagram 
Notes: Abbreviations: WHO, World Health Organization; n, number; IPTp, Intermittent preventive treatment;                                  
SP, sulfadoxine‐ pyrimethamine; vs, versus. Qualitative studies included studies using focus group discussions or 
in‐depth interviews,     coverage surveys included surveys of IPTp uptake in the community. 
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38 Records identified through trial 
registries and other sources 
 25 Malaria in Pregnancy 
Library trial registry(Malaria in 
Pregnancy Consortium, 2012) 
 12 WHO International Clinical 
Trials Registry Platform 
 1 Personal communication 
 
 
 
Records after duplicates removed 
(n=241) 
188 Records excluded 
 167 Treatment studies 
 12 Pharmacokinetics & 
Ongoing studies  
 9 Case control studies 
44 Full-text articles excluded 
 19 Two-dose IPT-SPvs.other 
drugs or  combined with other 
drugs 
 9 Cross sectional studies 
 8 Two-dose IPTp-SP vs. other 
strategies 
 4 Review articles 
 4 Qualitative studies or 
coverage surveys 
 
Studies included in 
quantitative synthesis 
(meta-analysis) 
(n=7) 
2 Studies excluded  
 1 IPTp  not given 
presumptively because all 
women scheduled to receive 
IPTp with SP were also 
screened for malaria at each 
visit and treated with quinine 
if positive(Agomo et al., 2011) 
1 observational study with 2 
arms; comparing 3 vs 0 doses (not 
a trial) (Aziken et al., 2011) 
In
cl
u
d
ed
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4.2.3 Data collection and analysis 
Data extraction was conducted independently by 2 unblinded investigators (K.K. and 
A.M.v.E.) using pretested standardized data extraction forms. Authors of primary studies 
were contacted for missing information or if reported data did not fit the required 
format. For each study, the following information was extracted: first author, publication 
year, year of study start and end, study design, randomization procedures, inclusion 
criteria (eg, any restrictions by gravidity, age, or HIV status), insecticide-treated net or 
bed net use, folate supplementation and dosage, local malaria transmission, details of 
study groups, number of women enrolled, and outcomes assessed, including adverse 
events overall and stratified by subgroup. The Cochrane Collaboration's tool for assessing 
the risk of bias (Higgins et al., 2011) was used to determine the quality of included trials 
as low (high risk of bias), high (low risk of bias), or unclear. Uncertainties were resolved 
by consensus and by contacting the corresponding authors (Collaboration., 2008). 
Time and location-matched data on molecular resistance to sulfadoxine-pyrimethamine 
were obtained from published articles, as described previously (Naidoo and Roper, 2011), 
and through correspondence with the authors of the trials. The prevalence of the K540E 
mutation in the dihydropteroate synthase (DHPS) gene was used as a proxy for the 
prevalence of the combined dihydrofolate reductase DHFR (N51I, C59R, and S108N) 
/DHPS (A437G, K540E) quintuple genotype that is strongly associated with treatment 
failure of sulfadoxine-pyrimethamine (Picot et al., 2009). 
4.2.4 Synthesis  
The primary outcome measures were LBW and mean birth weight. Secondary outcomes 
included maternal haemoglobin level, maternal anaemia (haemoglobin level <11 g/dL) 
and moderate to severe anaemia (defined by the individual trials as haemoglobin level 
<6, 7, or 8 g/dL) at term or delivery, maternal malaria infection (peripheral blood) at 
delivery, placental malaria infection (all species), preterm delivery (<37 weeks' gestation), 
spontaneous miscarriage, stillbirth, and neonatal death (death within 0-27 days in live-
born infants). All analyses were stratified a priori by HIV status and gravidity status (G1-
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G2 vs ≥G3 pregnancies [multigravida]), with the aim to provide independent subgroup 
estimates and overall estimates of the pooled data. 
We used both random-effects (primary method) and fixed-effects models to calculate 
the summary relative risks (RRs) for dichotomous outcomes (Mantel-Haenszel) or 
differences in means for continuous outcomes (inverse variance) and we prespecified 
that any heterogeneity would be investigated by subgroup analysis. To provide estimates 
of absolute risk and effect, values for the assumed control-group risk in 2-dose recipients 
and the corresponding intervention-group risk and 95% CI in ≥3-dose recipients were 
computed as assumed control-group risk = median risk (expressed per 1000 women) 
across the included trials in the 2-dose group; corresponding intervention-group 
risk = assumed control-group risk × RR (95% CI), where the RR was taken from random-
effects models (Schunemann, 2008). The absolute risk reduction was calculated as the 
assumed control-group risk × (1 − RR) and expressed per 1000 women. Similar methods 
were used with the lower and upper CI of the RR to obtain the 95% CI of the absolute risk 
reduction. The number needed to treat (NNT) for LBW (the primary end point) was 
computed as NNT = 1/(assumed control-group risk × [1 − RR]) (Schunemann, 2008). For 
the continuous end points, the observed median birth weight or haemoglobin 
concentration in the 2-dose group was reported as the assumed control-group median. 
The corresponding value in ≥3-dose recipients was expressed as the corresponding 
intervention-group median and 95% CI, which were computed as the assumed control-
group median + mean difference (95% CI). 
Heterogeneity was quantified with the I2 statistic and χ2 test (Higgins et al., 2003). The 
Deeks and Higgens method was used to test for heterogeneity between the different 
summary estimates across subgroups (Deeks, 2010, Holmes et al., 2011) . Publication and 
small-study bias was assessed by visual inspection of funnel plots and the Harbord test. 
To evaluate the change in pooled summary estimates for the RR with addition of new 
evidence, we created cumulative meta-analysis plots (Holmes et al., 2011). Prespecified 
sensitivity analysis for the primary outcomes was performed by excluding all studies that 
were scored as low quality for allocation concealment or other sources of bias (Higgins et 
al., 2011). Further sensitivity analysis was conducted to test the effect of each study on 
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the pooled estimates and heterogeneity by removing one study at a time from the meta-
analysis. We used P < .05 to indicate statistical significance (2-sided tests). Data were 
analyzed with Review Manager version 5.2, GradePro version 3.6, and Stata version 12. 
4.3 Results 
4.3.1 Studies and outcomes   
A total of 241 studies were screened, and 7 trials including a total of 6281 pregnancies 
were included (Figure 4.1), (Diakite et al., 2011, Filler et al., 2006, Luntamo et al., 2010, 
Luntamo et al., 2012, MaArthur, 2005, Parise et al., 1998, Valea et al., 2010) one of which 
was unpublished (MacArthur and Abdulla, 2005) (Table 4. 1). Authors of all primary 
studies provided further unpublished information where available. Five trials compared 
monthly sulfadoxine-pyrimethamine against the 2-dose regimen and the remaining 2 
compared 3- vs 2-dose intermittent preventive therapy during pregnancy with 
sulfadoxine-pyrimethamine (Diakite et al., 2011, Valea et al., 2010). Sulfadoxine-
pyrimethamine intake was supervised in all trials. Three trials in Kenya and Malawi 
involved both HIV-infected and uninfected women (Filler et al., 2006, Luntamo et al., 
2010, Parise et al., 1998) and 1 trial in Zambia involved HIV-infected women only (Hamer 
et al., 2007). In 3 other trials, the HIV status was unknown (Diakite et al., 2011, Valea et 
al., 2010, MacArthur and Abdulla, 2005), 2 of which were from areas with very low HIV 
prevalence among pregnant women (1% in Burkina Faso and 1.3% in Mali) (Diakite et al., 
2011, Valea et al., 2010); results were therefore pooled with those of the HIV-negative 
women. The third trial from Tanzania (MacArthur and Abdulla, 2005) was conducted in 
an area with high HIV prevalence and analyzed as a separate “HIV status unknown” 
stratum. Two of the 7 trials were considered of low quality (Figure 4.2), including a trial in 
Burkina Faso, in which two-thirds of participants did not receive the intended regimen 
(Valea et al., 2010). The other study was a quasi-randomized trial (Parise et al., 1998) 
conducted before the introduction of the Consolidated Standards of Reporting Trials 
(CONSORT) guidelines for clinical trials (Begg et al., 1996) (Table 4. 1). 
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Figure 4.2 : Risk of bias assessment representing the authors' judgements about each risk of bias item 
for each included study across the domains  
Figure note: Graph represents the risk of bias assessment using criteria described by Higgins et 
al.(Higgins et al., 2011). Two studies were classified as low quality, including the study by Valea et al 
which had a high risk of ‘other’ bias because the study was designed to provide all IPT courses by study 
staff in the home of the participants. Because of logistical constraints, only a minority received the 
number of intended doses with marked differences in missed doses between the study arms (only 23% 
and 41% of the women in the 3+, - and 2-dose arms received a third and second dose, respectively).  
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Table 4. 1: Characteristics of included Trials  
 Parise Filler Hamer Luntamo Valea Diakite MacArthur 
Country Kenya Malawi Zambia Malawi Burkina Faso Mal Tanzania 
Year Published 1998 2006 2007 2010 2010 2011 Unpubl.
a
 
Study years 1994-1996 2002-2005 2003-2004 2003-2006 2006-2008 2006-2008 2003-2006 
Gravidae G1-G2 G1-G2 All All All All G1-G2 
Number of women 3+dose 661 351 224 441 656 413 400 
 2-dose 680 347 232 436 640 401 399 
 Total (G1-
G2) 
1341 (1341) 698 (698) 456 (251) 877 (371) 1296 (536) 814 (339) 799 (799) 
Intervention arm regimen Monthly Monthly Monthly Monthly 3-dose
b
 3-dose  Monthly 
Number of doses in 3+ arm, 
median (range) 
3 (1-5) 5 (1-5) 4 (1-6) 4 (1-6) 2 (1-3)
b
 3 (1-3) 3 (1-5) 
Median Number of 
ANC Visits 
3+dose Designed to be 
equal-
 c
  
Designed to be 
equal-
 c
  
Designed to be 
equal-
 c
  
4.4 (1-9)
d
 4 (1-7) 3 (1-6) 4 (1-6) 
2-dose 4.4 (1-9)
d
 4 (1-6) 3 (1-6) 3 (1-7) 
HIV status Pos+Neg Pos+Neg Pos only Pos+Neg
e
 All
 f
 All
 f
 Pos+Neg 
g
 
Malaria Transmission 
h
 Holoendemic Holoendemic Holoendemic
i
 Holoendemic  Hyperendemic Hyperendemic Holoendemic 
Entomological Inoculation rate 
(EIR)/yr 
j 
 
60-300 18-27 NA NA NA NA 367 
SP resistance N (% dhps K540E)
k
 77 (14%) 76 (96%) 24 (46%) 88 (86%) 80 (0%) 9 (0%) 120 (46%) 
Folic Acid dose in mg/day 5 0.5 5 0.25 0.4 0.4 0.4 
Bednet coverage, N (%) 148 (11) 698 (15) 456 (25) 1320 (60) 288 (14)  814 (17) 799 (37) 
Random Sequence Generation Not random Adequate Adequate Adequate Adequate Adequate Adequate 
Sequence Allocation By day of visit Inadequate Adequate Adequate Adequate Adequate Adequate 
Open label /Placebo controlled Open Label Open Label Placebo Open Label Open Label Open Label Open Label 
Assessor blinding birthweight No No Yes Yes No Yes Yes 
Loss-to-follow-up (%) 478 (36) 143 (22) 68 (15) 86 (10) 259 (20) 73 (9) 56 (7) 
Abbreviations: HIV, Human Immunodeficiency Virus; SP, Sulfadoxine-Pyrimethamine; dhps, dihydropteroate synthase; G1-G2, first and second pregnancies; G3+, 2 or more previous pregnancies;  
ANC, Antenatal Clinic; Pos, HIV-Positive and Neg, HIV-Negative. NA, Not available 
a 
All information was provided by two of the co-authors (AM, JRM)
  
b
 Drug administration was provided as directly observed therapy in the home environment. However, because of logistical reasons only 149 (23%) of the women in the 3-dose group received the third 
sulfadoxine-pyrimethamine dose and only 261 (41%) in the 2-dose group received a second sulfadoxine-pyrimethamine dose. 
c 
Actual number of visits not reported, but the studies were designed to have identical antenatal care schedules in both arms 
d
 Mean (range) instead of the median 
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e
 The HIV negative group includes 82 women (42 in the 3+dose group) with unknown/undetermined HIV status. 
f
 HIV screening and testing was not conducted, but the HIV prevalence in the general antenatal clinic population were 1.0% and 1.3% in the study sites in Burkina Fasoand Malirespectively.  
g
 HIV screening and testing was conducted, but HIV tests results were not available. 
h
 Holoendemic: transmission occurs all year long; Hyperendemic: intense, but with periods of no transmission during dry season. 
i
 Transmission during the study period was reported to be lower than usual as described as ‘mild malaria transmission’. 
J
 The Entomological inoculation rate (EIR) is a measure of malaria transmission intensity and is the number of infectious bites per person per unit time (usually expressed per year). It is the product of the 
human biting rate and the sporozoite rate. 
k
 sulfadoxine-pyrimethamine resistance data matched for time and location (<=100km) and defined as the proportion of symptomatic children less than 5 or 12 years old carrying dhps K540E mutations for 
sulfadoxine-pyrimethamine resistance, except for the study by Diakite in Mali and Luntamo in Malawi, which were based on samples from women attending antenatal care prior to their first 
dose of sulfadoxine-pyrimethamine. 
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Figure 4.3: Meta-analysis of the risk of low birthweight in trials comparing the  2-dose vs 3+ doses of 
IPTp with sulfadoxine-pyrimethamine 
Figure note: HIV, human immunodeficiency virus; G1-G2, first and second pregnancies; G3+, 2 or more 
previous pregnancies; n, number of events; N, Total number of women; RR, relative risk; CI, confidence 
interval; D+L, Dersimonian-Laird method for random effects models; M-H, Mantel-Haenszel method for 
fixed effects models. P-values following the I2 statistics represent the Chi-square test for heterogeneity. 
Weights are from random effects analysis. Data-marker sizes indicate the weight applied to each study 
using random-effects meta-analysis. Diamonds represent summary effect of studies. 
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Figure 4. 4: Meta-analysis of mean birthweight in 7 trials comparing the 2-dose vs 3+ doses of IPTp 
with sulfadoxine-pyrimethamine 
Figure note: HIV, human immunodeficiency virus status; dhps, dihydropteroate synthase; G1-G2, first 
and second pregnancies; G3+, 2 or more previous pregnancies; n, number of events; N, sample size; 
RR, relative risk; CI, confidence interval; D+L, Dersimonian-Laird method for random effects models; 
I-V, Inverse-Variance method used in the fixed effects models. P-values following the I2 statistics 
represent the chi-square test for heterogeneity. Weights are from random effects analysis. Data-
marker sizes indicate the weight applied to each study using random-effects meta-analysis. 
Diamonds represent summary effect of studies.  
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4.3.2 Primary outcomes: Birth weight  
Women in the ≥3-dose group had fewer infants with LBW (random-effects model RR=0.80; 
95% CI, 0.69-0.94; P=0.006; I2=0%) (Figure 4. 3), corresponding to an RR reduction (RR 
reduction = 100% × [1 − RR]) of 20% (95% CI, 6-31). The absolute risk reduction was 33 per 
1000 women (95% CI, 10-52), from a median risk of 167 per 1000 in the 2-dose group 
(assumed control-group risk) to 134 per 1000 in the ≥3-dose recipients (NNT = 31). The 
median birth weight in the 2-dose group was 2870 g (range, 2722-3239 g) and on average 56 
g (95% CI, 29-83 g) higher in the ≥3-dose group (Figure 4. 4 & Table 4. 2). Analyses by gravida 
and HIV subgroup showed that the mean difference in birth weight was statistically 
significant in HIV-negative women (random-effects mean difference = 58 g; 95% CI, 26-90 g), 
HIV-positive women (mean difference = 97 g; 95% CI, 22-172) (Table 4. 2), G1-G2 women 
(mean difference = 57 g; 95% CI, 22-93 g), (Table 4. 3) , and multigravida (mean 
difference = 53 g; 95% CI, 11-95 g) (Table 4. 4)  (between-subgroup difference, I2 = 0%; 
P = .53) . The RR estimates for LBW, however, were significant only in HIV-negative women 
(RR = 0.77 [95% CI, 0.63-0.94] (Table 4. 2); assumed control-group risk = 106 per 1000; 
absolute risk reduction = 24 per 1000 [95% CI, 6-39]; NNT = 42) and G1-G2 women (RR = 0.80 
[95% CI, 0.68-0.95] ; assumed control-group risk = 181 per 1000; absolute risk reduction = 36 
per 1000 [95% CI, 9-58]; NNT = 28) but not in HIV-positive women (RR = 0.86 [95% CI, 0.53-
1.39] (Table 4. 2); assumed control-group risk = 175 per 1000; absolute risk reduction = 24 
per 1000 [95% CI, −68 to 82]; NNT = 42) or multigravida (RR = 0.79 [95% CI, 0.49-1.27], (Table 
4. 4); assumed control-group risk = 78 per 1000; absolute risk reduction = 16 per 1000 [95% 
CI, −21 to 40]; NNT = 63). The difference in the RR estimates between the subgroups was not 
significant (between-subgroup difference (I2=0%; P=0.96) (Figure 4.3). The results of fixed-
effects models overall and by gravidity or HIV groups were mostly identical or very similar 
(Table 4. 5)  
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Table 4. 2:: Random effects meta-analysis of trials comparing the 2-dose vs 3+ doses of IPTp with sulfadoxine-pyrimethamine by HIV status 
  2- dose  3+dose  Random effects model 
 No. of 
studies 
No. 
Even
ts 
Total 
No. 
 
ACR per 1000 or 
ACM (Range)
 a
  
 
 
No. 
Even
ts 
Total 
No. 
CIR per 1000 
 or CIM (95% 
CI)
 a
  
 
 
Relative Risk 
(95% CI)
 b
 
ARR per 1000 or  
Mean Difference 
(95% CI)
 c
 
P-
Valu
e
b
 
I
2
 
Primary Endpoints 
Low Birthweight             
HIV-positive 4 62 366 175 (91-222)  51 361 151 (93-243)  0.86 (0.53-1.39) 24 (-68-82) .54 33% 
HIV-negative 5 186 1462 106 (42-231)  143 1486 82 (67-100)  0.77 (0.63-0.94) 24 (6-39) .01 0% 
Unknown  1 65 362 180
d
  57 368 155 (112-214)  0.86 (0.62-1.19) 25 (-34-68) .37 -
 d
 
Overall 7 313 2190 167 (42-231)  251 2215 134 (115-157)  0.80 (0.69-0.94) 33 (10-52) .006 0% 
Birthweight, grams             
HIV-positive 4  366 2783 (2722-3177)   361 2880 (2805-2955)   97 (22-172) .01 0% 
HIV-negative 5  1462 2928 (2750-3239)   1486 2986 (2954-3018)   58 (26-90) <.001 0% 
Unknown  1  362 2882
d
   368 2893 (2825-2961)   11 (-57-79) .75 -
 d
 
Overall  7  2190 2870 (2722-3239)   2215 2926 (2899-2953)   56 (29-83) <.001 0% 
Secondary Endpoints 
Maternal haemoglobin, g/dL            
HIV-positive 4  349 11.0 (9.7-11.4)   327 11.1 (10.9-11.4)   0.11 (-0.15-0.37) .40 0% 
HIV-negative 5  1395 10.8 (10.2-11.6)   1461 11.0 (10.8-11.1)   0.15 (0.04-0.26) .009 0% 
Unknown 1  344 11.1
d
   340 11.1 (10.8-11.4)   0.00 (-0.31-0.31) 1 -
 d
 
Overall  7  2088 10.9 (9.7-11.6)   2128 11.0 (10.9-11.1)   0.13 (0.03-0.22) .009 0% 
Maternal anaemia (<11g/dL)           
HIV-positive 4 214 349 582 (333-795)  190 327 559 (506-623)  0.96 (0.87-1.07) 23 (-41-76) .51 0% 
HIV-negative 5 665 1395 473 (269-660)  682 1461 459 (426-492)  0.97 (0.90-1.04) 14 (-19-47) .37 0% 
Unknown  1 175 344 509
 d
  152 340 448 (382-524)  0.88 (0.75-1.03) 61 (-15-127) .11 -
 d
 
Overall  7 1054 2088 509 (269-795)  1024 2128 484 (458-514)  0.95 (0.90-1.01) 25 (-5-51) .10 0% 
Moderate-severe maternal anaemia (<8 or <=7 or <=6 g/dL)        
HIV-positive 2 7 124 00 (00-65)  3 135 00 (00-00)  0.60 (0.06-5.85) 0 (0-0) .66 48% 
HIV-negative 4 38 1296 38 (09-63)  27 1376 27 (14-52)  0.70 (0.36-1.36) 11 (-14-24) .29 34% 
Unknown  2
e
 25 776 32 (30-35)  21 771 27 (15-48)  0.85 (0.48-1.50) 5 (-16-17) .57 0% 
Overall  6 70 2196 34 (00-65)  51 2282 25 (16-38)  0.73 (0.48-1.11) 9 (-4-18) .14 15% 
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(Table 4. 2. continued) 
 2- dose  3+dose  Random effects model 
 No. of 
studies 
No. 
Event
s 
Total 
No. 
 
ACR per 1000 or 
ACM (Range)
 a
  
 
No. 
Even
ts 
Total 
No. 
CIR per 1000 
or CIM (95% CI)
 
a
  
Relative Risk 
(95% CI)
 b
 
ARR per 1000 or  
Mean Difference 
(95% CI)
 c
 
P-
Valu
e
b
 
I
2
 
Maternal parasitemia           
HIV-positive 4 51 338 112 (00-359)  13 328 29 (17-52)  0.26 (0.15-0.46) 83 (60-95) <.001 0% 
HIV-negative 5 265 1407 104 (31-350)  234 1445 89 (77-105)  0.86 (0.74-1.01) 15 (-1-27) .06 0% 
Unknown 1 7 351 20
 d
  2 349 06 (01-27)  0.29 (0.06-1.37) 14 (-7-19) .12 -
 d
 
Overall  7 323 2096 92 (00-359)  249 2122 63 (48-82)  0.68 (0.52-0.89) 29 (10-44) .005 47% 
Placental malaria             
HIV-positive 4 39 338 102 (00-256)  14 320 39 (21-70)  0.38 (0.21-0.69) 63 (32-81) .001 0% 
HIV-negative 4 82 753 67 (00-201)  47 782 38 (26-55)  0.57 (0.39-0.82) 29 (12-41) .003 9% 
Unknown  1 7 345 20
 d
  4 344 11 (03-39)  0.57 (0.17-1.94) 9 (-19-17) .37 
d
 
Overall  6 128 1436 63 (00-256)  65 1446 32 (24-43)  0.51 (0.38-0.68) 31 (20-39) <.001 0% 
Preterm delivery             
HIV-positive 3 130 331 306 (46-655)  113 340 278 (211-370)  0.91 (0.69-1.21) 28 (-64-95) .51 32% 
HIV-negative 4 209 1479 107 (16-248)  191 1554 93 (72-122)  0.87 (0.67-1.14) 14 (-15-35) .32 41% 
Unknown 2
e
 51 769 61 (21-102)  66 777 78 (55-111)  1.28 (0.90-1.82) -17 (-50-6) .17 1% 
Overall  7 390 2579 122 (16-655)  370 2671 116 (98-137)  0.95 (0.80-1.12) 6 (-15-24) .52 35% 
Miscarriage             
HIV-positive 2 3 147 00 (00-30)  5 171 00 (00-00)  1.54 (0.38-6.28) 0 (0-0) .55 -
 d
 
HIV-negative 4 19 1515 00 (00-29)  28 1587 00 (00-00)  1.31 (0.64-2.70) 0 (0-0) .46 20% 
Unknown 2
e
 5 809 06 (00-12)  9 809 11 (04-32)  1.80 (0.61-5.34) -5 (-26-2) .29 -
d
 
Overall  6 27 2471 00 (00-30)  42 2567 00 (00-00)  1.43 (0.88-2.33) 0 (0-0) .15 0% 
Stillbirth              
HIV-positive 3 11 352 40 (00-56)  8 362 27 (11-70)  0.68 (0.27-1.74) 13 (-30-29) .43 0% 
HIV-negative 4 44 1515 30 (15-53)  60 1587 40 (27-59)  1.33 (0.90-1.95) -10 (-29-3) .15 0% 
Unknown  2
e
 24 809 30 (25-34)  24 809 29 (13-68)  0.97 (0.42-2.27) 1 (-38-17) .95 54% 
Overall  7 79 2676 30 (00-56)  92 2758 34 (26-46)  1.14 (0.85-1.55) -4 (-16-4) .38 0% 
Neonatal death
f
             
HIV-positive 2 10 137 77 (29-167)  6 160 39 (14-112)  0.51 (0.18-1.45) 38 (-35-63) .21 0% 
HIV-negative 4 25 1472 19 (08-31)  32 1549 23 (13-39)  1.19 (0.69-2.05) -4 (-20-6) .54 0% 
Unknown 
HIV status 
2
e
 
14 796 18 (14-22) 
 
7 800 08 (02-33) 
 
0.47 (0.12-1.84) 10 (-15-16) .28 
37% 
Overall  6 49 2405 21 (08-167)  45 2509 18 (12-28)  0.88 (0.57-1.35) 3 (-7-9) .55 0% 
Abbreviation: No, number; 3+dose, monthly or 3 doses of sulfadoxine-pyrimethamine; ACR, Assumed Control-Group Risk; ACM, Assumed Control-Group 
Median; CIR Corresponding Intervention-Group Risk; CIM, Corresponding Intervention-Group Median; ARR, Absolute Risk Reduction (risk difference), HIV, 
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Human Immunodeficiency Virus; RR, summary Relative risk adjusted by stratification for gravidity group (G1-G2, G3+) obtained from random  effect models ; 
CI, Confidence Interval; g/dl, gram per deciliter; I
2
, statistical test for heterogeneity across trials. 
a 
ACR represents the observed median risk (expressed per 1000 women) across the trials in the 2-dose arm; the CIR (and its 95% CI) is based on the assumed risk 
in 3+dose recipients computed as ACR x RR (Schunemann, 2008).  For the 2 continuous endpoints, the ACM represents the median birthweight or haemoglobin 
concentration in the 2-dose arm (the range is provided to illustrate high and low risk populations); The CIM values were computed as the ACM + Mean Difference 
(95% CI). 
b 
Effect size, 95% confidence intervals and P-values for the overall effect (last rows) and for each HIV-status subgroup were obtained from random effects models 
and are adjusted for gravidity group (all estimates [G1-G2, G3+]) plus for HIV status (for last rows representing the overall effect), by using the independent 
subgroups as the unit of analysis. 
c 
The absolute risk reduction (ARR) was calculated as the ACRx(1-RR) and expressed per 1000 women. 
d 
 Range or heterogeneity cannot be estimated, either because the data contains only a single trial in the subgroup, or no events occurred in 1 of the 2 included 
studies ((Parise et al., 1998)  
e 
Results for the study by Parise et al in Kenya  were not reported by HIV status for these endpoints 
f 
Death of a live-born baby within the first 28 days of life. One study assessed early neonatal death only (death within 7 days of life) .(MacArthur et al., 2007 ).  
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Table 4. 3: Random effects meta-analysis of trials comparing the 2-dose vs 3+ doses of IPTp with sulfadoxine-pyrimethamine by HIV status 
among first and second pregnancies 
  2- dose  3+dose  Random effects model 
 No. of 
studies 
No. 
Event
s 
Total 
No. 
 
ACR
a
 per 1000 
or ACM
a
 (Range)  
 
 
No. 
Event
s 
Total 
No. 
CIR
a
 per 1000 or 
CIM
a
 (95% CI)  
 
 
Relative Risk 
(95% CI)
 b
 
ARR per 1000 
or  
Mean 
Difference 
(95% CI)
 c
 
P-
Valu
e
b
 
I
2
 
Primary Endpoints 
Low Birthweight            
HIV-positive 4 48 256 175 (128-222)  40 244 147 (100-217)  0.84 (0.57-1.24) 28 (-42-75) .39 0% 
HIV-negative 5 138 757 208 (51-231)  105 768 158 (123-202)  0.76 (0.59-0.97) 50 (6-85) .03 7% 
Unknown  1 65 362 180
d
  57 368 155 (112-214)  0.86 (0.62-1.19) 25 (-34-68) .37 -
 d
 
Overall 7 251 1375 181 (51-231)  202 1380 145 (123-172)  0.80 (0.68-0.95) 36 (9-58) .01 0% 
Birthweight, grams            
HIV-positive 4  256 2783 (2739-3177)  
 
244 2885 (2795-2975)   102 (12-192) .03 0% 
HIV-negative 5  757 2763 (2750-3239)  
 
768 2830 (2783-2877)   67 (20-114) .005 0% 
Unknown  1  362 2882
 d
  
 
368 2893 (2825-2961)   11 (-57-79) .75 -
 d
 
Overall  7  1375 2795 (2739-3239)  
 
1380 2852 (2817-2888)   57 (22-93) .002 0% 
Secondary Endpoints   
Maternal haemoglobin, g/dL           
HIV-positive 4  259 10.5 (9.7-11.2)  
 
238 10.6 (10.3-10.9)   0.08 (-0.21-0.38 .58 0% 
HIV-negative 5  737 10.4 (10.2-11.6)  
 
793 10.6 (10.5-10.8)   0.24 (0.08-0.39) .003 0% 
Unknown  1  344 11.1
 d
  
 
340 11.1 (10.8-11.4)   0.00 (-0.31-0.31 1 -
 d
 
Overall  7  1340 10.6 (9.7-11.6)  
 
1371 10.8 (10.6-10.9)   0.17 (0.04-0.30) .008 0% 
Maternal anaemia (<11g/dL)          
HIV-positive 4 172 259 651 (333-795)  152 238 631 (566-710)  0.97 (0.87-1.09) 20 (-59-85) .60 0% 
HIV-negative 5 381 737 522 (269-660)  396 793 496 (454-548)  0.95 (0.87-1.05) 26 (-26-68) .32 0% 
Unknown  1 175 344 509
 d
  152 340 448 (382-524)  0.88 (0.75-1.03) 61 (-15-127) .11 -
 d
 
Overall  7 728 1340 525 (269-795)  700 1371 499 (462-530)  0.95 (0.88-1.01) 26 (-5-63) .09 0% 
Moderate-severe maternal anaemia (<8 or <=7 or <=6 
g/dL)       
 
 
 
HIV-positive 2 7 113 3.3 (0.0-6.5)  2 124 09 (02-41)  0.26 (0.06-1.23) 24 (-8-31) .09 -
 d
 
HIV-negative 4 25 638 3.8 (3.4-4.3)  12 708 16 (06-43)  0.43 (0.17-1.13) 22 (-5-32) .09 37% 
Unknown  2
e
 25 776 3.2 (3.0-3.5)  21 771 27 (15-48)  0.85 (0.48-1.50) 5 (-16-17) .57 0% 
Overall  6 57 1527 3.6 (0.0-6.5)  35 1603 22 (13-36)  0.60 (0.36-0.99) 14 (0-23) .045 20% 
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Table 4.3 
(continued) 
  2- dose  3+dose  Random effects model 
 No. of 
studies 
No. 
Event
s 
Total 
No. 
 
ACR
a
 per 1000 
or ACM
a
 
(Range)  
 No. 
Event
s 
Total 
No. 
CIR
a
 per 1000 or 
CIM
a
 (95% CI)  
 Relative Risk 
(95% CI)
 b
 
ARR per 1000 
or  
Mean 
Difference 
(95% CI)
 c
 
P-
Value
b
 
I
2
 
Maternal parasitemia           
HIV-positive 4 50 250 161 (80-359)  12 234 40 (23-71)  0.25 (0.14-0.44) 121 (90-138) <.001 0% 
HIV-negative 5 166 731 117 (65-350)  138 770 95 (77-116)  0.81 (0.66-0.99) 22 (1-40) .04 5% 
Unknown  1 7 351 20
 d
  2 349 06 (01-27)  0.29 (0.06-1.37) 14 (-7-19) .12 -
 d
 
Overall  7 223 1332 130 (20-359)  152 1353 70 (48-104)  0.54 (0.37-0.80) 60 (26-82) .002 56% 
Placental malaria            
HIV-positive 4 38 253 179 (61-256)  12 229 61 (34-113)  0.34 (0.19-0.63) 118 (66-145) <.001 0% 
HIV-negative 4 50 463 67 (39-201)  30 492 41 (23-71)  0.61 (0.35-1.06) 26 (-4-44) .08 23% 
Unknown H 1 7 345 20
 d
  4 344 11 (03-39)  0.57 (0.17-1.94) 9 (-19-17) .37 -
 d
 
Overall  6 95 1061 71 (20-256)  46 1065 35 (25-50)  0.50 (0.35-0.70) 36 (21-46) <.001 0% 
Preterm delivery            
HIV-positive 3 83 215 250 (46-655)  68 216 228 (185-280)  0.91 (0.74-1.12) 22 (-30-65) .37 0% 
HIV-negative 4 124 703 176 (16-248)  108 750 150 (109-202)  0.85 (0.62-1.15) 26 (-26-67) .29 26% 
Unknown  2
e
 51 769 61 (21-102)  66 777 78 (55-111)  1.28 (0.90-1.82) -17 (-50-6) .17 1% 
Overall  7 258 1687 107 (16-655)  242 1743 102 (87-119)  0.95 (0.81-1.11) 5 (-12-20) .52 7% 
Miscarriage              
HIV-positive 2 3 111 15 (00-30)  5 128 23 (06-94)  1.54 (0.38-6.28) -8 (-79-9) .55 -
e
 
HIV-negative 4 9 723 08 (00-29)  19 775 14 (05-40)  1.70 (0.57-5.05) -6 (-32-3) .34 19% 
Unknown  2
e
 5 809 06 (00-12)  9 809 11 (04-32)  1.80 (0.61-5.34) -5 (-26-2) .29 -
e
 
Overall  6 17 1643 06 (00-30)  33 1712 11 (06-19)  1.75 (0.97-3.13) -5 (-13-0) .06 0% 
Stillbirth               
HIV-positive 3 4 111 20 (00-40)  6 128 23 (07-78)  1.13 (0.33-3.89) -3 (-58-13) .84 0% 
HIV-negative 4 24 723 33 (15-53)  31 775 42 (25-71)  1.27 (0.75-2.15) -9 (-38-8) .37 0% 
Unknown 2
e
 24 809 30 (25-34)  24 809 29 (13-68)  0.97 (0.42-2.27) 1 (-38-17) .95 54% 
Overall  7 52 1643 30 (00-53)  61 1712 34 (24-49)  1.14 (0.79-1.65) -4 (-19-6) .48 0% 
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Neonatal death
 f
 Table 4.3 (continued) 
HIV-positive 2 9 103 122 (77-167)  4 117 46 (15-151)  0.38 (0.12-1.24) 76 (-29-107) .11 0% 
HIV-negative 4 15 701 21 (13-31)  18 747 24 (12-48)  1.13 (0.55-2.29) -3 (-27-9) .74 0% 
Unknown 2
e
 14 796 18 (14-22)  7 800 08 (02-33)  0.47 (0.12-1.84) 10 (-15-16) .28 37% 
Overall  6 38 1600 22 (13-167)  29 1664 16 (10-27)  0.74 (0.45-1.24) 6 (-5-12) .26 0% 
Abbreviation: No, number; 3+dose, monthly or 3 doses of sulfadoxine-pyrimethamine; ACR, Assumed Control-Group Risk; ACM, Assumed Control-Group 
Median; CIR Corresponding Intervention-Group Risk; CIM, Corresponding Intervention-Group Median; ARR, Absolute Risk Reduction (risk difference), HIV, 
Human Immunodeficiency Virus; RR, summary Relative risk adjusted by stratification for gravidity group (G1-G2, G3+) obtained from random effect models ; CI, 
Confidence Interval; g/dl, gram per deciliter; I
2
, statistical test for heterogeneity across trials. 
a 
Assumed Control-Group Risks represents the median risk (expressed per 1000 women) across the trials in the 2-dose arm; the Corresponding Intervention-
Group Risk (and its 95% CI) is based on the assumed risk in 3+dose recipients computed as ACR x RR.(Schünemann et al., 2008) For the 2 continuous endpoints, 
the assumed Control-Group Median represents the median birthweight or haemoglobin concentration in the 2-dose arm (the range is provided to illustrate high 
and low risk populations); The corresponding Intervention-Group values were computed as the ACM + Mean Difference (95% CI). 
b 
Effect size, 95% confidence intervals and P-values for the overall effect (last rows) and for each HIV-status subgroup were obtained from random effects 
models and are adjusted for HIV status (for last rows representing the overall effect), by using the independent subgroups as the unit of analysis. 
c 
The absolute risk reduction (ARR) was calculated as the ACRx(1-RR) and expressed per 1000 women.  
d 
The range or heterogeneity cannot be estimated, either because the data contains only a single trial in the subgroup, or no events occurred in 1 of the 2 
included studies  
e 
Results for the study by Parise et al in Kenya were not reported by HIV status for these endpoints 
f 
Death of a live-born baby within the first 28 days of life. One study assessed early neonatal death only (death within 7 days of life).(MacArthur et al., 2007 ) 
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Table 4. 4: Random effects meta-analysis of trials comparing the 2-dose vs 3+ doses of IPTp with sulfadoxine-pyrimethamine by HIV status 
among multigravidae (G3+) 
   2- dose  3+dose  Random effects model 
  
No. of  
studies 
No. 
Event
s 
Total 
No. 
 
ACR
a
 per 1000 
or ACM
b
 
(Range)  
 
 
No. 
Event
s 
Total 
No. 
CIR
a
 per 1000  or 
CIM
b
 (95% CI)  
 
 
Relative Risk (95% 
CI)
 c
 
ARR per 1000 or  
Mean 
Difference 
(95% CI)
 c
 
P-
Valu
e
c
 
I
2
 
Primary Endpoints 
Low Birthweight              
HIV-positive 2 14 110 152 (91-212)  11 117 74 (06-869)  0.49 (0.04-5.72) 78 (-717-146) .57 80% 
HIV-negative 3 48 705 77 (42-78)  38 718 60 (40-91)  0.78 (0.52-1.18) 17 (-14-37) .24 0% 
Overall 4 62 815 78 (42-212)  49 835 62 (38-99)  0.79 (0.49-1.27) 16 (-21-40) .33 30% 
Birthweight, grams            
HIV-positive 2  110 2867 (2722-3012)  
 
117 2967 (2766-3168)   100 (-101-301) .33 53% 
HIV-negative 3  705 3020 (2986-3049)  
 
718 3070 (3026-3114)   50 (6-94) .03 0% 
Overall  4  815 3012 (2722-3049)  
 
835 3065 (3023-3107)   53 (11-95) .01 0% 
Secondary Endpoints 
Maternal haemoglobin, g/dL            
HIV-positive 2  90 11.2 (10.9-11.4)  
 
89 11.4 (10.9-11.9)   0.20 (-0.33-0.73 .46 0% 
HIV-negative 3  658 11.1 (10.8-11.5)  
 
668 11.2 (11.0-11.3)   0.06 (-0.09-0.21 .45 0% 
Overall  4  748 11.1 (10.8-11.5)  
 
757 11.2 (11.0-11.3)   0.07 (-0.08-0.22 .35 0% 
Maternal anaemia (<11g/dL)           
HIV-positive 2 42 90 540 (443-636)  38 89 475 (313-729)  0.88 (0.58-1.35) 65 (-189-227) .57 18% 
HIV-negative 3 284 658 429 (317-469)  286 668 425 (373-480)  0.99 (0.87-1.12) 4 (-51-56) .85 0% 
Overall  4 326 748 443 (317-636)  324 757 434 (385-487)  0.98 (0.87-1.10) 9 (-44-58) .72 0% 
Moderate-severe maternal anaemia (<8 or <=7 or <=6 g/dL)        
HIV-positive 1
 
 0 11 00 (00-00)  1 11 00 (00-00)  3.00 (0.14-66.53 0 (0-0) .49 - 
HIV-negative 3 13 658 19 (09-63)  15 668 21 (10-46)  1.12 (0.52-2.40) -2 (-27-9) .77 0% 
Overall  3 13 669 14 (00-63)  16 679 17 (08-35)  1.18 (0.56-2.48) -3 (-21-6) .66 0% 
Maternal parasitemia             
HIV-positive 2 1 88 06 (00-13)  1 94 06 (00-89)  0.94 (0.06-14.75 0 (-83-6) .96 -
 d
 
HIV-negative 3 99 676 92 (31-263)  96 675 89 (69-114)  0.97 (0.75-1.24) 3 (-22-23) .79 0% 
Overall  4 100 764 31 (00-263)  97 769 30 (23-38)  0.97 (0.75-1.24) 1 (-7-8) .79 0% 
Placental malaria             
HIV-positive 2 1 85 07 (00-14)  2 91 13 (01-142)  1.87 (0.17-20.23 -6 (-135-6) .61 -
 d
 
HIV-negative 2 32 290 71 (00-143)  17 290 48 (11-210)  0.68 (0.16-2.96) 23 (-139-60) .61 31% 
Overall  3 33 375 07 (00-143)  19 381 05 (02-14)  0.71 (0.26-1.95) 2 (-7-5) .50 21% 
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           Table 4. 4 Continued 
  
No. of  
studies 
No. 
Event
s 
Tot
al 
No. 
 
ACR
a
 per 1000 
or ACM
b
 (Range)  
 No. 
Event
s 
Total 
No. 
CIR
a
 per 1000  or 
CIM
b
 (95% CI)  
 Relative Risk (95% 
CI)
 c
 
ARR per 1000 or  
Mean 
Difference 
(95% CI)
 c
 
P-
Valu
e
c
 
I
2
 
Preterm delivery             
HIV-positive 2 47 116 378 (306-450)  45 124 242 (64-896)  0.64 (0.17-2.37) 136 (-518-314) .51 82% 
HIV-negative 3 85 776 94 (77-137)  83 804 82 (46-145)  0.87 (0.49-1.54) 12 (-51-48) .63 66% 
Overall  3 132 892 137 (77-450)  128 928 116 (77-174)  0.85 (0.56-1.27) 21 (-37-60) .42 65% 
Miscarriage             
HIV-positive 1 0 36 00 (00-00)  0 43  (-)  . (.-.) . (.-.)  - 
HIV-negative 3 10 792 00 (00-27)  9 812 00 (00-00)  0.90 (0.37-2.19) 0 (0-0) .82  -
 d
 
Overall  3 10 828 00 (00-27)  9 855 00 (00-00)  0.90 (0.37-2.19) 0 (0-0) .82 -
 d
 
Stillbirth              
HIV-positive 1 2 36 56 (56-56)  0 43 10 (01-190)  0.17 (0.01-3.39) 46 (-134-55) .24 - 
HIV-negative 3 20 792 30 (16-36)  29 812 42 (22-78)  1.39 (0.74-2.59) -12 (-48-8) .30 15% 
Overall  3 22 828 33 (16-56)  29 855 41 (20-82)  1.24 (0.61-2.50) -8 (-49-13) .55 29% 
Neonatal death
 e
             
HIV-positive 1 1 34 29 (29-29)  2 43 46 (04-485)  1.58 (0.15-16.71 -17 (-456-25) .70 - 
HIV-negative 3 10 771 15 (08-19)  14 802 18 (07-51)  1.23 (0.44-3.38) -3 (-36-8) .69 27% 
Overall  3 11 805 17 (08-29)  16 845 22 (10-50)  1.31 (0.59-2.93) -5 (-33-7) .51 0% 
Abbreviation: No, number; 3+dose, monthly or 3 doses of sulfadoxine-pyrimethamine; ACR, Assumed Control-group Risk; ACM, Assumed Control-group Median; 
CIR Corresponding Intervention-group Risk; CIM, Corresponding Intervention-group Median; ARR, Absolute Risk Reduction (risk difference), HIV, Human 
Immunodeficiency Virus; RR, summary Relative risk adjusted by stratification for gravidity group (G1-G2, G3+) obtained from randomeffect models ; CI, 
Confidence Interval; g/dl, gram per deciliter; I
2
, statistical test for heterogeneity across trials. 
a 
Assumed Control-Group Risks represents the median risk (expressed per 1000 women) across the trials in the 2-dose arm; the Corresponding Intervention-Group 
Risk (and its 95% CI) is based on the assumed risk in 3+dose recipients computed as ACR x RR.(Schünemann et al., 2008) For the 2 continuous endpoints, the 
assumed Control-Group Median represents the median birthweight or haemoglobin concentration in the 2-dose arm (the range is provided to illustrate high and 
low risk populations); The corresponding Intervention-Group values were computed as the ACM + Mean Difference (95% CI). 
b 
The absolute risk reduction (ARR) was calculated as the ACRx(1-RR) and expressed per 1000 women.  
c 
Effect size, 95% confidence intervals and P-values for the overall effect (last rows) and for each HIV-status subgroup were obtained from random effects models 
and are adjusted for HIV status (for last rows representing the overall effect), by using the independent subgroups as the unit of analysis. 
d 
Heterogeneity cannot be estimated, either because the data contains only a single trial in the subgroup, or no events occurred in 1 of the 2 included studies 
(Parise et al., 1998) 
e 
Death of a live-born baby within the first 28 days of life. One study assessed early neonatal death only (death within 7 days of life).(MacArthur et al., 2007 ) 
Chapter 4 
103 
 
 
Chapter 4 
104 
 
Table 4. 5: Fixed effects meta-analysis of trials comparing the 2-dose vs 3+ doses of IPTp with SP by HIV status and gravidity groups 
 All Gravidae   Primi, and secundigravidae    Multigravidae (G3+)  
  RR (95% CI) or Mean 
Difference (95% CI)
 a
 
P-
Value 
I
2
  
 
RR (95% CI) or Mean 
Difference (95% CI)
 a
 
P-Value I
2
  RR (95% CI) or Mean 
Difference (95% CI)
 a
 
P-Value I
2
 
Primary Endpoints 
Low Birthweight            
HIV-positive 0.81 (0.58, 1.15) .54 33%  0.84 (0.57, 1.23) .37 0%  0.74 (0.35, 1.56) .43 80% 
HIV-negative 0.76 (0.62, 0.93) .01 0%  0.75 (0.60, 0.95) .02 7%  0.78 (0.52, 1.18) .24 0% 
Unknown  0.86 (0.62, 1.19) .37 -
b
  0.86 (0.62, 1.19) .37 -
b
  - .16 30% 
Overall 0.79 (0.68, 0.92)  .003 0%  0.80 (0.67, 0.94) .009 0%  0.77 (0.54, 1.10)   
Birthweight, grams           
HIV-positive 97 (22, 172) .01 0%  102(12, 192) .03 0%  80 (-49, 221) .21 53% 
HIV-negative 58 (26, 90) <.001 0%  67 (20, 114) .005 0%  50 (6, 94) .03 0% 
Unknown 11 (-57, 79) .75 -
b
  11.(-57, 79) .75 -
b
  - .01 0% 
Overall  56 (29, 83) <.001 0%  57 (22, 93) .002 0%  53 (12, 95)   
Secondary Endpoints 
Maternal haemoglobin, g/dL           
HIV-positive 0.11 (-0.15, 0.37) .40 0%  0.08 (-0.21-0.38) .58 0%  0.20 (-0.33, 0.73) .46 0% 
HIV-negative 0.15 (0.04, 0.26) .009 0%  0.24 (0.08-0.39) .003 0%  0.06 (-0.09, 0.21) .45 0% 
Unknown 0.00 (-0.31, 0.31) 1 -
b
  0.00 (-0.31-0.31) 1 -
b
  - .35 0% 
Overall  0.13 (0.03, 0.22) .009 0%  0.17 (0.04-0.30) .008 0%  0.07 (-0.08, 0.22)   
Maternal anaemia (<11g/dL)           
HIV-positive 0.93 (0.82, 1.05) .23 0%  0.94 (0.83, 1.06) .33 0%  0.91 (0.66, 1.27) .59 18% 
HIV-negative 0.97 (0.89, 1.04) .37 0%  0.95 (0.86, 1.04) .28 0%  0.99 (0.87, 1.12) .86 0% 
Unknown  0.88 (0.75, 1.03) .59 -
b
  0.88 (0.75, 1.03) .11 -
b
  - .73 0% 
Overall  0.94 (0.89, 1.00) .06 0%  0.93 (0.87, 1.00) .042 0%  0.98 (0.87, 1.10)   
Moderate-severe maternal anaemia (<8 or <=7 or <=6 g/dL)         
HIV-positive 0.44 (0.13, 1.50) .19 48%  0.26 (0.06, 1.23) .09 -
 c
  3.00 (0.14, 66.53) .49 -
b
 
HIV-negative 0.68 (0.42, 1.10) .12 34%  0.44 (0.22, 0.87) .02 37%  1.16 (0.56, 2.42) .69 0% 
Unknown  0.85 (0.48, 1.50) .57 0%  0.85 (0.48, 1.50) .57 0%  - .57 0% 
Overall  0.71 (0.50, 1.01) .06 15%  0.59 (0.39, 0.89) .01 20%  1.23 (0.60, 2.50)   
Maternal parasitemia           
HIV-positive 0.26 (0.15, 0.46) <.001 0%  0.25 (0.14, 0.44) <.001 0%  0.94 (0.06, 14.75) .96 -
b
 
HIV-negative 0.86 (0.74, 1.00) .054 0%  0.80 (0.66, 0.97) .02 5%   0.97 (0.75, 1.25)  .81 0% 
Unknown  0.29 (0.06, 1.37) .12 -
b
  0.29 (0.06, 1.37) .12 -
b
  - .80 0% 
Overall  0.75 (0.65.0.87) <.001 47%  0.66 (0.55. 0.79) <.001 56%  0.97 (0.75, 1.23)   
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         Table 4.5 (continued) 
 All Gravidae   Primi, and secundigravidae   Multigravidae (G3+)  
  RR (95% CI) or Mean 
Difference (95% CI)
 a
 
P-Value I
2
 
 
RR (95% CI) or Mean 
Difference (95% CI)
 a
 
P-Value I
2
  RR (95% CI) or Mean 
Difference (95% CI)
 a
 
P-Value I
2
 
Placental malaria            
HIV-positive 0.38 (0.22, 0.68) .001 0%  0.34 (0.19, 0.63) .0006 0%  1.87 (0.17, 20.23) .61 -
b
 
HIV-negative 0.56 (0.40, 0.78) <.001 9%  0.58 (0.38, 0.89) .01 23%  0.52 (0.30, 0.91) .02 31% 
Unknown  0.57 (0.17, 1.94) .37 -
b
  0.57 (0.17, 1.94) .37 -
b
  - .03 21% 
Overall  0.51 (0.38, 0.67) <.001 0%  0.49 (0.35, 0.68) <.001 0%  0.56 (0.33, 0.96)   
Preterm delivery            
HIV-positive 0.90 (0.77, 1.09) .30 32%  0.91 (0.73, 1.12) .35 0%  0.92 (0.68, 1.25) .60 82% 
HIV-negative 0.90 (0.75, 1.07) .23 41%  0.86 (0.68, 1.08) .19 26%  0.95 (0.72, 1.27) .74 66% 
Unknown  1.29 (0.91, 1.83)) .15 1%  1.29 (0.91, 1.83) .15 1%  - .58 65% 
Overall  0.95 (0.84, 1.08) .44 35%  0.96 (0.83, 1.11) .58 7%  0.94 (0.76, 1.17)   
Miscarriage            
HIV-positive 1.54 (0.38, 6.28) .55 -
 b
  1.54 (0.38, 6.28) .55 -
b
     
HIV-negative 1.38 (0.78, 2.43 .27 20%  1.84 (0.86, 3.92) .11 19%  0.90 (0.37, 2.19) .82 -
b
 
Unknown 1.80 (0.61, 5.34) .29 -
b
  1.80 (0.61, 5.34) .29 -
b
  - .82 -
 b
 
Overall  1.47 (0.92, 2.36) .55 0%  1.78 (1.01, 3.14) .046 0%  0.90 (0.37, 2.19)   
Stillbirth             
HIV-positive 0.68 (0.27, 1.68) .40 0%  1.9 (0.36, 3.98) .78 0%  0.17 (0.01, 3.39) .24 -
b
 
HIV-negative 1.34 (0.91, 1.96) .14 0%  1.28 (0.76, 2.15) .36 0%  1.40 (0.80, 2.46) .23 15% 
Unknown  1.00 (0.57, 1.75) 1 54%  1.00 (0.57, 1.75) 1.00 54%  - .40 29% 
Overall  1.14 (0.85, 1.53) .38 0%  1.14 (0.80, 1.64) .47 0%  1.26 (0.74, 2.16)   
Neonatal death
 c
            
HIV-positive 0.48 (0.18, 1.32) .16 0%  0.36 (0.11, 1.15) .08 0%  1.58 (0.15, 16.71) .70 -
b
 
HIV-negative 1.18 (0.70, 1.99) .53 0%  1.07 (0.54, 2.14) .84 0%  1.34 (0.60, 3.00) .47 27% 
Unknown  0.50 (0.20, 1.22) .13 37%  0.50 (0.20, 1.22) .13  37%  - .42 0% 
Overall  0.84 (0.56, 1.26) .40 0%  0.69 (0.43, 1.12) .13 0%  1.37 (0.64, 2.93)   
Abbreviation: No, number; 3+dose, monthly or 3 doses of sulfadoxine-pyrimethamine; HIV, Human Immunodeficiency Virus; RR, summary Relative Risk; CI, 
Confidence Interval; g/dl, gram per deciliter; I
2
, statistical test for heterogeneity across trials. 
a 
Effect size, 95% confidence intervals and P-values for the overall effect (last rows) and for each HIV-status subgroup were obtained from fixed effects 
models. The overall effect estimates (last rows) are adjusted for HIV status by using the independent subgroups as the unit of analysis. 
b 
Heterogeneity cannot be estimated, either because the data contains only a single trial in the subgroup, or no events occurred in 1 of the 2 included studies 
(Parise et al., 1998)  
c 
Death of a live-born baby within the first 28 days of life. One study assessed early neonatal death only (death within 7 days of life).(MacArthur et al., 2007 ) 
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There was no evidence for publication bias after visual inspection of funnel plots or 
with the Harbord modified test for small-study effects (P = .74) (Figure 4. 5). Cumulative 
meta-analysis, ordered by publication date, showed that a significant association with LBW 
emerged with the addition of new evidence from trials reported since 2010 (Figure 4.6 & 
Figure 4.7). Sensitivity analysis showed that after removal of both low-quality studies, the 
point estimates for LBW and mean birth weight were RR = 0.76 (95% CI, 0.61-0.93), I2 = 16%; 
and mean difference = 62 g (95% CI, 29-95 g), I2 = 0%. Removal of any individual trial also had 
relatively little effect and pooled results remained statistically significant at P < .05 for all 7 
analyses with fixed-effects models and at P = .06 with random-effects models (Figure 4. 8 & 
Figure 4.9). 
 
 
Figure 4. 5:  Funnel plot of standard error by log relative risk 
 Notes: Dots represent each study’s log Relative Risk for the effect on low birthweight. Harbord's 
modified test for small-study effects: P=.74 
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Figure 4.6: Cumulative Meta-analysis of the association with low birthweight, ranked by year of publication, 
overall and by HIV status 
Figure note: n, cumulative number of events; N, cumulative total number of women per treatment arm; LBW, 
low birthweight (<2500 gram), RR, relative risk; CI, confidence interval; HIV, human immune deficiency virus. 
Dots represent composite estimates for the effect on low birthweight adjusted for HIV status (upper strata ‘All 
women’) and gravidity (all 3 strata) obtained by performing random effect meta-analysis (Mantel Haenszel) on 
the HIV and gravidity subgroups for each study. Reference numbers refer to those in the main manuscript.  
 
 
 
Chapter 4 
108 
 
 
 
 
  
 
 
Figure 4.7: Cumulative Meta-analysis of the association with mean birthweight, ranked by year of 
publication, overall and by HIV status 
Figure note: N, Cumulative number of women per treatment arm. CI, confidence interval; HIV, 
human immune deficiency virus. Dots represent composite estimates for the effect on mean 
birthweight adjusted for HIV status (upper strata ‘All women’) and gravidity (all 3 strata) obtained by 
performing random effect meta-analysis (inverse variance) on the HIV and gravidity subgroups for 
each study. Reference numbers refer to those in the main manuscript. 
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Figure 4.8: Influence of removing 1 study at a time on the meta-analysis summary estimates for 
low birthweight 
Figure note: CI, Confidence Interval. RR, Relative Risk; LBW, low birthweight. The number of events (n) 
and total number (N) are the crude sums of all events and women within each The summary RRs for low 
birthweight are the weighted average of the trial-specific relative risks. The trial specific relative risks 
represent the composite point estimates for each study obtained by performing random effects 
meta-analysis on the HIV and gravidity subgroups for that study. The solid vertical line represents the 
pooled effect estimate with all studies included and the 2 broken vertical lines in red represent the 
corresponding 95% CI. When fixed effects models were used (not shown), the pooled results 
remained statistically significant at P<0.05 for all 7 analyses, also for the study by Diakite et al, 2011, 
from Mali (RR=0.85, 0.77-0.996). Reference numbers refer to those in the main manuscript. 
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Figure 4.9: Influence of removing 1 study at a time on the meta-analysis summary estimates for 
differences in mean birthweight 
Figure note: CI, Confidence Interval. No., Cumulative number of women. The summary estimates for 
the mean differences are the weighted averages of the trial-specific mean differences. The trial 
specific mean differences represent the composite point estimate for each study obtained by 
performing random effects meta-analysis on the HIV and gravidity subgroups for that study. The solid 
vertical line represents the pooled effect estimate with all studies included and the 2 broken vertical 
lines in red represent the corresponding 95% CI. Reference numbers refer to those in the main 
manuscript. 
  
Chapter 4 
111 
 
4.3.3 Secondary outcomes 
The median maternal haemoglobin level at term in the 2-dose group was 10.9 g/dL (range, 
9.7-11.6 g/dL), and this was on average 0.13 g/dL higher (95% CI, 0.03-0.22 g/dL) in the ≥3-
dose group (Figure 4.10 & Table 4. 2).  
This group had a lower risk of moderate to severe maternal anaemia, but this was evident 
only in G1-G2 women (RR = 0.60 [95% CI, 0.36-0.99]; I2 = 20%), not overall (RR = 0.73 [95% 
CI, 0.48-1.11]; I2 = 15%) (Figure 4.11 & Table 4. 2). Women in the ≥3-dose group were 
approximately half as likely to have placental malaria (6 studies) compared with those in the 
2-dose group, regardless of HIV status (RR = 0.51 [95% CI, 0.38-0.68]; I2 = 0%) (Table 4. 2 & 
Figure 4.12), but this was evident only in G1-G2 women (RR = 0.50 [95% CI, 0.35-0.70]; 
I2 = 0%) (Table 4. 3), not in multigravida (RR = 0.71 [95% CI, 0.26-1.95]; I2 = 21%) (Table 4.4) . 
Similarly, ≥3 doses were associated with less peripheral (maternal) malaria (RR = 0.68 [95% 
CI, 0.52-0.89]; I2 = 47%) (Table 4. 2), but this was evident in G1-G2 women only (RR = 0.54 
[95% CI, 0.37-0.80]; I2 = 56%) (Table 4. 3), not in multigravida (RR = 0.97 [95% CI, 0.75-1.24]; 
I2 = 0%) (Table 4. 4). No difference in preterm delivery was detected (RR = 0.95 [95% CI, 0.80-
1.12]; I2 = 35%) or in the number of stillbirths (RR = 1.14 [95% CI, 0.85-1.55]; I2 = 0%), 
miscarriages (RR = 1.43 [95% CI, 0.88-2.33]; I2 = 0%), or neonatal deaths (RR = 0.88 [95% CI, 
0.57-1.35]; I2 = 0%) (Table 4. 2). 
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Figure 4.10: Meta-analysis of mean maternal haemoglobin at birth in trials comparing the 2-dose vs 3+ doses of 
IPTp with sulfadoxine-pyrimethamine 
Figure note: N, sample size; HIV, human immunodeficiency virus status; G1-G2, first and second pregnancies; G3+, 2 
or more previous pregnancies; CI, confidence interval; D+L, Dersimonian-Laird method for random effects models; I-
V, Inverse-Variance method used in the fixed effects models;  SD, Standard Deviation. Data-marker sizes indicate the 
weight applied to each study using random-effects meta-analysis. Diamonds represent summary effect of studies. P-
values following the I2 statistics represent the Chi-square test for heterogeneity. Reference numbers refer to those in 
the main manuscript. 
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Figure 4.11:Meta-analysis of moderate-severe maternal anaemia at birth in trials comparing the 2-
dose vs 3+ doses of IPTp with sulfadoxine-pyrimethamine 
Figure note: n, number of events; N, sample size; HIV, human immunodeficiency virus status; G1-G2, 
first and second pregnancies; G3+, 2 or more previous pregnancies; CI, confidence interval. D+L, 
Dersimonian-Laird method for random effects models; M-H, Mantel-Haenszel method for fixed 
effects models. Moderate-severe maternal anaemia was defined as haemoglobin concentrations <8 
or <=7 or <=6 g/dL, depending on the trial definition used. Data marker sizes indicate the weight 
applied to each study using random-effects meta-analysis. Diamonds represent summary effect of 
studies. Moderate-severe anaemia was defined by the individual trials as Hb <6, 7 or 8 g/dl. P-values 
following the I2 statistics represent the Chi-square test for heterogeneity. Reference numbers refer to 
those in the main manuscript. 
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Figure 4.12: Meta-analysis of placental malaria in trials comparing the 2-dose vs 3+ doses of IPTp 
with sulfadoxine-pyrimethamine 
Figure note: n, number of events; N, sample size; HIV, human immunodeficiency virus status; G1-G2, 
first and second pregnancies; G3+, 2 or more previous pregnancies; CI, confidence interval. D+L, 
Dersimonian-Laird method for random effects models; M-H, Mantel-Haenszel method for fixed 
effects models. Data-marker sizes indicate the weight applied to each study using random-effects 
meta-analysis. Diamonds represent summary effect of studies. P-values following the I2 statistics 
represent the Chi-square test for heterogeneity. Reference numbers refer to those in the main 
manuscript. 
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4.3.4 Stratified analysis for low birth weight and mean birth weight 
There was no clear correlation between resistance level and the strength of the association 
between treatment regimen and LBW or mean birth weight; the point estimates were 
similar in areas with less than 50% DHPS -K540E mutations (5 trials) and areas with 50% or 
more DHPS -K540E (2 trials) (Figure 4.13 & Figure 4.14). There was also no evidence that 
intensity of malaria transmission or the median number of sulfadoxine-pyrimethamine doses 
in the ≥3-dose group modified the association (P > .17 for all tests for subgroup differences). 
There was no clear difference in the association between the dose group and the risk of LBW 
or mean birth weight in the 2 trials that used high-dose folate supplementation (5 mg/d) 
(Hamer et al., 2007, Parise et al., 1998) (which has since been contraindicated) vs the 
standard dose (0.25-0.5 mg/d). Three studies reported results stratified by insecticide-
treated net use (Diakite et al., 2011, Luntamo et al., 2010, MaArthur, 2005); the associations 
with LBW and mean birth weight were statistically significant in the nonusers only. There 
was no evidence for an association with LBW in insecticide-treated net users (Figure 4.13 & 
Figure 4.14). 
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Figure 4.13:: Subgroup analysis and analysis of determinants of the association with low 
birthweight 
Figure notes: n, number of events; N, total number; G1-G2, first and second pregnancy; G3+, 2 or more 
previous pregnancies; DHPS-540E, dihydropteroate synthase 540 mutation; LBW, Low birthweight defined as a 
birthweight <2500 grams. ACR, Assumed Control-group Risk; CIR, Assumed Intervention-group Risk; HIV, 
human immunodeficiency virus status; mg, milligram; CI, confidence interval; SP, sulfadoxine-pyrimethamine 
a
 number events (n) and total number (N) are the crude sums of all events and women across studies within 
each subgroup.  
b
 The ACR represents the observed median risk (expressed per 1000 women) and range for each subgroup in 
the 2-dose arm. The CIR is the corresponding risk in the 3-dose group computed as the ACR x RR (95% CI).  
c 
The relative risks are the weighted averages of the trial or subgroup-specific relative risks within each strata 
(row), adjusted for HIV status and gravidity obtained from random effects models, expect for the analysis of 
HIV status itself (first 4 rows), which was adjusted for gravidity only, and the analysis of gravidity (rows 5 to 7), 
which was adjusted for HIV status only  
d
 Heterogeneity relating to the extent that the RRs vary between trials or subgroups are shown as the I
2 
statistic, which depicts the % of the between-study or between subgroup heterogeneity that is attributable to 
variability in the effect, rather than sampling variation. The corresponding P-value is based on the Chi-square 
statistic 
e
 In one trial in Burkina Faso, the median number of doses in the 3+dose arm was only 2 because 2/3 of 
participants failed to receive the intended regimen. The median number of doses in the 2-dose group in that 
same trial was 1. 
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Figure 4.14: Subgroup analysis and analysis of determinants of the association with mean 
birthweight.  
Figure notes: N, total number; G1-G2, first and second pregnancy; G3+, 2 or more previous pregnancies; 
DHPS-K540E, dihydropteroate synthase 540. ACM, Assumed Control-group Median; CIM, Corresponding 
Intervention-group Median; HIV, human immunodeficiency virus status; mg, milligram; CI, confidence interval; 
SP, sulfadoxine-pyrimethamine 
a
 The ACM represents the observed median and range for each subgroup in the 
2-dose arm, CIM is the corresponding median in the 3-dose group computed as the ACM + the mean 
difference.  
b
 The mean differences are the weighted averages of the trial or subgroup-specific mean differences within 
each strata (row), adjusted for HIV status and gravidity obtained from random effects models, expect for the 
analysis of HIV status itself (first 4 rows), which was adjusted for gravidity only, and the analysis of gravidity 
(rows 5 to 7), which was adjusted for HIV status only  
c
 Heterogeneity relating to the extent that the RRs vary between trials or subgroups are shown as the I
2 
statistic, which depicts the % of the between-study or between subgroup heterogeneity that is attributable to 
variability in the effect, rather than sampling variation. The corresponding P-value is based on the Chi-square 
statistic 
d
 In one trial in Burkina Faso, the median number of doses in the 3+dose arm was only 2 because 2/3 of 
participants failed to receive the intended regimen. The median number of doses in the 2-dose group in that 
same trial was 1.  
 
4.3.5 Adverse events 
The risks of neonatal icterus and congenital malformation were comparable between the 
groups, as were the number of adverse events in the mother. One study reported a case of 
Stevens-Johnson syndrome, which occurred in the 3 or more dose group, 3 weeks after the 
first dose ( Table 4. 6) (Hamer et al., 2007). 
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Table 4. 6:Summary of Adverse Events in Women and Neonates Following IPTp with 3+ versus 2-dose of sulfadoxine-pyrimethamine during pregnancy 
 Sulfadoxine-
pyrimethamine 
treatment 
Neonatal Icterus, n/N(%) 
of newborns 
Congenital 
abnormalities, n/N (%) of 
newborns 
Maternal Drug Reaction to SP, 
n/N (%) of women 
Severe Skin 
Reactions 
Studies Number 
of SP 
courses 
Number of 
women  
3+ dose 2-dose 3+ dose 2-dose 3+ dose 2-dose  
Parise et al. 1998 2276 1086
a
 60/431(14) 69/432(15) Not reported 7/661(1.4) 14/680 (2.3) None observed 
b
 
Filler et al. 2006 1734 641
a
 0.4%
c
 Not reported <1%
c
 None observed 
Hamer et al. 2007 1039 456 1/189 (0.5) 0/198 (0) Not reported 1.13 (0.56-2.18)
d
 1 case reported in 
the monthly arm
e
 
Luntamo et al. 2010 2603 877 Not reported 3/443 (0.7) 4/439(0.9) Not reported Not reported 
Valea et al. 2010 2213 1296 Not reported Not reported Not reported Not reported 
Diakite et al. 2011 1997 814 11/400 (2.7) 10/383(2.5) 1/400 (0.3) 3/383(0.8) 0/413(0) 0/401(0) None observed 
McArthur et al  1692 799 14/272 (5.1) 21/290 (7.2) 5/383(1.3) 7/384(1.8) 23/399(5.7)
f
 28/400 (6.7)
f
 None observed 
relative risk and 95% 
CI;  
I
2 
(95% CI), P-value 
for heterogeneity 
 0.87 (0.66, 1.14); 
I
2
=0%(0-61%), P=.76 
0.65 (0.28, 1.50); 
I
2
=0%(0-53), P=.80 
0.73 (0.46, 1.15); 
I
2
=0%(0-0), P=.38 
 
Notes: n, numerator representing the number of events; N, denominator representing the number assessed for the event; (%), percentage of the event unless otherwise 
indicated; 3+, monthly or 3 doses; IPT Intermittent Preventive Treatment; None observed, cases were assessed during the study but not observed by investigators; Not 
reported, cases were not reported in the article by authors; CI, confidence interval; I
2
, I-squared, representing the percentage of heterogeneity between studies that 
contribute to the overall effect represented by the relative risk; P-value is the value of the probability testing for between studies heterogeneity 
a
 Only reported for women followed prospectively 
b
 in 193 treatment episodes among 94 HIV-positive and 502 treatment episodes among 230 HIV-negative women. Although no severe cutaneous reactions were observed, 
“two (2%) of 94 HIV-positive and none of 230 HIV-negative women had sulfadoxine-pyrimethamine withheld because of ADRs (mild rash or oral lesions).”
 
c 
Reported only for all groups pooled, but no statistical difference was observed between treatment groups. 
d Numerator and denominators were not reported. 
e 
The case of Stephen Johnson reported in the monthly arm occurred 3 weeks after the 1
st
 dose of sulfadoxine-pyrimethamine. 
f 
Maternal drug reactions collected from the 1
st
 dose (enrolment) to the last dose including diarrhoea, rash, weakness, seizures, sleepiness, and difficulties to walk. 
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4.4 Comments and conclusion  
This meta-analysis of 7 trials demonstrated that regimens of intermittent preventive therapy 
during pregnancy consisting of ≥3 doses of sulfadoxine-pyrimethamine were well tolerated 
and, compared with the 2-dose regimen, were associated with higher mean birth weight, 
less LBW, and less placental and maternal malaria at delivery. The ≥3-dose regimen was also 
associated with slightly higher mean maternal haemoglobin levels at term overall, but a 
significant association with moderate to severe maternal anaemia was observed only in G1-
G2 women. The associations with birth weight were consistent across trials despite 
variations in study design, malaria endemicity, and the degree of sulfadoxine-pyrimethamine 
resistance. Although the number of trials was limited, there was no suggestion of publication 
or other small-study bias. There was also no suggestion that the results were affected by the 
weight of a single influential study. Two of the trials were classified as low quality, but 
sensitivity analysis indicated that their effect on the overall pooled estimate for LBW was 
minor. The consistency of these findings across the trials suggests the results are 
generalizable. 
Although the summary point estimates of the association with mean birth weight were 
modest (56-g difference overall and 67 g among HIV-negative G1-G2 women), these were 
associated with clinically relevant changes in the risk of LBW, particularly among HIV-
negative G1-G2 women (RR reduction = 25%). These estimates were comparable to that 
reported in previous studies for 2-dose intermittent preventive therapy during pregnancy 
relative to none (mean difference = 79 g; RR reduction = 29%) and for insecticide-treated 
nets alone (mean difference = 55 g; RR reduction = 23%) (Gamble et al., 2007, Ter Kuile and 
Steketee, 2007). The magnitude of the observed association is remarkable, given that 
approximately 28% of women were protected by insecticide-treated nets in these 7 trials 
and considering that the control group benefited from protection of the 2-dose intermittent 
preventive therapy during pregnancy with sulfadoxine-pyrimethamine. The association 
mainly reflects an association with foetal growth, rather than with preterm delivery, and 
indicates that more complete protection in the second and third trimesters, including the 
last 6 to 10 weeks of pregnancy, may be pivotal for foetal growth. This result is consistent 
with observations in healthy pregnancies, which show that of the total foetal weight gain, 
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28% and 55% of it occurs during the last 6 and 10 weeks of pregnancy, respectively 
(Mikolajczyk et al., 2011). 
Although the lack of heterogeneity across the sulfadoxine-pyrimethamine resistance range is 
encouraging, it does not imply that sulfadoxine-pyrimethamine efficacy is unaffected at 
higher levels of resistance. A possible explanation is that the extra doses compensate for any 
reductions in efficacy of the 2-dose regimen resulting from a progressive decrease of the 
duration of post-treatment prophylaxis. 
The association with placental infections is an expected outcome because the 3 or more 
dose group received their last dose on average 1 month closer to delivery and is likely to 
reflect clearance of existing infections near term and prevention of new infections by the 
extra period of prophylaxis. However, the association with mean birth weight among 
multigravida was unexpected because most multigravida in endemic countries have acquired 
a pregnancy-specific protective immunity during exposures in previous pregnancies. Overall, 
the evidence for a beneficial association in multigravida was weak, and the finding in this 
study may therefore reflect a chance observation (eg, because of multiple comparisons) or 
mechanisms other than the prevention of malaria. Although the point estimates for LBW (RR 
reduction 21%) and placental malaria (RR reduction 29%) were in the same direction as 
those observed in primigravida and secundigravida, none were statistically significant and 
there was no suggestion that ≥3 doses were associated with less maternal malaria or 
moderate to severe anaemia. On the other hand, the lack of significant association with LBW 
may reflect lack of power because only 4 of the 7 studies included multigravida. 
Our meta-analysis has some limitations. First, although all trials were designed to 
standardize the number of visits and antenatal care (eg, hematinic supplementation) 
between the 2 groups, in one trial in Tanzania the women in the ≥3-dose group had on 
average 1 extra visit compared with the 2-dose group and thus potentially better antenatal 
care (MacArthur and Abdulla, 2005). However, exclusion of this study in the sensitivity 
analysis did not change the conclusion (Figure 4.8 & Figure 4.9). Second, only 1 of the 7 trials 
was placebo controlled, which may have biased the results and affected some outcomes 
because of lack of expectations in a 2-dose group or differential behaviors across 
intervention groups. We did not use blinding in the selection, evaluation, and data 
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abstraction phases, and because the authors were familiar with all included studies, this 
could have introduced bias (Jadad et al., 1996). Third, none of the trials were conducted in 
regions where additional DHFR 164L or DHPS 581G mutations are prevalent, as reported 
from parts of Rwanda, Uganda, and northern Tanzania, conferring the highest level of 
sulfadoxine-pyrimethamine resistance (Naidoo and Roper, 2011, Gesase et al., 2009, 
Harrington et al., 2011, Harrington et al., 2009). Last, only 3 trials reported results stratified 
by insecticide-treated net use, limiting our evaluation of the potential modifying role of 
insecticide-treated nets. In this smaller subgroup of studies, significant associations with 
LBW and mean birth weight were observed among the nonusers of insecticide-treated nets 
only, consistent with results of previous evaluations of 2-dose intermittent preventive 
therapy during pregnancy against placebo (van Eijk et al., 2012, Leke and Taylor, 2011, 
Peters et al., 2007).  
Only 1 serious cutaneous reaction was reported in the current meta-analysis involving 
13,554 sulfadoxine-pyrimethamine treatments among 6,281 pregnancies, and this occurred 
in an HIV-positive woman 3 weeks after she received her first dose of sulfadoxine-
pyrimethamine for intermittent preventive therapy during pregnancy (Hamer et al., 2007). 
We found no indication that more frequent dosing (ie, resulting in doses administered closer 
to delivery) was associated with increased risk of neonatal jaundice, the main safety signal of 
interest in neonates. Sulfonamides have the potential to displace unconjugated bilirubin 
from albumin, which could increase a newborn's risk of kernicterus if received near delivery. 
Our observations, combined with the evidence reviewed by Peters et al (Peters et al., 2007)  
from the experience with sulfonamides for rheumatic fever prophylaxis, urinary tract 
infections, and congenital toxoplasmosis (which involve higher doses and prolonged use of 
sulfadoxine-pyrimethamine), suggest that concerns regarding kernicterus should not restrict 
the use of monthly sulfadoxine-pyrimethamine for intermittent preventive therapy during 
pregnancy. There was no indication that ≥3-dose regimens increased or reduced the risk of 
stillbirth or neonatal death. The risk of spontaneous miscarriages in G1-G2 women was 
higher among the 3-dose group (RR = 1.78, P = .046 with fixed-effects models and RR = 1.75, 
P = .06 with random-effects models). These miscarriages, however, were not associated with 
the third dose because in 3 of the 4 trials that contributed 80% of the study weight, they 
occurred before 28 weeks of gestation when the third dose had not yet been provided 
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(Diakite et al., 2011, Filler et al., 2006, Valea et al., 2010) . In the fourth trial, the risk of 
miscarriage was 2.0% with a monthly regimen, higher than the 1.1% in the 2-dose group but 
similar to the 2.3% in a third control group consisting of women randomized to passive case 
detection only instead of intermittent preventive therapy during pregnancy (Parise et al., 
1998).  
Since the strategic framework for the control of malaria in pregnancy in sub-Saharan Africa 
was first developed, at least 3 doses of sulfadoxine-pyrimethamine for intermittent 
preventive therapy during pregnancy has been recommended by WHO for HIV-infected 
women or for all women in high-HIV-prevalence areas (>10%) where screening for HIV is not 
conducted. Some countries, such as Cameroon (Leke and Taylor, 2011), Ghana, Zambia, and 
Zimbabwe, selected 3 doses of sulfadoxine-pyrimethamine in their policy for all pregnant 
women, but most other countries, including many high-HIV-prevalence countries, 
implemented the 2-dose regimen and use cotrimoxazole for HIV-infected women (Van Eijk 
et al., 2011). However, more recently other countries, including Kenya and Malawi, 
implemented a monthly regimen among HIV-negative women mainly because of concerns 
about sulfadoxine-pyrimethamine resistance and for pragmatic reasons to minimize the risk 
for missed opportunities to deliver a second dose (Gill et al., 2007) and to achieve better 
alignment with WHO's focused antenatal care schedule (a goal-oriented antenatal care 
approach consisting of 4 visits providing essential evidence-based interventions). In southern 
Malawi, this has resulted in a marked increase in the uptake of 2 or more doses of 
sulfadoxine-pyrimethamine (Kalilani et al., 2011). 
Our cumulative meta-analysis showed that, with the accumulation of results from the 4 most 
recent trials reported since 2010, evidence has emerged that 3-dose or monthly sulfadoxine-
pyrimethamine for intermittent preventive therapy during pregnancy was associated with a 
higher birth weight and lower risk of LBW than the 2-dose regimens among pregnant women 
in sub-Saharan Africa. These data provide support for the new WHO recommendation that 
intermittent preventive therapy during pregnancy with sulfadoxine-pyrimethamine be 
provided at each scheduled focused antenatal-care visit in the second and third trimesters in 
all settings in which intermittent preventive therapy during pregnancy with sulfadoxine-
pyrimethamine is recommended (WHO, 2013). Future research should focus on how best to 
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implement the updated WHO guidelines for intermittent preventive therapy during 
pregnancy with sulfadoxine-pyrimethamine (WHO, 2013) and specifically their integration 
with focused antenatal care. Continued monitoring of the association between population-
level sulfadoxine-pyrimethamine resistance and the effectiveness of intermittent preventive 
therapy during pregnancy is required. 
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5. Chapter 5-Parasite clearance following treatment with 
sulfadoxine-pyrimethamine for intermittent preventive treatment 
in Burkina-Faso and Mali: 42-day in-vivo follow-up study 
5.1 Introduction 
In sub-Saharan Africa, malaria places 32 million pregnancies at risk of maternal anaemia and 
intrauterine growth retardation resulting in low birth weight (LBW) annually (Dellicour et al., 
2010, Desai et al., 2007, Steketee et al., 2001). The World Health Organization (WHO) 
recommends Intermittent Preventive Treatment in pregnancy (IPTp) with at least two doses 
of  sulfadoxine-pyrimethamine (SP) for the control of malaria in pregnancy (WHO/AFRO, 
2004). The 2-dose IPTp-SP regimen has been shown to be very effective and is associated 
with an average reduction in the risk of LBW of 29% (Ter Kuile et al., 2007). More recent 
meta-analysis has shown that this can be enhanced further by providing three or more doses 
of SP during pregnancy (Kayentao et al., 2013). 
However, the emergence of SP resistance is potentially reducing the effectiveness of SP. In 
the early 2000s, SP was abandoned as first line treatment for symptomatic malaria in the 
general population in sub-Saharan Africa in favour of more effective artemisinin based 
combination therapy (ACT). Because IPTp with SP continued to provide significant protection 
in areas with moderate to high parasite resistance (Ter Kuile et al., 2007) SP continues to be 
recommended by WHO for IPTp, and is currently the only anti-malarial used for this 
indication (World Health Organization; Global Malaria Program, 2007). The degree of SP 
resistance correlates with the frequency of single nucleotide polymorphisms (SNPs) that 
encode amino acid substitutions in the dihydrofolate reductase (dhfr) and dihydropteroate 
synthetase (dhps) genes of Plasmodium falciparum (Pf) which encode the drugs’ target 
enzymes. High grade resistance is a particular concern in eastern and southern Africa 
(Naidoo and Roper, 2011), where high frequencies of parasites bearing haplotypes with 
three mutations in dhfr (encoding the N51I, C59R, and S108N) and two in dhps (encoding the 
A437G and K540E substitutions) exist, especially if the additional dhfr164L or dhps581G 
mutations occur (Gesase et al., 2009, Harrington et al., 2009). The latter has recently been 
associated with poor birth outcomes in IPTp-SP recipients (Harrington et al., 2011), although 
this association has not yet been confirmed in other studies in eastern and southern Africa 
(Kalilani et al., 2011, Menendez et al., 2011, Taylor et al., 2012). 
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In contrast, the parasite populations in western Africa seem to be mostly sensitive to SP 
(Coulibaly et al., 2006, Diakite et al., 2011, Dokomajilar et al., 2006, Naidoo and Roper, 
2011), and IPTp-SP has proven to be highly effective and efficacious in clinical trials and 
observational studies (Diakite et al., 2011, Kayentao et al., 2013, Sirima et al., 2006). 
However, spread of SP resistance from eastern and southern Africa, or the de-novo 
development of high-level SP resistance may occur and monitoring of the effectiveness of SP 
when employed as IPTp is essential. 
Despite this need, there are no internationally standardized methods to evaluate the in vivo 
effectiveness of IPTp-SP. Furthermore, the relationship between the level of SP resistance as 
measured by molecular markers and impact of IPTp-SP on birth parameters, or the 
treatment response in asymptomatic women receiving SP for IPTp is not known. Hitherto, 
monitoring SP resistance was predominantly based on in vivo treatment responses among 
symptomatic children with acute malaria. However, extrapolation from children to 
asymptomatic pregnant women is not appropriate as protective immunity against P. 
falciparum malaria is acquired progressively with cumulative exposure and age. As a result 
pregnant women in endemic areas remain typically asymptomatic when infected and have 
lower parasites densities than sick children and as a result have better treatment responses 
to antimalarials, including SP (Kalanda et al., 2006, Tagbor et al., 2007). We therefore 
conducted a single arm 42 days in vivo efficacy study of SP to determine the parasitological 
treatment response to SP and the duration of post-treatment prophylaxis among 
asymptomatic parasitaemic women receiving SP for IPTp in Mali and Burkina Faso. We also 
assessed the prevalence of molecular markers for SP resistance to correlate with the 
treatment responses.  
5.2 Methods 
5.2.1 Study sites and study period 
In Mali, the study was conducted from July 2009 to March 2010 in 2 district health centres 
located in the towns of Kita in the Kayes region in western Mali and in San in the Segou 
region situated approximately 500 kilometres east of Kita (Figure 5. 1). Malaria transmission 
in the two sites is typical for most of the Sahel region with highly seasonal transmission 
restricted to a single period of 3 to 5 months during and shortly after the rainy season, with 
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peak transmission in October. The degree of SP resistance is low in these areas and the 
quintuple dhfr/dhps haplotype has not been found yet (Diakite et al., 2011), although the 
dhps581G mutation has been described in isolation of other mutations in other settings 
(Thera et al., 2005, Wang et al., 1997). 
In Burkina Faso, the study was conducted from January 2010 to December 2011 in 5 
recruitment centres in Ziniaré town, Oubritenga Province, located 400 km South-East of San. 
Malaria transmission is seasonal peaking in September-October. In 2003, the Polymerase 
Chain Reaction (PCR) adjusted parasitological failure rate by day-28 was 13% among 
symptomatic primi-secundigravida with acute falciparum malaria in Ouagadougou, 50 
kilometers from the study site (Coulibaly et al., 2006). 
 
 
Figure 5. 1 :Study sites: Kita and San for Mali, Ziniare for Burkina-Faso 
 
5.2.2 Participants and procedures 
In both countries, pregnant women of all parities with a gestational age between 16-30 
weeks attending for antenatal care for their first dose of IPT-SP were included. Women were 
screened for malaria infection using HRP2 and pLDH-based combo Rapid Diagnostic Tests 
(RDTs, CareStart™Malaria HRP-2/pLDH[Pf/pan] Combo Test) (Sharew et al., 2009, Maltha et 
al., 2010). Women with a positive RDT were then screened for malaria parasitaemia by 
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microscopy and eligible for enrolment if they had a positive blood smear, were 
asymptomatic, were willing to participate in the 6-week follow-up and provided written 
informed consent. Women were excluded if they had a history of hypersensitivity to SP or its 
components, a history of prior use of IPTp-SP during this pregnancy, or a history of receipt of 
other antimalarials or antibiotics with antimalarial activity in the previous month.  
On enrolment, clinical, obstetric and demographic data were obtained and information on 
bednet type and use recorded. A finger-prick blood sample was taken for malaria smears, 
haemoglobin assessment, and dried blood spots (DBSs) for parasite DNA.  
Three tablets of SP containing a total dose of 1,500 mg sulfadoxine and 75 mg of 
pyrimethamine were administered as a single dose on day 0 by the study staff. If vomiting 
occurred within 30 minutes after administration, the full dose was re-administered. Women 
were scheduled to be seen again weekly from day 7 onwards for 42 days for a brief clinical 
exam, assessment of the axillary temperature and collection of blood by finger prick for 
malaria smears, RDT, and DBSs for PCR. Participants were asked to return to the study clinic 
any time they felt ill in between the scheduled visits. Women with positive smear or severe 
malaria at any time on or after day 4 were treated according to national guidelines.  
In Mali, the study drug used was manufactured by Kinapharma limited Ltd, Ghana and in 
Burkina Faso this was also from Kinapharma limited Ltd, Ghana and Medreich limited, India. 
A sample of 50 tablets from each batch was assessed for quality using high-performance 
liquid chromatography (HPLC) conducted in Atlanta, GA, USA by the US Centers for Disease 
Control and Prevention (CDC) to determine the amount of the active ingredient and the 
dissolution profile. Both brands passed the dissolution and content analyses criteria set by 
the United States Pharmacopeia (USP). 
5.2.3 Laboratory methods 
Haemoglobin concentrations were measured using HemoCue® (301 System) on days 0, 14, 
28 and 42, and on the day of parasite recurrence. Giemsa stained malaria smears were 
assessed in duplicate and if a discrepancy was found (positive vs negative) the smear was 
read by a third expert microscopist. Asexual parasites were counted against 300 leukocytes 
and densities expressed per mm3 of blood assuming a leucocyte count of 7,500/mm3. Smears 
were declared negative if no parasites were detected in 100 high-power fields. 
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PCR assays were performed in the laboratories of the Gillings School of Global Public Health, 
University of North Carolina, Chapel Hill, NC, USA using genomic DNA (gDNA) extracted from 
dried blood spots (DBSs)stored on Whatman 3MM filter papers. To differentiate between 
recrudescence and new infection in follow-up specimens with parasite recurrence, a 
standard method was employed to genotype parasites at the merozoite surface protein-1 
(msp-1), merozoite surface protein-2 (msp-2), and glutamate rich protein (GLURP) genes 
(Taylor, 2013). 
To assess the prevalence of genomic markers of parasite SP resistance, genomic DNA from 
all parasitemic women was pooled by study site (2 in Mali and 1 in Burkina Faso). Fragments 
of the dhfr and dhps genes containing the SNPs of interest were PCR-amplified from the 
pooled gDNA from each site to produce a mixture of gene fragments (Taylor, 2013), and 
these PCR products were sequenced on a Roche GS Junior next-generation sequencing 
system. 
5.2.4 Study endpoints classification 
The primary outcome was the PCR-unadjusted % of patients with parasites recurrence by 
day 42, defined as a positive diagnostic test for malaria at any visit between days 4 and 42. 
To define treatment failure, the standard WHO criteria (WHO, 2003) were used. 
5.2.5 Statistical analysis 
Data were analyzed using STATA v12 and SPSS version 20. The treatment responses are 
summarized by weeks of follow-up. The therapeutic response was  estimated using the 
Kaplan-Meier product limit formula (WorldWide Antimalarial Resistance Network (WWARN), 
2011). In the PCR-unadjusted analysis, recurrences were treated as treatment failures and all 
other events (e.g. withdrawal or protocol deviations) resulted in censoring at the time of 
that event, or at the time of their last follow-up visit in case of loss to follow-up. A similar 
strategy was used for the PCR-adjusted analysis except that patients with new P. falciparum 
infections (reinfections) were censored at the time of parasite reappearance (WorldWide 
Antimalarial Resistance Network (WWARN), 2011). 
5.2.6 Ethical considerations  
The protocol was approved by the Faculty of Medicine, Pharmacy and Dentistry, University 
of Bamako, Mali, the National Ethical Review Committee and Ministry of Health, Burkina-
Chapter 5 
 
130 
 
Faso, the University of North Carolina, United States, and the Liverpool School of Tropical 
Medicine, United Kingdom. 
5.3 Results 
5.3.1 Treatment responses    
Overall 580 of 584 women who fulfilled all enrollment criteria were enrolled (99.3%, Figure 
5.2 & Table 5.1), and 572 of the 580 contributed to the survival analysis. Eight of the 33 
women lost to follow-up were not seen after day 0; 3 from Mali and 5 from Burkina-Faso. 
The remaining 25 were censored on the day they were last seen. 
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Total screened: 1,894 
Mali: 1,148 Burkina-Faso: 746 
Enrolled: 268 Enrolled: 312    
    880 Excluded 
           862 Negative microscopy  
              16 Previous SP or other 
antimalarials  
                1 Refusal 
                1 Fever 
               
434 Excluded          
       428 Negative 
microscopy3 No       
             1 HIV positive  
             3 Refusals 
             2 Did not return  
Gravida>=3: 83 Gravida 1&2: 204 
2204133
Gravida>=3: 108 Gravida 1&2: 185 
Moved= 1 
Not traced=0 
Refusal=0 
Other= 0 
 
Moved= 0 
Not traced=1 
Refusal=2 
Other= 2 
 
Moved= 1 
Not traced=0 
Refusal=0 
Other= 0 
 
Moved= 2 
Not traced=2 
Refusal=2 
Other= 1 
 
Day 14: 199 Day 14: 107 Day 14: 178 Day 14: 82 
Moved= 0 
Not traced=0 
Refusal=0 
Other= 0 
 
Moved= 2 
Not traced=0 
Refusal=2 
Other= 4 
 
Moved= 0 
Not traced=0 
Refusal=0 
Other=0 
 
Moved= 0 
Not traced=1 
Refusal=0 
Other= 0 
 
Day 28: 191 Day 28: 107 Day 28: 177 Day 28: 82 
Moved= 0 
Not 
traced=0 
Refusal=0 
Other= 1 
Moved= 0 
Not traced=1 
Refusal=0 
Other= 2 
 
Moved= 0 
Not traced=1 
Refusal=0 
Other= 0 
 
Moved= 0 
Not traced=3 
Refusal=0 
Other= 2 
 
Day 42: 188 Day 42: 106 Day 42: 172 Day 42: 81 
Figure 5.2 : Profile of women screened, enrolled, and completing the study. 
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Table 5.1: Baseline characteristics of women enrolled in SP in vivo efficacy study, Burkina-Faso and 
Mali 
 Burkina-Faso 
N = 312 
Mali 
N =268 
All 
N = 580 
Age, years,  
Mean (SD) 
 
23.6 (5.4) 
 
21.1 (5.1) 
 
22.5 (5.4) 
Residing in rural area, n (%) 81 (30.2) 146 (45.2) 222 (38.3) 
Knows the date of LMP, n (%) 44 (16.4) 61 (19.6) 105 (18.1) 
Pregnancy number 
Median (range) 
 First or second pregnancy, n (%) 
 
2 (1-8) 
204 (65.4) 
 
2 (1-9) 
185 (69.0) 
 
2 (1-9) 
389 (67.1) 
Use of a bed net last night a 
Any net, n (%) 
ITN, n (%) 
 
187 (60.1)  
171 (55.0) 
 
207 (77.2) 
180 (67.2) 
 
394 (68.1)  
351 (60.6) 
Use medicine in first trimester  
    Any medicine, n (%) 
    Antimalarial, n (%) 
 
6 (1.9) 
2 (0.6) 
 
25 (9.3) 
15 (5.6) 
 
31(5.3) 
17 (2.9) 
Fundal height, cm 
Mean (SD) 
 
21.5 (2.9) 
 
21.8 (3.2) 
 
21.7 (3.1) 
Gestational age, weeks 
Mean (SD) 
 
25.3 (3.1) 
 
25.4 (3.2) 
 
25.3 (3.1) 
Maternal height, cm  
Mean (SD) 
 
162.7 (6.2) 
 
162.2 (6.3) 
 
162.4 (6.2) 
Maternal weight, kgs 
Mean (SD) 
 
57.8 (7.5) 
 
56.4 (8.5) 
 
57.2 (8.0) 
Haemoglobin, g/dL b 
Mean (SD) 
Anaemia (Hb<11 /dL), n (%) 
Moderate-Severe anaemia (Hb<8 g/dL), 
n (%) 
 
10.1 (1.4) 
225 (72.4) 
22 (7.1) 
 
 
9.6 (1.6) 
198 (80.5) 
40 (16.3) 
 
9.9 (1.5) 
423 (75.9) 
62 (11.1) 
Peripheral parasitaemia 
GMPD/µl (95% CI) 
623 
(537-723) 
716 
(598-859) 
664 
(592-746) 
Notes:  Data are numberso (%), unless otherwise indicated. 
N, sample size; n, number of events;  SD, Standard deviation; LMP, Last Menstrual Period; ITN, 
Insecticide Treated Net; cm, centimeters; kgs, kilograms; g/dL, Gram per deci-Litre; Hb, Haemoglobin; 
GMPD/µl, Geometric Mean Parasite Density per microliter. 
aBed net use was not evaluated in 1 subject from Burkina-Faso. 
bHaemoglobin was not measured for 1 subject in Burkina-Faso and 22 in Mali.    
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PCR-unadjusted efficacy: Based on microscopy, overall 27 of the 572 women had a 
recurrence of parasitaemia by the end of follow-up (Mali 8; Burkina Faso 19). The cumulative 
recurrence risks by day 42 estimated by survival analysis were 4.9% overall, and 3.2% and 
6.5% in Mali and Burkina Faso respectively (Hazard Ratio [HR] Burkina vs Mali=2.14, 95% CI 
0.93-4.90; P=0.070 (Table 5.2 & Figure 5.3). The recurrence risk was higher among primi -
secundigravidae (6.4%) than multi-gravidae (2.2%), HR=3.01 (1.04-8.69; P=0.042) (Figure 5.4).  
PCR-adjusted efficacy: From 26 of the 27 recurrences, DNA could be extracted and 24 were 
genotyped successfully. This suggested that only 6 of the 24 were recrudescences. The PCR-
adjusted cumulative failure rate obtained by survival analysis was 1.1% overall, and 0.8% in 
Mali and 1.4% in Burkina-Faso (Figure 5.3). Overall, median (range) time to PCR-adjusted 
failure and to reinfection was 21 (7-35) and 35 (7-43) days, respectively.  
Haematological response: There was a significant increase in the mean haemoglobin 
concentrations compared to enrolment at all-time points measured in both countries and 
both among primi-secundigravida and multigravida (Figure 5. 5 & Table 5.3).  
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Table 5.2: Parasitological efficacy of SP among women enrolled in Burkina-Faso and Mali  
Characteristics  Burkina-Faso 
N = 312 
Mali 
N =268 
All 
N =580 
                           PCR 
Days 
non- 
adjusted 
adjusted non- 
adjusted 
Adjusted non- 
adjusted 
Adjusted 
Day 7:  
Number at risk 
Failures, n (%) 
      ETF 
      LCF 
      LPF 
 ACPR n (%) 
 
307 
 
     0  
     0 
     2 (0.5) 
305 (99.5) 
 
307 
 
    0 
    0 
    1 (0.3) 
306 (99.7 
 
265 
 
     0 
     0 
     1 (0.4) 
264 (99.6) 
 
265 
 
    0 
    0 
    1 (0.4) 
264 (99.6) 
 
572 
 
    0 
    0 
    3 (0.5) 
569 (99.5) 
 
572 
 
     0 
     0 
     2 (0.3) 
570 (99.7) 
Day 14:  
Number at risk 
Failures n (%) 
      ETF 
      LCF 
      LPF 
 ACPR n (%) 
 
306 
 
     0 
     0 
     3 (1.0) 
303 (99.0) 
 
306 
 
     0 
     0 
     2 (0.7) 
304 (99.3) 
 
260 
 
     0 
     0 
     1 (0.4) 
259 (99.6) 
 
260 
 
     0 
     0 
     1 (0.4) 
259 (99.6) 
 
566 
 
    0 
    0 
     4 (0.7) 
562 (99.3) 
 
566 
 
    0 
    0 
     3 (0.5) 
563 (99.5 
Day 21:  
Number at risk 
Failures n (%) 
      ETF 
      LCF 
      LPF 
 ACPR n (%) 
 
300 
 
    0 
    0 
     3 (1.0) 
297 (99.0) 
 
300 
 
     0 
     0 
     2 (0.7) 
298 (99.3) 
 
259 
 
    0 
    0 
    1 (0.4) 
258 (99.6) 
 
259 
 
     0 
     0 
     1 (0.4) 
258 (99.6) 
 
559 
 
     0 
     0 
     4 (0.7) 
542 (99.5) 
 
559 
 
    0 
    0 
     3 (0.5) 
556 (99.5) 
Day 28:  
Number at risk 
Failures n (%) 
      ETF 
      LCF 
      LPF 
 ACPR n (%) 
 
297 
 
     0 
     0 
     7 (2.4) 
290 (97.6) 
 
297 
 
     0 
     0 
     3 (1.0) 
294 (99.0) 
 
259 
 
     0 
     0 
     2 (0.8) 
257 (99.2) 
 
259 
 
    0 
    0 
     2 (0.8) 
257 (99.2) 
 
556 
 
     0 
     0 
     9 (1.6) 
547 (98.4) 
 
556 
 
    0 
    0 
     5 (0.9) 
551 (99.1 
Day 35:  
Number at risk 
Failures n (%) 
      ETF 
      LCF 
      LPF 
 ACPR n (%) 
 
295 
 
     0 
     0 
  14 (4.8) 
281 (95.2) 
 
294a 
 
     0 
     0 
     4 (1.4) 
290 (98.6) 
 
253 
 
    0 
    0 
    2 (0.8) 
251 (99.2) 
 
254 
 
     0 
     0 
     2 (0.8) 
252 (99.2) 
 
548 
 
     0 
     0 
  16 (2.9) 
532 (97.1) 
 
547a 
 
 
     0 
     6 (1.1) 
541 (98.9) 
Day 42:  
Number at risk 
Failures n (%) 
      ETF 
      LCF 
      LPF 
 ACPR n (%) 
Median (range) 
time in days  
 
293 
 
     0 
     0 
  19 (6.5) 
274 (93.5) 
35 (7-43)d 
 
292 a 
 
     0 
     0 
     4 (1.4) 
288 (98.6) 
21 (7-35)e 
 
 
253 
 
     0 
     0 
     8 (3.2) 
245 (96.8) 
42 (7-42)d 
 
251a,b 
 
    0 
    0 
    2 (0.8) 
249 (99.2) 
18 (7-29)e 
 
546 
 
     0 
     0 
  27 (4.9) 
519 (95.1) 
35 (7-43)d 
 
544 c 
 
     0 
     0 
     6  (1.1) 
538 (98.9) 
21 (7-35)e 
Notes: The table is showing in vivo cumulative response to sulfadoxine-pyrimethamine  
PCR, Polymerase Chain Reaction; ETF, Early Treatment Failure; LCF, Late Treatment Failure; LPF, Late 
Chapter 5 
 
135 
 
parasitological Failure; ACPR, Adequate Clinical and Parasitological Response 
aOne PCR inconclusive  
bOne recurrence of parasites not done for PCR analysis. 
cPCR inconclusive (1 from Mali, 1 from Burkina) and no PCR analysis (1 from Mali). These three cases 
were censored in the survival analysis. 
dMedian (range) time to reinfection  
eMedian (range) time to PCR-adjusted failure 
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Figure 5.3: Probability of parasitological failure by microscopy in Burkina-Faso and Mali: PCR 
unadjusted (Panel A) and PCR adjusted (Panel B)  
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Figure 5.4: Probability of parasitological failure by microscopy by gravida (Gravida1&2, primi-
secundigravida; Gravida>=3, multigravida): PCR unadjusted (Panel A) and PCR adjusted (Panel B) 
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Table 5.3 : Heamoglobin concentration and anaemia among women enrolled in Burkina-Faso and Mali  
Characteristics  Burkina-Faso 
 
Mali 
 
All 
 
Day 0 
N 
Mean haemoglobin (SD), g/dl 
Anaemia (<11 g/dl), n (%) 
 
311 
10.1 (1.4) 
225 (72.4) 
 
 
246 
9.6 (1.6) 
198 (80.5) 
 
557 
9.9 (1.5) 
423 (75.9) 
Day 14 
N 
Mean haemoglobin (SD), g/dl 
Anaemia (<11 g/dl), n (%) 
 
Mean difference, 95%CIa 
Risk Ratio, 95%CIb 
 
 
301 
10.2 (1.3) 
208 (69.1) 
 
  0.13 (0.004, 0.26)  
0.96 (0.86, 1.06) 
 
237 
10.1 (1.4) 
177 (74.7) 
 
  0.44 (0.28, 0.59) 
0.93(0.84, 1.02) 
 
 
538 
10.2 (1.3) 
385 (71.6) 
 
0.26 (0.16, 0.36) 
0.94(0.88, 1.01) 
 
 
Day 28 
N 
Mean haemoglobin (SD), g/dl 
Anaemia (<11 g/dl), n (%) 
 
Mean difference, 95%CIa 
Risk Ratio, 95%CIb 
 
 
 
290 
10.7 (1.2) 
171 (59.0) 
 
 0.60 (0.46,0.74) 
0.82 (0.72, 0.92) 
 
244 
10.6 (1.2) 
153 (62.7) 
 
 0.87 (0.69, 1.06) 
0.78 (0.70, 0.87) 
 
 
534 
10.6 (1.2) 
325 (60.7) 
 
 0.72 (0.61, 0.83) 
0.80 (0.74, 0.87 
 
Day 42 
N 
Mean haemoglobin (SD), g/dl 
Anaemia (<11 g/dl), n (%) 
 
Mean difference, 95% CIa 
Risk Ratio, 95% CIb 
 
 
265 
11.0 (1.2) 
127 (47.9) 
 
 0.87 (0.65, 1.09) 
0.66 (0.57, 0.77) 
 
 
249 
10.9 (1.3) 
120 (48.2) 
 
 1.30 (1.11, 1.49) 
0.60 (0.52, 0.69) 
 
 
514 
10.9 (1.3) 
247 (48.1) 
 
1.06 ( 0.93, 1.18) 
0.63 (0.57, 0.70) 
 
Notes:  
N, sample size; n, number of events; SD, standard deviation; g/dl, gram per decilitre; CI, confidence interval. 
aMean difference and 95% confidence interval for each time that haemoglobin was measured using day 0 as 
reference category. 
bRisk ratio and 95% confidence interval for each time that haemoglobin was measured using day 0 as 
reference category, adjusted for gravida and site (all), and for gravida (in each country) . 
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Figure 5. 5: Increase in haemoglobin by country in all gravida (top panel), by gravida 
(bottom panel). 
Analysis was done with repeated measures Generalized Estimating Equation (GEE), adjusted 
for the baseline haemoglobin levels on Day-0. Black squares or diamonds represent the point 
estimates and vertical lines the corresponding 95% confidence intervals 
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5.3.2 Prevalence of molecular markers for SP resistance at booking 
No dhfr 164L or dhps581G mutations were found in any of the three sites; the dhps 540E 
mutation was found in one site of the 2 sites Mali, but at a very low prevalence (Figure 5. 6). 
Several novel non-synonymous mutations in dhps were detected; in Kita, a V452I 
substitution was present in 1.43 % (1.28 – 1.59) of reads and a L590H substitution in 1.05% 
(0.78 – 1.32). In Ziniare, an R532S substitution was present in 1.02% (0.78 – 1.26) of reads, 
while a G533R substitution was present in 1.94% (1.61 – 2.27) (data not shown).  
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Figure 5. 6: Prevalence of SP resistance molecular makers in Burkina-Faso and Mali among women 
during antenatal booking; dhfr /dhps alleles (Top panel) and dhfr haplotypes (Bottom panel) 
Mixed/mutant Alleles (%) 
Mix
ed/ 
mut
ant 
Hap
loty
pes 
(%) 
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5.4 Discussion  
SP when given as IPTp to asymptomatic parasitaemic pregnant women was associated with a 
high cure rate and marked increases in haemoglobin concentrations by day 42 in the 3 study 
sites in Mali and Burkina-Faso. Overall, only 4.9% of women had a recurrence of parasites by 
day 42, and genotyping suggested that the vast majority of these were reinfections. Overall 
only 1.1% of treatments resulted in true treatment failures (recrudescence) and all of these 
were asymptomatic.  
The pooled molecular assays for the surveillance of SP resistance showed that almost 50% of 
the parasite population in Burkina Faso, but only 9% in San and <1% in Kita, carried the dhfr 
triple mutations. The pooled deep sequencing of Plasmodium falciparum parasitemias can 
provide estimates of the mutant allele frequencies, but does not provide estimates of the 
quadruple and quintuple dhfr/dhps haplotypes. Nevertheless, the dhps 540E mutation, 
which is a proxy for the quintuple haplotype conferring mid-level resistance to SP, was 
present in only one of the two sites of Mali and at very low frequency (0.73%, 95% CI 0.58-
0.87). The mutation at dhfr codon 164L and dhps codon 581G conferring very high-level 
resistance to SP were absent. In addition, there were several novel mutations in dhps which 
were limited to a very low frequency. Their clinical and biological significance is unknown, 
but their quantification underscores the ability of the pooled genotyping approach to 
uncover low-level subpopulations of parasites. 
The 1.4% failure rate in Burkina Faso among asymptomatic women in this study is in contrast 
to the 13% PCR-adjusted failure rate by day-28 observed in the previous in-vivo study among 
symptomatic pregnant women conducted in 2003 in an area located 32 miles south from 
the current site (Coulibaly et al., 2006). The average parasite densities in the previous study 
were 10 fold higher than in the current study, illustrating the differences in treatment 
responses when SP is used as IPTp in asymptomatic women with predominantly low-grade 
parasitaemia vs. acutely ill women requiring case-management drugs. This may in part 
explain the earlier findings from randomized controlled trials that IPTp-SP remained 
surprisingly effective in areas with moderate to high levels of SP resistance (Kayentao et al., 
2013, Ter Kuile et al., 2007). 
Our observations provide an important contribution to the understanding of the predictive 
value of the frequency of population estimates of the different dhfr and dhps mutations on 
Chapter 5 
 
143 
 
the efficacy of SP in clearing malaria infection among asymptomatic pregnant women, 
especially when our results are compared against day 42 failure rates in areas with higher 
resistance. For example, the dhfr triple mutation (Ile51+Arg59+Asn108) was present in 
almost 50% of the parasite population in Burkina Faso yet only 1.4% of the treatments 
recrudesced by day 42. The dhfr triple mutation is known to confer intense pyrimethamine 
resistance in vitro (Gregson and Plowe, 2005) and is associated with an approximate 1,000-
fold reduction in pyrimethamine susceptibility (White, 2005) and with an increased risk of SP 
treatment failure in children with acute malaria (Kublin et al., 2002, Mockenhaupt et al., 
2005, Picot et al., 2009). These combined data suggests that parasite densities and immunity 
contribute importantly to parasite clearance, which in turn influences the association of 
treatment outcome with dhfr and dhps alleles. 
It is likely that the results of this study are representative for large parts of West and Central 
Africa that have a similar low geographic prevalence of the dhfr/dhps quadruple or quintuple 
mutations reflecting low and mid-level resistance to SP (Naidoo and Roper, 2011). A key 
question is whether this situation can be sustained or whether further development of SP 
drug resistance is inevitable in this region. Mutations arise under antifolate pressure in a 
stepwise fashion, with successive mutations conferring higher levels of resistance (Cortese et 
al., 2002). Previous studies from Ghana showed a rapid increase in the prevalence of the 
triple-mutant dhfr alleles among falciparum isolated from pregnant women in an area where 
pyrimethamine prophylaxis (as mono-therapy) was used 6 to 8 years previously for the 
prevention of malaria (Mockenhaupt et al., 2008). Some fitness-reducing mutations, such as 
the dhfr I164L can only be sustained under conditions of sustained drug pressure. The switch 
from SP as first line treatment for symptomatic malaria in the general population to ACTs 
will have  a marked impact on reducing SP drug pressure in the population (Malisa et al., 
2010). Modelling of the impact of the introduction of IPTi in infants suggest that use of SP in 
small target populations such as infants or pregnant women may not sustain sufficient drug 
pressure to impact on the spread of drug resistance. This was also suggested in field studies 
in Mali (Dicko et al., 2010). However, many West African countries including Mali and 
Burkina are seeking to implement Seasonal Malaria Chemoprevention (SMC) (WHO, 2012) in 
children which would provide presumptive treatment over the course of the transmission 
season to a much larger fraction of the population. Although, the combination of 
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amodiaquine and SP is one of the main candidate antimalarials for SMC, it is unclear if the 
introduction of this strategy will indeed increase SP drug pressure. The effect of SMC on drug 
pressure may be minimal if implemented on a large enough scale to impact on malaria 
transmission and the total parasite biomass in the SMC population, especially if ACTs are 
used as case-management for clinical episodes caused by any SP resistant parasites that may 
have escaped the drug action of SMC. It will be clearly important to monitor the prevalence 
of molecular markers of parasite resistance to SP as part of any SMC policy that uses 
combination therapy containing SP. 
Our investigation found a high prevalence of anaemia and showed that SP treatment was 
associated with a marked increase in mean haemoglobin levels by day 42. The fact that the 
impact was most pronounced in the primi- and secundigravidae, the group most susceptible 
to adverse effect of malaria, may indicate that even these asymptomatic infections are an 
important cause of maternal anaemia in this subgroup. These findings are consistent with 
previous findings that showed IPTp has a marked beneficial impact on moderate-to-severe 
anaemia in Mali (Kayentao et al., 2005).  
Our study was limited by the lack of genotyping of parasites from individual women for 
molecular markers of SP resistance, and the genomic DNA from pooled sequencing by study 
site was not able to explore the correlation between treatment efficacy or the 
haematological response in individual women and SP resistance molecular markers.  
5.5 Conclusion  
This is among the first studies to examine the 42-day in vivo response of IPTp-SP in 
asymptomatic women in areas with low level of SP resistance in West Africa. Despite 
growing concerns about the impact of SP resistance in eastern and southern Africa, this 
study shows that SP remains effective at clearing existing infections and improving 
haemoglobin concentration when provided as IPTp to asymptomatic pregnant women in 
Mali and Burkina-Faso. SP has many attributes that makes it an excellent candidate for IPTp, 
and it is thus likely that it could remain the drug of choice for IPTp in this region for the 
foreseeable future. However continued monitoring of SP resistance over the next years in 
this region coupled with monitoring of IPTp-SP effectiveness on birth parameters is essential.  
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6. Chapter 6-Effectiveness of intermittent Preventive Therapy for the 
Control of Malaria in Pregnancy in five health districts of Mali: an 
observational study 
6.1 Introduction 
In sub-Saharan Africa, approximately 32 million pregnancies are at risk of acquiring P. 
falciparum infections each year (Dellicour et al., 2010) causing maternal anaemia and low 
birth weight (LBW) (Desai et al., 2007, Steketee et al., 2001).  
Intermittent preventive treatment in pregnancy (IPTp) with sulphadoxine-pyrimethamine 
(SP) is recommended by the World Health Organization (WHO) for reducing the risks of 
adverse birth outcomes associated with malaria in pregnancy and this strategy has been 
shown to be very effective in controlled trials across different malaria endemic regions in 
sub-Saharan Africa (Kayentao et al., 2005, Njagi et al., 2003, Parise et al., 1998, Shulman, 
1999, Ter Kuile and Steketee, 2007). Implementation of this strategy began in East-Africa in 
the 1990s followed by West-African countries in the 2000s. To date, IPTp in combination 
with insecticide treated nets (ITN) is policy in 37 countries of sub-Saharan Africa (Van Eijk et 
al., 2011).  
In Mali, IPTp-SP was first introduced for pilot implementation in few districts in 2003 by the 
Ministry of Health with support of UNICEF. In 2006, a demographic health survey (DHS) 
suggested the coverage of 2 doses SP to be only 4% despite the efforts deployed by UNICEF 
and the international children's charity “Save the Children” (DHS, 2006), but this had 
increased to 19.9% in 2012 following further support from the Global Fund and other donors 
to the National Malaria Control Program (DHS, 2012-2013) . Similar efforts to increase the 
uptake of IPTp-SP are under way across Africa (van Eijk et al., 2013). 
However, increasing resistance to SP is threatening the effectiveness of this important 
strategy, especially in eastern and southern Africa (Naidoo and Roper, 2011, Harrington et 
al., 2011). In western Africa, P. falciparum has remained largely sensitive to SP (Flegg et al., 
2013) and IPTp-SP appears to maintain good effectiveness in improving birth outcomes in a 
series of studies in this region (Diakite et al., 2011, Valea et al., 2010, Naidoo and Roper, 
2013, Sirima et al., 2006, Vanga-Bosson et al., 2011). However, SP resistance has continued 
to increase and there are no recent reports assessing its effectiveness under programmatic 
conditions.  
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Here we report the results of 6 observational cross-sectional studies conducted between 
2006 and 2010 among women attending for delivery in 5 districts with different levels of 
malaria transmission in Mali. The surveys were conducted to assess the uptake and 
effectiveness of IPTp-SP in a context of high ITN use and low population levels of SP 
resistance as determined by molecular markers (Dicko et al., 2010). The results also 
contribute to a larger pool of similar studies designed to support the development by WHO 
of a practical standardized protocol for monitoring the impact of SP resistance on IPTp-SP 
effectiveness in pregnant women in sub-Saharan Africa. 
6.2 Methods  
6.2.1 Ethics statement 
Before enrollment, women were asked to provide written informed consent after the study 
procedures were explained in their local language (Bambara). The study protocol was 
approved by the research ethics committees or institutional review boards of the Faculty of 
Medicine, Pharmacy, and Dentistry of Mali (FMPOS) (all surveys), the Centers of Diseases 
Control and Prevention (CDC) (for the first 4 surveys), and the Liverpool School or Tropical 
Medicine (LSTM) (last 2 surveys).  
6.2.2 Study sites 
The study consisted of 6 surveys conducted between September 2006 and January 2010 in 5 
sites in 5 different health districts across Mali, namely Koro, Djenne, Bougouni, Kita (1 survey 
each), and San (2 surveys). These 5 districts were the initial pilot implementation districts for 
IPTp in 2003-2004 and received specific support from UNICEF and Save the Children. The 
uptake of IPTp and ITNs is therefore probably higher in these pilot districts than in other 
parts of Mali. In all 5 sites malaria transmission is highly seasonal with single transmission 
season peaking between September-October (Figure 6.1). The length of the transmission 
season is longest in the South where Bougouni is located, lasting 4 to 6 months and starting 
around June. Further north, the transmission season gets progressively shorter and starts 
later following the northward migration of the Sahel rainfall pattern typical for this region.  
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Figure 6.1: Map of different study location in Mali  
Source: This map is a product of the MAP 
project(http://www.map.ox.ac.uk/client_media/pdf/Pf_mean_2010/Pf_mean_2010_MLI.pdf)  
Notes: Open circles  depict the location of the 5 survey sites  
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6.2.3 Clinical procedures 
All 6 cross-sectional surveys were designed to evaluate the effectiveness of IPTp on birth 
parameters among all gravida aged 15 years and older. A woman was screened in the 
delivery unit and if informed consent was obtained an enrolment questionnaire was filled to 
obtain socio-demographic characteristics, information on the history of fever, and use of 
ITNs and IPTp. The number of reported SP doses used during pregnancy was verified using 
antenatal clinic cards or any other ANC records available. The axillary temperature was 
measured and a maternal capillary blood sample was taken for haemoglobin and malaria 
smears (thin and thick) and dried blood spots for polymerase chain reaction (PCR) based 
analyses. Placental blood was collected from the maternal side of the placenta for thick 
smears and dried blood spots for PCR analysis. Umbilical cord blood was also taken for thick 
blood smears. Within 24 hours of delivery, singleton neonates were weighed using the same 
brand of digital scale at each site. Gestational age was assessed using a standardized Ballard 
examination (Ballard et al., 1979).  
6.2.4 Laboratory procedures  
Thick blood smears were stained with 4% Giemsa for 20 minutes and examined for malaria 
parasites. Parasite densities were counted against 300 leucocytes and expressed using an 
assumed leukocyte count of 7,500 leukocytes /mm3 of blood. Smears were considered 
negative if no parasites were detected after counting 100 high power fields. For quality 
control, 10% of positive and 10% of negative slides were randomly selected and read by an 
expert microscopist from the Malaria Research and Training Centre (MRTC) in Bamako.  Thin 
smears were used for parasite species diagnosis. A HemoCue machine® (Hemoglobin AB, 
Ångelholm, Sweden) was used to assess maternal haemoglobin concentrations.    
6.2.5 PCR 
DNA extraction: A simple DNA extraction method for filter paper strips was used (Djimde et 
al., 2001). Briefly, approximately 1 x 2 mm piece of blood-soaked filter paper was placed in 
50 µl of methanol for 15 min. The methanol was poured off and the paper heated at 95-100o 
C in 50 µl of water for 10 min. The resulting solution was used as a PCR template. Samples 
that failed to yield PCR amplification with the methanol method were re-extracted using an 
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alternative Chelex-based method (Plowe et al., 1995). For the last two surveys the Chelex-
based method was used for all samples. 
Real time PCR for parasite detection: For the last two surveys (two sites in 2009, (Table 
6.1)), parasites were detected in the maternal (antenatal booking and delivery), placental 
and cord blood using real-time PCR cascade testing approach as previously described (Taylor 
et al., 2011a). Briefly, parasite DNA was pooled in groups of 4 and tested in a real-time PCR 
assay targeting all species of Plasmodia. Those demonstrating amplification were re-tested 
individually in the same assay, and those with positive amplification were then tested in a 
second real-time PCR assay that differentiates between Plasmodia sp. Those demonstrating 
amplification in this P. falciparum assay were considered positive. All assays were performed 
in duplicate with appropriate negative and positive controls. 
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Table 6.1: Site and socio demographic characteristics and malaria prevention measures in women who delivered in the five study sites 
Characteristics Bougouni 
(N=424) 
 
Djenne  
(N=424) 
 
Koro  
(N=424) 
 
San (1) 
(N=424) 
Kita 
(N=615) 
San (2) 
(N=471) 
Total 
(N=2782) 
Year of study conduct Sep06-Mar07 Sep06-Mar07 Sep06-Mar07 Sep06-Mar07 Jul09-Jan10 Jul09-Jan10  
   P.f. prevalence in children 2-9 yrs 52.6 a 50.5 a 48.2 a 64.7 a  39.5 a 66.6 a  
SP resistance        
By modelling or pool deep sequencing in unknown population (first four surveys), and in pregnant women before first SP dose (last two surveys) 
   DHPS A437G 33.4a 32.7 a 44.8 a  32.6 a  15.2 b d 27.5 b d  
   DHPS K540E 0.20 a 0.00 a 0.11 a 0.10 a 0.73 b d 0 b d  
  By nested PCR or pool deep sequencing, women  at delivery* 
   DHPS A437G 29/45 (64.4) c 18/27 (66.7) c 24/28 (85.7) c 36/55 (67.3) c 219/1854 (15.7) 
b  
124/428(29.0) b   
   DHPS K540E 0 c  0 c  0 c 0 c 0 b  0 b   
   DHFR triple** 25/38 (65. 8)c 5/18 (27.8)c 12/24 (50.0)c 21/44 (47.7) c 0.66 b  8.7 b   
   DHPS/DHFR quadruple ** 16/38 (42.1)c 4/18 (22.2)c 7/18 (38.9)c 15/44 (34.1) c    
Age years        
       Mean  (SD) 24.24 (6.79) 26.04 (6.55) 25.34 (6.97) 25.13 (6.13) 24.47 (6.97) 26.45 (6.95) 25.24 (6.80) 
       Age <20, n/N (%) 67/424 (15.8) 26/424 (6.1) 56/424 (13.2) 38/424 (9.0) 102/615 (16.6) 19/471(4.0) 308/2782 (11.1) 
Living in rural area 71/424 (16.8) 116/424 (27.4) 131/424 (30.9 19/424 (4.5) 173/609 (28.4) 84/469 (17.9) 594/2774 (21.4) 
Season delivery 
       Rainy, n/N (%) 
 
 
410/424 (96.7) 233/424 (55.0) 248/424 (58.5) 424/424 (100) 601/615 (97.7) 455/471 (96.6) 2,371/2,782 (85.2) 
Median number 
of pregnancies (range) 
 
 
3(1-12) 4(1-15) 3(1-15) 3(1-10) 4(1-12) 4(1-13) 3(1-15) 
G1-G2, n/N (%) 187/424 (44.1) 149/424 (35.1) 
 
176/424 ( 41.5) 
 
185/424 (43.6) 165/615 (43.1) 
 
181/471 (38.4) 1143/2782 (41.10) 
 
Bed net during pregnancy, n/N (%)*** 239/424  (56.4) 416/424 (98.1) 338/424 (79.7) 371/424 (87.5) 558/613 (91.0) 455/470 (96.8) 2377/2779 (85.53) 
ITN last night 152/424 (35.9) 288/424(67.9) 249/424(58.7) 260/424 (61.3) 542/613 (88.4) 444/470 (94.5) 1935/2779 (69.63) 
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SP, n/N (%) 
     Table 6.1 continued 
0 111/424 (26.2) 154/424 (36.3) 180/424 (42.5) 147/424 (34.7) 155/611 (25.4) 128/470 (27.2) 875 /2777 (31.51) 
1 187/424 (44.1) 119/424 (28.1) 147/424 (34.7) 186/424 (43.9) 132/611 (21.6) 175/470 (37.2) 946/2776 (34.1) 
2 126/424 (29.7) 151/424 (35.6) 97/424 (22.9) 91/424 (21.5) 322/611 (53.0) 157/470 (33.4) 946/2777 (34.1) 
3 0 0 0 0 0 9/470 (1.9) 9 /2777 (0.3) 
4 0 0 0 0 0 1/470 (0.2) 1/2777 (0.04) 
median time between 1st and 2nd 
dose-IPTp (range), N, days  
58 (18-134),  
125 
61 (8-166), 151 61 (17-148), 97 59 (8-154), 
 90 
25 (6-141),  
311 
35 (4-154), 167 42 (4-166),  
941 
median time between last  dose and 
delivery (range), N, days  
74 (8-193),  
306 
65 (2-172), 270 60 (1-172), 240 80 (1-213), 
275 
72 (6-141),  
440 
80 (6-193), 342 72 (3-190),  
1873 
Notes: N, sample size; n, number of events; SD, standard deviation; G1-G2, first and second pregnancy; ITN, insecticide treated net; SP, sulfadoxine-pyrimethamine; IPT, 
intermittent preventive treatment in pregnancy; g/dl, gram per decilitre  
aPrevalences obtained by modelling : Malaria transmission intensity from the published malaria project estimates for 2007 (first 4 surveys)  and 2010 (last 2 surveys) of the P. 
falciparum parasite prevalence in children aged 2-10 years (Gething et al., 2011, Hay et al., 2009) and Pfdhps (unknown source of sample) assessed by high throughput 
sequencing-specific oligonucleotide probe-based method (Alifrangis et al., 2005, Lynch et al., 2008, Pearce et al., 2003)  
bObtained by pool deep sequencing (Taylor et al., 2013) 
cAssessed by nested mutation-specific PCR (Diourte et al., 1999)   
dSample from IPTp recipients at antenatal clinic visit booking (pre-SP dosing)   
*Maternal peripheral blood sample at delivery  
**DHFR triple include mutant allele at DHFR codons N51I, C59R, and S108N; DHFR/DHPS quadruple include mutants for DHFR triple + mutant allele at DHPS codon A437G.  
***Use of all types of bednets including treated and non-treated 
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Determination of dhfr and dhps genotypes  
To determine the degree of resistance to SP in the population, mutations in Plasmodium 
falciparum dihydrofolate reductase (dhfr) and dihydropteroate synthase (dhps) were 
assessed  by PCR amplification and sequencing  using maternal blood samples collected at 
delivery. During the first 4 surveys, nested mutation-specific PCR and/or PCR-RFLP were 
performed (Diourte et al., 1999). DHFR mutations at codons 108, 51 and 59 and the DHPS 
mutations at codons 437 and 540 were analysed. During the last two surveys, pooled 
deep sequencing of Plasmodium falciparum isolates was used to quantify the mutant allele 
frequencies in the Pfdhfr and dhps in mixed isolates using parasite DNA from 130 samples in 
San and 117 in Kita that had previously tested positive for P. falciparum using rtPCR. The 
pooled DNA was PCR amplified at the gene, and PCR products were sequenced using a 
second-generation sequencing platform, which provided the frequency of the drug-
resistance mutation in the parasite population (Taylor et al., 2013) (Table 6.1) .  
Because use of SP during pregnancy may select for resistant mutations, we also determined 
the degree of resistance in samples collected from pregnant women at antenatal booking; 
i.e. before the first dose of SP. These samples were collected from pregnant women in the 
same study site and period. This information was only available for the last two surveys (San 
and Kita). For the first 4 surveys, data on the location and time specific population 
prevalence of mutations in the pfdhps /pfdhfr genes was obtained from spatiotemporal 
mathematical modelling courtesy of the World Wide Antimalarial Resistance Network (Flegg 
et al., 2013). 
6.2.6 Definition  
LBW was defined as a live singleton weight of <2500 grams, and prematurity as gestational 
age of <37 weeks by Ballard examination. Anaemia was defined as an Hb level of <11g/dL, 
and severe anaemia as Hb level <8 g/dL. Small for gestational age (SGA) was determined as 
<10th percentile in birth weight for attained gestational age (Landis et al., 2009). 
Malaria transmission intensity data was obtained using the published Malaria Atlas Project 
(MAP) estimates for 2007 and 2010 of the P. falciparum parasite prevalence in children aged 
2-10 years (Gething et al., 2011, Hay et al., 2009). 
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6.2.7 Sample size calculation and statistical approach  
For the first four surveys, the sample size had been calculated based on a study conducted 
by Kayentao in Mali (Kayentao et al., 2005) which found a placental malaria prevalence of 
25% among women who had received 2 doses of IPT with SP. We estimate that the 
prevalence of placental malaria in the subsequent studies would be slightly lower at 20% 
because of the anticipated high ITN coverage in these populations. It was calculated that a 
sample of 385 women was needed per study site to detect a prevalence of 20% with a 
precision of 4%, and 424 women to allow for 10% of missing data. Because smaller sample 
sizes were required to detect the proportion of anaemia and low birth weight with similar 
precision, 424 women was considered to be sufficient for multiple endpoints in each study 
site. 
For the last two surveys, placental malaria, was also used as primary outcome because it is 
the most malaria-specific end-point and more likely to reflect changes of SP-resistance. The 
sample size at delivery was based on detecting a 2-fold difference in placental malaria in 
primi-and secundi gravida who have received the full 2 course of SP versus women who 
received <2 courses of IPTp (e.g. 10% vs 20%, with 80% power and 95% confidence). If the 
coverage of 2 course IPTp-SP was very high (>67%) or very low (<33%), enrolment was to be 
stratified by the history of the number of doses of IPTp received based on their history and 
antenatal clinic records, to obtain at least a 2:1 or 1:2 ratio of women who received at least 2 
courses versus less courses. Sample sizes ranging from 948 to 1103 were needed in settings 
where placental malaria is less common, e.g. 5% in women receiving 2 dose IPTp and 10% in 
women receiving less than 2 doses (see table below). Thus based on the local circumstances 
at least 438 and at most 1103 deliveries would need to be included per site.  
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 Sample size calculations to detect 2-fold difference in placental malaria (5% in women 
receiving 2+ course and 10% in the <2 courses of IPTp-SP) 
coverage of IPTp Sample size 
Coverage Ratio 2+ courses <2 courses 2+ courses (n) <2 courses (n) Total N 
1:1 50.0% 50.0% 474 474 948 
4:1 80.0% 20.0% 1092 273 1365 
3:1 75.0% 25.0% 888 296 1184 
2:1 66.7% 33.3% 682 341 1023 
1:2 33.3% 66.7% 368 735 1103 
1:3 25.0% 75.0% 332 995 1327 
1:4 20.0% 80.0% 313 1253 1566 
 
Data entry was done using Access 2000 (Microsoft office) and data analysis using 
Stata 12.0 (StataCorp LP, Texas, USA). Site specific estimates of the effect of IPTp doses on a 
range of dichotomous outcomes (0, 1, 2) were obtained using log binomial regression in 
Stata’s generalized linear models (GLM) command and expressed as the adjusted prevalence 
ratio (aPR) and 95% CI. If models did not converge the “difficult” or “binreg” options were 
used (Cummings, 2009). In all the models, the variable for IPTp dose (0, 1, 2 doses) was 
forced into the model as the primary exposure variable of interest. Other variables 
considered for inclusion as possible confounders included location (rural versus urban), age 
(<18 versus >=18 years), season of delivery (dry versus rainy), gravida group (G1-G2 versus 
G3+) and ITNs (use versus none use). The delivery endpoints were compared between 
women who received 2 or more doses of IPTp versus those who received only one course of 
IPT, or no IPT (e.g. because they did not attend ANC).  
Chapter 6 
 
156 
 
6.3 Results 
6.3.1 Characteristics 
A total of 2,782 women were recruited at delivery during the 6 surveys in the 5 districts. 
Their mean (SD) age was 25.2 (6.8) years and 11.1% were younger than 18 years old. The 
median (range) gravida number was 3 (1-15) and 41.1% were primi or secundigravidae. 
Overall, 2,377 (85.5%) used a bednet and for 1,935 (69.6%) of them this was a treated net 
used the night before delivery. Overall, 10 women (0.3%) received 3 or 4 doses (1 site), 946 
(34.1%) received two, a further 946 (34.1%) one dose, and 875 (31.5%) received no SP (Table 
6.1). Among the 1,902 women who received IPTp-SP, the median time between first and 
second dose was 42 days and that between last dose and delivery was 72 days. The 
prevalence of anaemia and severe anaemia was 56.5% and 10.8%, respectively with similar 
risks observed in all the sites. The mean birth weight (SD) among singleton live births was 
3,094 (512) grams and 8.2%, 1.9% and 30.1% were classified as LBW, preterm and SGA, 
respectively, with similar risk across the surveys (Table 6.2).  
The prevalence of maternal and placental parasitemia was 18.6% and 16.2%, respectively, 
and these differed significantly between sites (p<0.001 for both) (Table 6.2). The median 
time between the last dose of SP and delivery was just over 10 weeks (72 days), and this was 
approximately 11 weeks (78 days) in women with placental malaria vs 71 days in women 
without evidence of infection at delivery (P=0.067)  
Parasite detection PCR data was available for the last two surveys only, both conducted in 
2009. The prevalence of P. falciparum infection detected by PCR was 3 times (maternal), ≥ 5 
times (placental), and 50 times (cord blood) higher than the estimates obtained by 
microscopy (Table 6.2 ).  
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Table 6.2: Clinical and biological characteristics of women who delivered in the five study sites # 
Characteristics Bougouni (N=424) Djenne 
(N=424) 
Koro 
(N=424) 
San (1) 
(N=424) 
Kita 
(N=615) 
San (2) 
(N=471) 
Total 
(N=2782) 
Axill temp >=37.5
o
C, n/N (%) 35/424 (8.3) 32/424 (7.6) 45/424 (10.6) 136/424 (32.1)* 43/611 (7.0) 16 /469 (3.4) 307 / 2776 (11.1) 
Haemoglobin in g/dl         
     Mean (SD) 10.69 (2.03) 10.36 (2.13) 10.55 (2.16) 10.16 (2.00) 10.61 (2.00) 10.53 (1.75) 10.48 (2.01) 
     Hb<11 g/dL, n/N (%) 210/424 (49.5) 239/424  (56.4) 239/424 (56.4) 286/424 (67.5 218/429 (50.8) 267/457 (58.4) 1459/2582 (56.5) 
     Hb<8 g/dL, n/N (%) 45/424 (10.6) 54/424 (12.7) 46/424 (10.9) 55/424 (13.0) 42/429 (9.8) 36/457 (7.9) 278/2582 (10.8) 
Birth weight in grams        
     Mean  (SD) 3130 (519) 3151 (499) 3183 (562) 3089 (518) 3022(516) 3042(445) 3094 (512) 
     LBW, n/N (%) 28/407 (6.9) 23/355 (6.5) 27/351 (7.7) 29/398 (7.3) 58/552 (10.5) 40/434 (9.2) 205/2497 (8.2) 
Premature, n/N (%) 7/403 (1.7) 9/350 (2.6) 10/349 (2.9) 8/398 (2.0) 12/550 (2.2) 1/430 (0.2) 47/2480 (1.9) 
SGA, n/N (%) 121/403 (30.0) 96/350 (27.4) 68/348 (19.5) 125/398 (31.4) 183/549 (33.3) 152/429 (35.4) 745/2477 (30.1) 
Maternal parasitemia by microscopy       
     Positive, n/N (%) 121/423 (28.6) 48/418 (11.5) 126/423 (29.8) 117/424 (27.6) 58/613  (9.5) 44/464 (9.5) 514/2765 (18.6) 
     GMPD, µl (95% CI) 1291 
(877-1900) 
1093 
(587-2035) 
1488 
(1109-1997) 
971 
(690-1366) 
1459 
(805-2644) 
1146 
(599-2192) 
1238 
(1043-1471) 
Maternal parasitemia by PCR - - - 44/610 (7.2) 137/450 (30.4) 181/1060 (17.1) 
Placental parasitemia by microscopy       
     Positive, n/N (%) 88/423 (20.8) 49/418 (11.7) 126/407 (31.0) 99/424 (23.4) 51/602 (8.5) 31/463 (6.7) 444/2737 (16.2) 
     GMPD, µl (95% CI) 1600  
(1060-2600) 
1662 
(938-2945) 
1727 
(1246-2396) 
2274 
(1587-3259) 
2633 
(1563-4436) 
712 
(352-1440) 
1791 
(1496-2144) 
Placental parasitemia by PCR- - - - 60/587 (10.2) 152/439 (34.6) 212/1026 (20.7) 
Cord parasitemia by miscroscopy       
Positive, n/N (%) 0/411 (0) 0/414 (0) 0/403 (0) 0/420 (0) 0/600 (0) 6/461 (1.3) 6/2709  (0.22) 
Cord parasitemia by PCR
 
- - - - 16/497 (3.2) 80/368 (21.7) 96/865 (11.1) 
Notes: N, Total sample size; n, number with events; SD, standard deviation; LBW, low birth weight; SGA, small for gestational age; GMPD, geometric mean of parasite density; µl, 
microliter; CI, confidence interval; C, centigrade;  Hb, haemoglobin concentration; PCR, polymerase chain reaction (PCR for speciation was done only for two sites) . 
* The high incidence of fever in San may reflect the high ambient temperature and the use of a defective thermometer. Hence the body temperature data was not 
used for any subsequent analysis in the different models. 
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6.3.2 Association between the number of SP doses received and birth outcomes    
Clinical outcomes: Overall, use of 1 or more doses of IPTp-SP was associated with less LBW 
deliveries (Table 6.3), and severe anaemia (Table 6.4 & Figure 6.2), and higher mean 
haemoglobin concentrations, but not with a significantly higher mean birthweight (Table 
6.5).  
Infection status: IPTp was only associated with less maternal and placental malaria in primi 
and secundigravida, not in multigravida (Table 6.6 & Figure 6.2). SP dosing was not 
associated with preterm delivery or SGA (Table 6.3). In the 2 sites in 2009 that used 
detection PCR for malaria, two doses were also associated with a decrease in the risk of 
maternal (0.85 [0.56-1.00], p=0.049) and placental (0.62 [0.47-0.82], p=0.001) malaria 
infections among all gravida.  
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Table 6.3: Number of SP doses and prevalence risk of low birth weight and small for gestational age among 
women who delivered in the 5 districts 
 LBW Small for gestational age  
  No. with  
LBW (%) 
*aPR 
(95% CI) 
P-
value 
 No. with 
SGA (%) 
*aPR 
(95% CI) 
P-value 
All  N    N    
0  dose 714 87 (12.2) 1  705 220 (28.5) 1  
1 dose 882 62 (7.0) 0.63 (0.46-.86) 0.004 874 260 (35.4) 0.94 (0.81-1.09) 0.412 
>=2 doses 896 56 (6.3) 0.57 (0.40-0.79) 0.001 893 264 (36.1) 0.96 (0.82-1.12) 0.574 
G1-G2          
0 dose 294 50 (17.0) 1  290 111 (38.3) 1  
1 dose 358 40 (11.2) 0.68 (0.46-1.00) 0.050 354 134 (37.9) 1.02 (0.84-1.23) 0.860 
>=2 doses 368 36 (9.8) 0.62 (0.41-0.95) 0.028 367 134 (36.5) 1.00 (0.81-1.23) 0.997 
G3+          
0 dose 420 37 (8.8) 1  415 109 (26.3) 1  
1 dose 524 22 (4.2) 0.54 (0.31-0.94) 0.028 520 126 (24.2) 0.87 (0.69-1.10) 0.231 
>=2 doses 528 20 (3.8) 0.45 (0.25-0.81) 0.008 526 130 (24.7) 0.91 (0.72-1.15) 0.434 
ITN          
0 dose 454 51 (11.2) 1  450 139 (30.9) 1  
1 dose 592 43 (7.3) 0.67 (0.45-0.99) 0.047 586 167 (28.5) 0.87 (0.71-1.05) 0.143 
>=2 doses 701 47 (6.7) 0.64 (0.42-0.96) 0.030 698 204 (29.2) 0.93 (0.77-1.13) 0.482 
Non ITN          
0 dose 260 36 (13.9) 1  255 81 (31.8) 1  
1 dose 290 19 (6.6) 0.58 (0.34-0.98) 0.044 288 93 (32.3) 1.05 (0.83-1.33) 0.683 
>=2 doses 195 9 (4.6) 0.41 (0.20-0.85) 0.016 195 60 (30.8) 0.96 (0.72-1.27) 0.758 
Notes: LBW, low birth weight; APR, adjusted prevalence ratio; CI, confidence interval; N, sample size; SGA, 
small for gestational age; G1-G2, first or second pregnancy; G3+,  three or more pregnancies ; ITN, insecticide 
treated net used last night.  
*Adjusted for location (rural versus urban); age (≥18 versus <18 years), season of delivery, anaemia, site, and 
[gravidity (G1-G2 versus G3+) and ITN (users versus non-users ) where applicable] 
Chapter 6 
 
160 
 
 
Table 6.4: Number of SP doses and prevalence risk of moderate to severe anaemia and severe anaemia among 
who delivered in the 5 districts 
 Any anaemia (Hb < 11.0 g/dL) Severe anaemia (Hb < 8.0 g/dL) 
 
  No. with 
anaemia 
(%) 
*aPR 
(95% CI) 
P-
value 
 No. with 
severe 
anaemia (%) 
*aPR 
(95% CI) 
P-
value 
All  N    N    
0  dose 822 530 (64.5) 1  822 130 (15.8) 1  
1  dose 904 516 (57.1) 0.93(0.86-1.00) 0.059 904 80 (8.9) 0.69 (0.53-0.90) 0.007 
>=2 doses 854 411 (48.1) 0.82 (0.74-0.89) <0.001 854 68 (8.0) 0.69 (0.52-0.93) 0.013 
G1-G2          
0 dose 333 233 (70.0) 1  333 62 (18.6) 1  
1 dose 371 226 (60.9) 0.92 (0.82-1.03) 0.138 371 40 (10.8) 0.68 (0.47-0.98) 0.037 
>=2 doses 357 175 (49.0) 0.79 (0.69-0.91) 0.001 357 28 (7.8) 0.62 (0.40-0.97) 0.035 
G3+          
0 dose 489 297 (60.7) 1  489 68 (13.9) 1  
1 dose 533 290 (54.4) 0.95 (0.85-1.06) 0.345 533 40 (7.5) 0.72 (0.49-1.07) 0.108 
>=2 doses 497 236 (47.5) 0.84 (0.74-0.95) 0.006 497 40 (8.1) 0.75 (0.50-1.11) 0.153 
ITN          
0 dose 510 306 (60.0) 1  510 74 (14.5) 1  
1 dose 593 345 (58.2) 0.98 (0.89-1.08) 0.701 593 44 (7.4) 0.58 (0.40-0.83) 0.003 
>=2 doses 649 311 (47.9) 0.85 (0.76-0.95) 0.005 649 42 (6.5) 0.53 (0.36-0.77) 0.001 
Non ITN          
0 dose 312 224 (71.8) 1  312 56 (18.0)   
1 dose 311 171 (55.0) 0.85 (0.75-0.97) 0.016 311 36 (11.6) 0.81 (0.54-1.21) 0.302 
>=2 doses 205 100 (48.8) 0.77 (0.65-0.91) 0.002 205 26 (12.7) 0.95 (0.60-1.49) 0.815 
Notes: aPR, adjusted prevalence ratio; CI, confidence interval; N, sample size; G1-G2, first or second pregnancy; G3+, 
three or more pregnancies ; ITN, insecticide treated net used last night.  
*Adjusted for location (rural versus urban); age (≥18 versus <18 years), season of delivery, site, and [gravidity (G1-G2 
versus G3+) and ITN (users versus non-users) where applicable]. 
Chapter 6 
 
161 
 
 
 
 
 
Table 6.5: Number of SP doses and mean birth weight and haemoglobin among women who delivered in the 5 
districts 
 Mean birthweight 
 
*Adjusted Mean difference, 95% CI Mean 
haemoglobin 
 
*Adjusted Mean difference, 
95% CI 
All  N Mean (SD) grams 95% CI P-value N Mean (SD) g/dL 95% CI P-value 
0-dose   714 3067 (578) ref   822 10.0 (2.2) ref   
1-dose 882 3105 (504) 23.8 -27.8 to 73.3 0.377 904 10.6 (1.9) 0.46 0.27 to 0.65 <0.001 
>=2 doses 896 3107 (463) 32.4 -18.6 to  83.4 0.213 854 10.9 (1.9) 0.70 0.51 to 0.89 <0.001 
G1-G2            
0-dose   294 2940 (577) ref   333 9.9 (2.2) ref   
1-dose 358 2991 (540) 36.4 -43.6 to 116.4 0.372 371 10.6 (1.9) 0.56 0.27 to 0.86 <0.001 
>=2 doses 368 3013 (452) 55.0 -27. to 136.6 0.186 357 10.9 (1.9) 0.95 0.64 to 1.25 <0.001 
G3+            
0-dose   420 3156 (563) ref   489 10.2 (2.2) ref   
1-dose 524 3182 (462) 13.7 -51.8 to 79.2 0.682 533 10.8 (1.8) 0.38 0.13 to 0.63 0.003 
>=2 doses 528 3172 (461) 19.3 -46.3 to 84.9 0.564 497 10.9 (1.9) 0.53 0.28 to 0.78 <0.001 
ITN            
0-dose   545 3089 (581) ref   510 10.2 (2.2) ref   
1-dose 592 3101 (474) 9.4 -51.2 to 70.1 0.760 593 10.6 (1.7) 0.35 0.13 to 0.58 0.002 
>=2 doses 701 3105 (458) 27.2 -32.1 to  86.5 0.368 649 10.9 (1.8) 0.63 0.40 to 0.85 <0.001 
Non ITN            
0-dose   260 3030 (573) ref   312 9.7 (2.2) ref   
1-dose 290 3113 (560) 49.8 -44.1 to 143.7 0.298 311 10.5 (2.1) 0.61 0.26 to 0.96 0.001 
>=2 doses 195 3116 (484) 45.9 -57.0 to 148.8 0.382 205 10.7 (2.1) 0.79 0.40 to 1.17 <0.001 
Notes: SD, standard deviation; CI, confidence interval; N, sample size; G1-G2, first or second pregnancy; G3+,  three or more 
pregnancies ; ITN, insecticide treated net used last night.  
*Adjustment was done by location (rural versus urban); age (≥18 versus <18 years), season of delivery and [gravidity (G1-G2 
versus G3+) and ITN (users versus non-users ) where applicable], and anaemia (for birth weight) and without anaemia (for 
haemoglobin) 
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Table 6.6: Number of SP doses and prevalence risk of placental and maternal parasitemia among who 
delivered in the 5 districts 
 Placental parasitemia Maternal parasitemia 
  No. with 
infection 
(%) 
*aPR 
(95% CI) 
P-
value 
 No. with 
infection 
(%) 
*aPR 
(95% CI) 
P-
value 
All  N    N    
0-dose   850 161 (18.9) 1  873 182 (35.4) 1  
1-dose 939 162 (17.3) 0.97(0.80-1.16) 0.704 941 197 (38.3) 1.01 (0.85-1.19) 0.969 
>=2 doses 946 121 (12.8) 0.85 (0.69-1.05) 0.132 949 135 (26.3) 0.83 (0.68-1.01) 0.066 
G1-G2          
0-dose   336 95 (28.3) 1  349 109 (31.2) 1  
1-dose 386 95 (24.6) 0.95 (0.76-1.19) 0.634 388 111 (28.6) 0.95 (0.78-1.17) 0.655 
>=2 doses 398 67 (16.8) 0.77 (0.59-1.01) 0.062 400 77 (19.5) 0.77 (0.60-0.99) 0.042 
G3+          
0-dose   514 66 (12.8) 1  524 73 (13.2) 1  
1-dose 553 67 (12.1) 1.00 (0.73-1.38) 0.994 553 86 (15.6) 1.12 (0.83-1.50) 0.452 
>=2 doses 548 54 (9.9) 0.99 (0.70-1.40) 0.964 549 58 (10.6) 0.95 (0.68-1.33) 0.771 
ITN          
0-dose   537 83 (15.5) 1  551 94 (17.1) 1  
1-dose 628 92 (14.7) 1.07 (0.82-1.40) 0.626 630 111 (17.6) 1.09 (0.85-1.38) 0.501 
>=2 doses 741 74 (10.0) 0.83 (0.61-1.22) 0.227 744 80 (10.8) 0.78 (0.59-1.03) 0.081 
Non ITN          
0 dose 313 78 (24.9) 1  322 88 (27.3) 1  
1 dose 311 70 (22.5) 0.89 (0.69-1.15) 0.375 311 86 (27.7) 0.94 (0.741.19) 0.619 
>=2 doses 205 47 (22.9) 0.93 (0.69-1.25) 0.615 205   55 (26.8) 0.92 (0.70-1.21) 0.541 
Notes: aPR, adjusted prevalence ratio; CI, confidence interval; N, sample size; G1-G2, first or second 
pregnancy ; G3+, third pregnancy or higher ; ITN, insecticide treated net used last night.  
*Adjusted for location (rural versus urban); age (≥18 versus <18 years), season of delivery, site, and 
[gravidity (G1-G2 versus G3+) and ITN (users versus non-users) where applicable]. 
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Figure 6.2: Number of SP doses and risk of adverse birth outcomes for women who delivered in the 5 
districts 
 
Notes: LBW, low birth weight; n, number of events; N, sample; CI, confidence interval; aPR, prevalence  ratio  
adjusted for location (rural versus urban); age (≥18 versus <18 years), season of delivery, site, gravidity (G1-G2 versus 
G3+), ITN (users versus non-users), and anaemia (for LBW only); SGA, small for gestation age ( defined as <10th 
percentile in birth weight for attained gestational age (Landis et al., 2009).  
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6.3.3 Molecular markers for SP resistance  
The prevalence of the DHPS A437G and K540E mutation assessed by modelling (first 4 
surveys) or pooled deep sequencing on samples from women attending ANC visit (pre-SP 
dosing, last 2 surveys), ranged from 15.2% to 44.8% for DHPS A437G and from 0 to 0.73% for 
dhps K540E mutation (Table 6.1). At delivery, the observed prevalence of triple dhfr (N51I, 
C59R, S108N) haplotype varied from 0.66% to 65.8% and that of quadruple dhfr (N51I, C59R, 
S108N)/dhps (A437G) haplotype from 22.2% to 42.1%; and no dhps K540E allele mutation 
was found (Table 6.1) .  
6.4 Discussion  
IPTp with SP was associated with significant and marked reductions in the risk of LBW (by 
43%) and severe maternal anaemia (by 31%). The results were consistent across the 6 
surveys and 5 sites with no evidence for heterogeneity across surveys (I2=0%) and evident in 
all gravida groups (Figure 6. 3), including multigravida, and in ITN users and non-users. LBW 
due to preterm birth or intrauterine growth retardation is a strong predictor of infant health 
(Katz et al., 2013) thus the improvements in birth weight may have important health 
benefits in the first month to first year of life.  
The risk reduction of LBW may not just reflect the effect of SP and may be confounded by 
other factors. For example, the number of ANC visits is likely to be correlated with the 
number of SP doses received (Van Eijk et al., 2004), and thus potentially more intensive or 
more complete antenatal care potentially resulting in improved birthweight. These include 
increased uptake of iron-folate tablet doses, tetanus toxoid, and treatment of potential 
infections. Other confounding factors such as a higher socio-economic status and education 
levels have also been found to be associated with high IPTp uptake (Van Eijk et al., 2011). 
Thus, because of the observational design used in our study, it may be possible that effect 
estimates overestimate the true effect of SP. 
Our data are consistent with earlier findings from similar observational studies of IPTp with 
SP in west Africa including in Nigeria (Aziken et al., 2011), Burkina Faso (Sirima et al., 2006), 
Senegal (Olliaro et al., 2008), and Cote D’Ivoire (Vanga-Bosson et al., 2011), and Ghana (Tutu 
et al., 2011, Hommerich et al., 2007). Some of these earlier studies failed to show a 
statistically significant association with LBW, but that may be explained by the smaller 
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sample sizes in these earlier studies and other factors affecting the effect size such as high 
concomitant ITN usage or higher levels of SP resistance in the local parasite population.  
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Placental Malaria 
 
Low birth weight 
 
Severe anaemia (HB<8 g/dL) 
 
Figure 6. 3 : Associations between 2-dose IPTp use and risk of placental malaria, Low birth weight 
and severe anaemia in 6 surveys in 5 districts in Mali. 
Note: n, number of events; N, sample; aPR, prevalence ratio obtained from random effects models adjusted 
for location (rural vs urban); age (≥18 vs <18 years), gravidity (G1-G2 vs G3+); ITN (users vs non-users); season 
of delivery, and anaemia (only for LBW); CI, confidence interval.  
Severe anaemia was defined as haemoglobin level <8 g/dL. 
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By contrast to the beneficial association with LBW, the reduction of the risk of maternal 
and placental malaria among women with 2 doses of SP was smaller and not statistically 
significant. The most likely explanation, given the high sensitivity of parasites  to SP 
observed in all 6 surveys and other studies in Mali (Diakite et al., 2011, Dicko et al., 2010, 
Kayentao et al., 2013, Tekete et al., 2009), is the possible re-infection of women after 
their last dose of SP as was suggested in earlier studies (Gies et al., 2009, Kayentao et al., 
2005, Sirima et al., 2006). The median time between the last dose of SP and delivery was 
just over 10 weeks (72 days), and this was approximately 11 weeks (78 days) in women 
with placental malaria vs 71 days in women without evidence of infection at delivery 
(P=0.067) (Table 6.1) . The duration of post treatment prophylaxis which is likely to be an 
important determinant of the benefit of SP-IPTp, is approximately 6 to 8 weeks in areas 
with no or low SP resistance (White, 2005). Since over half of the women received their 
last dose over 10 weeks before delivery, this would have left women unprotected 
towards the end of their pregnancy after the protective drug levels have waned. This is 
especially a problem during the rainy season, when 85 % of deliveries in these surveys 
occurred. The high risk of reinfections argues in favour of the more frequent dosing 
regimen as was recently recommended by WHO (WHO, 2013). Three or more doses of 
IPTp-Sp with SP has been shown to markedly enhance the efficacy of IPTp in reducing the 
risk of low birth weight and severe maternal anaemia compared to the 2-dose regimen 
(Kayentao et al., 2013). It remains to be determined if this may also modulate the infant 
susceptibility to malaria (Mutabingwa et al., 2005, Schwarz et al., 2008, Harrington et al., 
2013, Malhotra et al., 2009).  
The risk reduction in severe maternal anaemia and the increase in mean haemoglobin 
levels achieved in women using IPTp-SP is also consistent with previous reports by other 
authors reporting a risk reduction in anaemia (Tutu E.O., 2010) or severe anaemia 
(Shulman, 1999) in women using 2 versus 0 doses of SP-IPTp or placebo. It may be 
possible that effect estimates in observational studies overestimate the true effect of SP, 
as women attending for antenatal care also receive iron-folate supplementation during 
ANC visits (not assessed in our study) and the amount of supplementation may be 
correlated with the number of ANC visits and thus the number of SP doses received, as 
suggested by other authors (Van Eijk et al., 2004).  
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By contrast to previous observations in clinical trials in Kenya (Njagi et al., 2003, Njagi, 
2002), and the Gambia (Mbaye et al., 2006b), and observational studies in Malawi (Feng 
et al., 2010), we found that the 2-dose IPTp regimen was associated with the reduction in 
the risk of severe anaemia and LBW among both ITN non-users and users, although the 
effect appeared greatest among non-users. The possible explanation for the significant 
effects among women protected by ITN could be the very high transmission pressure 
during the surveys, most of which coincided, at least in part, with the transmission 
season. It is possible that under such condition single intervention is inadequate to 
provide complete protection. Other explanations include discrepancies between ITN 
ownership and consistent use during pregnancy (not assessed).  
This observational study is not free of limitations. The study did not permit a critical 
assessment of effect modification by season of the association between IPTp-SP use on 
birth outcomes because the surveys were timed to coincide with the rainy season and 
85.2% of observed deliveries occurred during the transmission season. Malaria 
transmission is highly seasonal in Mali and the malaria attributable fraction towards LBW 
will be lower outside of the transmission seasons. It is thus likely that our study estimates 
obtained during the transmission seasons, overestimate the average impact that can be 
expected throughout the year.  
The analysis was in part designed to assess the impact of SP resistance on IPTp 
effectiveness. Although data on the frequency of SP resistance was available from all 
surveys at the time of delivery, this is not the best time to assess the parasite population 
level of resistance, as parasites present at delivery may have been selected under drug 
pressure from SP use during pregnancy. Nevertheless, the molecular data available at 
delivery suggested that parasites remain highly sensitive to SP in Mali where the dhps 
K540E mutation is largely absent and the prevalence of the dhps A437G mutation was 
<50%. This is also evident from the findings of the 42-day in vivo efficacy studies 
conducted in 2009 in two of the 5 sites, which showed near complete radical cure after a 
single dose of SP in asymptomatic women who were parasitaemic when they received 
their first dose of SP (Coulibaly et al., 2014) . The lack of clinically relevant variation in 
resistance between the sites prevented a meaningful analysis of the correlation between 
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the prevalence of SP molecular markers such as dhps A437G and the effectiveness of 
IPTp. 
Of note was the high proportion of women who received only one dose (34%) or no IPTp-
SP (32%) despite the support from multiple donors provided to these specific sites. Even 
in the survey conducted in 2012, 8 years after the introduction of IPTp, the 20% coverage 
of >=2-dose failed to reach the RMB targets of 60% by 2005 and 80% by 2010 by a wide 
margin (WHO, 2000a, van Eijk et al., 2013). Although reasons for the low coverage are 
not fully understood, recent studies in Mali identified many missed opportunities due to 
factors related to poor ANC attendance or living outside the health facilities catchment 
area, but also because the delivery of IPTp was ineffective due to complex policy 
guidelines, lack of guidance on how to implement the guidelines, and the 
institutionalising of practices that undermine the national guidelines (Mali, Mars 2011). 
Although there were a number of broader health systems issues which were not specific 
to IPTp or antenatal care, other factor which were potentially actionable, accounted for 
the majority of the substantial loss in system effectiveness observed. These include 
misconceptions about the optimal timing of IPTp and specifically the upper limit of the 
gestational age at which it could be given, the required interval between doses and 
concerns about giving IPTp-SP on an empty stomach (Webster et al., 2013b). These could 
be addressed in the shorter-term whilst waiting for broader health systems issues need 
to be addressed.  
6.5 Conclusion  
Our study confirms that the parasite population in Mali remains highly sensitive to SP 
and that IPTp-SP is very effective in reducing the adverse consequences of malaria in 
pregnancy among women who receive at least 2 doses of SP. However the uptake of the 
2-dose regimen is disappointingly low due to ineffective processes in the delivery of IPTp. 
We also observed a very high risk of placental malaria in the 2-dose recipients, 
presumably reflecting the high risk of reinfection between the last dose of SP and 
delivery. WHO’s new IPTp policy update aims to address many of these intervention-
specific factors by simplifying the guidelines and improving messaging. The increase in 
the number of doses of SP from 2 doses to a dose at each scheduled antenatal visit in the 
2nd and 3rd trimester at least one month apart ensures better alignment with WHO’s 
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focused antenatal care schedule (WHO, 2013, van Eijk et al., 2013). This combined with 
the superior efficacy of this new regimen observed in trials (Kayentao et al., 2013) , 
including in Mali (Diakite et al., 2011), strongly suggest that these new WHO guidelines 
should be implemented as soon as possible with the aim to improving the coverage and 
effectiveness of this promising, yet underutilised intervention.  
Chapter 7 
171 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 7: General discussion and 
conclusion  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 7 
172 
 
7. Chapter 7-General discussion and conclusion 
Since the first descriptions of the association between malaria and pregnancy in the early 
20th century (Desai et al., 2007), malaria continues to burden pregnant women and her 
offspring. This is despite tremendous investments made recently in the fight against 
malaria through the RBM led initiative to control and eliminate the disease. In pregnant 
women living in sub-Saharan Africa, P. falciparum malaria is still one of the biggest public 
health problems and facing several major challenges related to its control requiring 
continued attention to the diagnosis, treatment and prevention of malaria in pregnancy. 
This thesis provides further insights into the epidemiology and burden of malaria in 
pregnancy in an area with intense, highly seasonal malaria, typical for the Sahel region 
and suggests improvements to the IPTp regimen using SP, the main drug-based 
prevention strategy in pregnant women, and evaluated the relationship between SP 
resistance and the effectiveness of IPTp in West Africa. This discussion chapter is 
structured around 4 themes based on the main results of this thesis.  
7.1 Burden of malaria in pregnancy in Mali 
The present thesis benefits from a wealth of data collected in 11 surveys conducted from 
January 2005 to December 2010 on the burden of malaria in pregnancy in different 
regions and transmission settings of Mali. It provides for the first time a national estimate 
analysis of pregnancy associated malaria (PAM) and emphasizes the potential benefit of 
the main two pronged approach recommended by WHO for malaria prevention during 
pregnancy in sub-Saharan Africa (WHO/AFRO, 2004). In that, the work addressed in 
chapter 2 of this thesis can be very informative as baseline information for future 
evaluation of PAM and its control strategies at regional or national level. It showed that 
malaria is highly seasonal, but that the intensity of its transmission suggested a marked 
regional variability with some unexpected changes in the transmission landscape unlike 
previously described in 1991 (Doumbo O., 1991). This may indicate the need of revising 
the county wide malaria transmission maps to reflect the recent ecological changes that 
have occurred in Mali with the introduction of large-scale irrigation projects that may 
have become the main drivers of transmission in the dry season in some areas. For 
example in Timbuktu, an area that was classified a priori as low transmission based on 
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the existing classification used in Mali, our observations suggested a prevalence of 
placental malaria infection of 13.3% in dry season which was almost 2 fold higher than 
that reported for Kita with 7.3%, an area classified a priori as high transmission. The 
prevalence of P. falciparum malaria of 13.3% in Timbuktu was a surprise as the survey 
took place towards the end of the dry season. The true prevalence at delivery and 
corresponding impact on birth outcomes may even be considerably higher if more 
sensitive diagnostic methods such as PCR and placental histology were used (Fried et al., 
2012, Taylor et al., 2010). Although PCR was not available for the Timbuktu surveys, 
diagnostic PCR data was available in the last two surveys conducted in 2009 in San and 
Kita, described in chapter 6. This suggested that the prevalence of P. falciparum infection 
detected by PCR was 3 times (maternal), ≥ 5 times (placental), and 50 times (cord blood) 
higher than the estimates obtained by microscopy (Table 6. 2). Other contributing factors 
to the difference observed between the traditional transmission strata and the 
prevalence data observed in pregnant women at delivery may include the persistence of 
parasitaemia for many months into the dry season and improvements in the coverage of 
malaria control strategies as observed in Kita (Table 2.8). 
In Timbuktu, despite the unexpected high prevalence of both maternal and placental 
malaria, no P. vivax infection was found, yet previous studies reported the presence of P. 
vivax in this site (Bernabeu et al., 2012) and other sites of northern Mali with similar 
characteristics (Koita et al., 2012, Doumbo O., 1991). However, the absence of P. vivax in 
our study does not preclude its presence in this ethnically and genetically diverse regions, 
where 34% of the population are Tuaregs (Timbuktu-Region), sometimes referred to 
locally as ‘brown’ people. They may have a Duffy-positive blood group antigen, which 
also serves as a receptor (the portal of entry) for P. vivax to invade red blood cells 
(Bernabeu et al., 2012). It is also possible that the Tuaregs, who traditionally have a 
nomadic pastoralist lifestyle, are relatively underrepresented among the antenatal clinic 
population. The presence of P. vivax in previous studies (Koita et al., 2012, Doumbo O., 
1991, Bernabeu et al., 2012) may also be suggestive of lack of power of the diagnostic 
method used (microscopy) in our study and the difficulty of accurate species 
differentiation at the low asexual and sexual stage parasite densities that are typical for 
semi-immune pregnant women.  
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In accordance with the literature (chapter 1), this thesis demonstrated that first and 
second pregnancies are most burdened by malaria and its impact, in that higher  
prevalence of placental malaria, LBW, and maternal anaemia were observed in that 
group as opposed to more than two pregnancies (chapter 2). Although malaria is a major 
contributing factor to LBW (Desai et al., 2007), our ecological analysis showed similar 
prevalence of LBW across transmission settings. Nevertheless, in chapter 2 and chapter 6 
it is shown that placental malaria was associated with higher risk of LBW, SGA, and the 
composite LBW or SGA or PTD and IPTp use was associated with a lower prevalence of 
LBW and maternal anaemia for which malaria is also a considerable contributor 
(Rogerson et al., 2007a, Katz et al., 2013, Desai et al., 2007). 
Although malaria is a contributor to LBW, our ecological analysis did not find any link 
between LBW and malaria transmission intensity. Thus, other factors in malaria endemic 
areas not assessed in our study may play an important role for the occurrence of LBW 
(Huang et al., 2007, Guyatt and Snow, 2004). 
A relatively low uptake of IPTp was observed (chapter 2). This suggests significant missed 
opportunities to further reduce the impact of malaria on new-born health. Our study 
suggested that increasing IPTp coverage to the audacious RBM target of universal 
coverage could result in a significant decrease of births with placental malaria, LBW, and 
anaemia among first and second pregnancies.  
Despite several limitations described in chapter 2, this is the first comprehensive study of 
the burden of PAM suggesting that malaria in pregnancy is a major public health problem 
in all endemic areas and suggest the potential for further reductions in the burden  
throughout Mali by upscaling IPTp and ITN coverage in pregnancy. For a better 
description of the true burden of PAM at the national level in this country with such 
varied transmission strata, prospective surveys should reflect seasonality, transmission 
intensity, and ideally use more sensitive diagnostic tests for malaria detection. Such 
studies are required for building malaria control strategies and to rationalize the 
distribution of scarce resources. 
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7.2 Increasing the dosing frequency of intermittent preventive therapy 
with sulfadoxine-pyrimethamine in Africa 
The trial conducted in Mali in 1998-2001 suggested that IPT-SP was superior to 
chemoprophylaxis with chloroquine. However, the prevalence of placental malaria was 
higher than expected among women taking two doses of SP (Kayentao et al., 2005). This 
was confirmed later by a more recent study in another part of the country (Diakite et al., 
2011) (chapter 3). As parasites are very sensitive to SP (chapter 5) in Mali, this high rate 
of placental malaria was more likely to reflect re-infection during the last 6-10 weeks 
gestation, an important period for foetal growth and weigh gain. This was further 
supported by our results of the observational studies described in chapter 6 showing that 
the median time from last dose of SP to delivery was around 10 to 11 weeks.  
Thus, more frequent doses of IPTp were suggested to prevent reinfection towards term. 
Testing this hypothesis, the trial described in Chapter 3 showed that three doses of IPTp 
with SP was considerably more effective in reducing maternal and placental malaria, low 
birth weight and premature delivery than the 2-dose regimen (chapter 3). Furthermore, 
the extra dose of SP was well tolerated (Diakite et al., 2011). This was the first trial that 
compares the 2-dose regimen to more frequent dosing schedules in west-Africa, it 
provided the evidence that more than 2-dose of SP would be more appropriate for the 
control of malaria in pregnancy and its sequelae in Mali and in the Sahel countries in sub-
Saharan west Africa, most of which currently have low levels of SP resistance (Naidoo 
and Roper, 2013). 
The study was followed by a meta-analysis that combined the result of this trial with 
evidence from 6 other clinical trials (chapter 4); including 1 similar trial comparing 3-dose 
versus 2-dose in a low SP resistance area in Burkina Faso, West Africa and 5 trials 
comparing monthly versus the 2-dose regimen in eastern and southern Africa in areas 
with high SP resistance. The pooled analysis confirmed the superiority of 3 or more doses 
over the 2-dose regimen in the reduction of placental malaria and low birth weight in 
both areas with low and moderate to high SP resistance (Kayentao et al., 2013). Among 
HIV infected first and second pregnancies, a previous meta-analysis of 3 trials suggested 
significant benefit of additional doses of sulfadoxine-pyrimethamine over the 2-dose 
regimen regardless of the degree of sulfadoxine-pyrimethamine resistance, but was 
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unpowered to conclude similar benefit among HIV negative pregnant women (Ter Kuile 
et al., 2007). Thus, our new meta-analysis of 7 trials of which 6 enrolled HIV negative 
pregnant women allowed the evidence of this benefit to emerge and showed that this 
occurs regardless of HIV status and the degree of SP resistance (Kayentao et al., 2013). 
The meta-analysis also showed that increasing the dosing frequency is not associated 
with an increase in SP related serious adverse events. This data provided support for the 
new WHO recommendation that intermittent preventive therapy during pregnancy with 
sulfadoxine-pyrimethamine should be provided at each scheduled focused antenatal-
care visit in the second and third trimesters in all settings in which intermittent 
preventive therapy during pregnancy with sulfadoxine-pyrimethamine is recommended 
(WHO, 2013).  
Countries with 2-dose regimen are now revising their policy for IPTp-SP frequent dosing. 
However, there is a need for research to be focused on how best to implement the 
updated WHO guidelines for IPT-SP in pregnant women, especially their integration with 
focused antenatal care, as recent reviews of surveys from 2009-2011 show that ¾ of sub-
Saharan-African countries have struggled to attain the original Abuja target of 60% by 
2005, a fortiori the 80% by 2010 (van Eijk et al., 2013). Nonetheless, the implementation 
of the updated policy may benefit from the lesson learned from a recent series of studies 
conducted to identify the successes and impediments to high coverage of the IPTp-SP 2-
dose strategy (Webster et al., 2013b, Webster et al., 2013a, van Eijk et al., 2013). This 
showed  that the coverage of IPTp was lower in uneducated, poorer, and rural women 
(Hill et al., 2013, van Eijk et al., 2013, Steketee and Eisele, 2009) and higher in educated 
and the wealthier, who usually live in urban areas where the need of IPTp is less crucial 
because of lower malaria endemicity (van Eijk et al., 2013). The programmatic 
deployment of the new strategy should take these findings of inequalities among IPTp-
recipients into account to ensure that the new strategy genuinely reaches women most 
in need. As the majority of sub-Saharan African countries struggle to support their own 
implementation program; and funding from international donors is frequently subject to 
shortfall, there is an urgent need for building a sustainable strategy for permanent 
domestic funding of implementation and surveillance programs for malaria control in 
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pregnant women. This is required to ensure high use and impact of the revised policy of 
IPTp and other malaria control strategies, in the era toward malaria elimination.  
7.3 Sulfadoxine-pyrimethamine resistance and IPTp-SP effectiveness 
on birth parameters 
With the anticipated further increase in use of SP for IPTp and seasonal malaria 
chemoprevention, the continued monitoring of SP resistance and the effectiveness of 
IPTp during pregnancy is essential. Parasite populations in western Africa seems to be 
mostly sensitive to SP (Naidoo and Roper, 2013, Flegg et al., 2013), and IPTp-SP has 
proven to be highly effective and efficacious in clinical trials and observational studies 
(Valea et al., 2010, Sirima et al., 2006, Kayentao et al., 2005, Diakite et al., 2011). 
However, spread of SP resistance from eastern and southern Africa, or de –novo 
development of high-level SP resistance may occur and monitoring of the effectiveness 
of IPTp with SP is essential.  
Previously, monitoring of SP resistance was based on results from in-vivo studies among 
symptomatic children under 5 years old with uncomplicated malaria. However this does 
not correlate with the response to treatment with SP in pregnant women with malaria 
(Kalanda et al., 2006, Tagbor et al., 2007). Thus, designing a study for the better 
understanding of the efficacy of IPTp-SP in pregnant women was essential. In chapters 5 
and 6 the results are describing studies aiming at obtaining a better understanding of the 
impact of SP resistance on the effectiveness of IPTp in clearing existing parasites and the 
duration of post-treatment prophylaxis to prevent new infections (Chapter 5), as well as 
on birth parameters in western Africa (Chapter 6).  
The 42-day in vivo efficacy study reported in Chapter 5 of this thesis was conducted in 
Mali and Burkina-Faso, two West African countries where malaria transmission is 
endemic but seasonal. This was among the first studies to examine the 42-day in vivo 
response of IPTp-SP in asymptomatic women in West Africa, and showed that SP remains 
very effective at clearing existing infections and improving haemoglobin concentration 
when provided as IPTp to parasitaemic asymptomatic pregnant women. The dhps K540E 
mutation, which is a proxy for the quintuple haplotype conferring mid-level resistance to 
SP, was present in only one of the two sites of Mali and at very low frequency (0.73%, 
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95% CI 0.58-0.87). The mutation at dhfr codon 164L and dhps codon 581G conferring 
very high-level resistance to SP were absent. Our observations provide an important 
contribution to the understanding of the predictive value of the frequency of population 
estimates of the different dhfr and dhps mutations on the efficacy of SP in clearing 
malaria infection among asymptomatic pregnant women, especially when our results are 
compared against day 42 failure rates in areas with higher resistance. For example, the 
dhfr triple mutation (Ile51+Arg59+Asn108) is known to confer intense pyrimethamine 
resistance in vitro (Gregson and Plowe, 2005) and is associated with an approximate 
1,000-fold reduction in pyrimethamine susceptibility (White, 2005) and was present in 
almost 50% of the parasite population in Burkina Faso, yet only 1.4% of the treatments 
recrudesced by day 42. This contrasts with previous findings in children with acute 
malaria, among whom the dhfr triple mutation was associated with an increased risk of 
SP treatment failure (Picot et al., 2009, Mockenhaupt et al., 2005, Kublin et al., 2002). 
IPTp-SP targets are birth weight and maternal anaemia, and low birth weight or anaemia 
have been associated separately or in concert to lead to neonatal and infant mortality 
(Desai et al., 2007). Monitoring both birth weight and anaemia are therefore essential 
markers for assessing IPTp-SP effectiveness.  
The results described in Chapter 6 suggest a strong beneficial association between the 
prevalence of LBW, and moderate-severe anaemia with the number of SP doses 
received.  
The study failed to show a correlation between the relative effectiveness and the level of 
SP resistance in the population as measured by the prevalence of different molecular 
markers. This is possibly due to the modest prevalence of both triple dhfr (N51I, C59R, 
S108N) and quadruple dhfr/dhps (Triple dhfr+ dhps A437G) mutants which were 50% and 
35%, respectively, and near absence of the dhps K540E mutation which is a good proxy 
for the quintuple haplotype. The effectiveness on delivery parameters and absence of a 
correlation with resistance markers is consistent with the good in-vivo response 
observed in chapter 5, suggesting that SP resistance is not yet a problem in Mali or this 
northern part of Burkina Faso.  
Results generated in chapter 5 and 6 had contributed significantly to the first 
multicountry effort to link population level of SP resistance and efficacy and effectiveness 
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of IPTp. Using meta-analysis approach, our findings in chapter 6 were combined with 
similar studies conducted in 4 countries of West Africa. A total of 11 studies 
observational studies concluded a significant pooled risk reduction of LBW in women 
with 2 doses versus those not receiving SP (Figure 9.1 in annex). This analysis also 
showed for the first time a decrease in birth weight with an increase in DHPS 437 
mutations level in West Africa (Figure 9.2 & Figure 9 3 in annex).   
Another important finding is the high proportion of women who received only one (34%) 
or even zero doses (32%) of IPTp-SP. Despite the support from multiple donors, in 2010 
the overall and specific site coverage of >=2-dose had never reached the RMB targets of 
60% by 2005 and 80% by 2010 (RBM, 2008, RBM, 2011, van Eijk et al., 2013). This is not 
unique to Mali and this observation was similar to that reported earlier for sub-Saharan 
Africa as a whole (van Eijk et al., 2013). This maybe a forewarning of difficulty days ahead 
for the updated IPTp policy (WHO, 2013). Thus, there is clear suggestion of additional 
efforts from program managers of African countries to achieve primarily their own target 
and secondly the above mentioned international target which was more recently 
updated to universal coverage (100%) (RBM, 2011). 
Results gathered from chapter 5 and 6 can be added to the mass body of data collected 
in other countries of sub-Sahara Africa to generate a practical standard protocol for 
monitoring the impact of SP resistance on IPTp-SP effectiveness in pregnant women 
(http://www.mip-consortium.org/ P: https://portal.mip-consortium.org) and to help 
define thresholds of SP resistance when countries should consider switching to 
alternative drugs and strategies. 
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All the chapters from this thesis provided useful national and regional information of 
public health interest. However, unlike chapter 3 and chapter 4 which were randomized 
controlled trials, our data generated in observational studies discussed in chapter 2, 
chapter 5 and chapter 6 are susceptible to bias as in any observational study. Although 
multi-variate analysis was used to adjust for known confounders where available, 
residual confounding cannot be excluded and the results need to be interpreted with 
caution as systematic bias can distort the estimated associations between a risk factor 
and outcomes.  
However, depending on the context, observational studies might help drive policy, 
especially because the results at delivery (most prone to bias) were supported by high 
levels of observed efficacy of SP in the in-vivo study in Mali and Burkina, and by the 
absence or very low population prevalence of the dhps 540 mutations (chapter 5) and a 
<50% prevalence of the dhps A437G mutation (chapter 6). This suggested that SP 
resistance is still low to modest in west Africa, and that IPTp-SP potentially has a long life 
ahead in Mali and Burkina, unlike in east and southern Africa, where the observational 
studies at delivery showed a lack of impact of IPTp-SP on birthweight in areas with high 
frequency of the dhps 540 mutation and where the additional mutation dhps 581 is 
present at > 10% (described as areas with super-SP resistances). Clinical trials are nearing 
completion to determine whether ISTP or IPTp with AL or DHA-PPQ may provide suitable 
alternative in these high resistance settings. A randomized controlled trial conducted in 
Ghana demonstrated that ISTp was not inferior to IPTp-SP in reducing the risk of LBW 
and third trimester anaemia (Tagbor et al., 2010). This was confirmed recently by data 
from a multicountry non-inferiority randomized controlled trial enrolling more than 
5,000 primi and second gravida (Tagbor et al, manuscript in preparation). Thus, for some 
location such as in northern Tanzania, switching to alternatives such as ISTp may be 
warranted even before definitive trial results are available, because clinical trials results 
take time, yet in the interim time pregnant women and their offspring are suffering.
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7.4 Ongoing and future research 
7.4.1 Burden of malaria in pregancy 
In Mali, a comprehensive diversity of malaria transmission entities and parasites species 
was first described in 1991 (Doumbo O., 1991). In community surveys conducted in 2010 
(PNLP-Mali, 2010) and 2012 (DHS, 2012-2013), the prevalence of parasitemia reported in 
children aged 6-59 months had shown a significant increase from 2010 to 2012 in some 
regions of the country indicating clearly that malaria is not declining in Mali, and is even 
increasing in parts of the country. This was contrary to a recent report on the global 
decline of malaria incidence, including in Africa (Kweka E.; Mazigo, 2013). Our evaluation 
(of which the last was conducted in 2010) of the burden of malaria during pregnancy 
carried out during a 5-year period in 9 different sites may not reflect the current situation 
because of increasing use of malaria control strategies, changes due to global warming or 
other ecological changes and increased human population activities. This may partially 
explain the case of Timbuktu, with unexpected high prevalence of placental malaria 
(chapter 2) and that of Kita with low prevalence. In addition, our study did not find any P. 
vivax as opposed to previous studies carried out in the region (Koita et al., 2012, Doumbo 
O., 1991, Bernabeu et al., 2012). Thus, an updated assessment of PAM data is required at 
national level, especially in northern Mali where malaria transmission is traditionally low 
or epidemic. Prospective burden surveys should aim to capture data throughout the 
year, ideally using sensitive diagnostic tests to detect malaria infection. Such a survey 
should include coverage estimates of interventions and assessment of molecular markers 
of SP resistance, for example by adding a malaria in pregnancy module to National 
Malaria Indicator Surveys or DHS surveys. 
7.4.2 Implementation of the updated WHO guidelines on IPTp-SP 
Despite one to two decades of implementation of IPTp-SP within national programmes in 
sub-Saharan African countries, the coverage of this proven intervention for protecting 
pregnant women is still low (van Eijk et al., 2013). Reasons have been extensively 
reported among which weak health systems, a lack of reasonably accurate monitoring 
data, and inadequate use of data for managing programmes at local level (Webster et al., 
2013b, Webster et al., 2013a, Hill and Kazembe, 2006, Hill et al., 2013). Thus, although 
much evidence exists on the efficacy of IPTp, there is little evidence on how best to 
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deploy it at programmatic conditions. Based on new findings from a meta-analysis 
(chapter 4 ), new WHO guidelines now recommend one IPTp-SP dose at each scheduled 
ANC visit from the second trimester (WHO, 2013). If no dedicated action is taken, this 
recommendation would face the same coverage issues as before.  
There is therefore an urgent need for research to be focused on how best to implement 
the updated WHO guidelines for IPT-SP in pregnant women, and especially their 
integration with focused antenatal care through which IPTp-SP is delivered. This requires 
a continued identification and quantification of barriers to IPTp-SP high coverage at 
district and facility levels through operational research and good monitoring methods as 
suggested earlier (Webster et al., 2013b). Moreover, additional training may be needed 
as well as revision of data collection tools and malaria in pregnancy indicators.  
7.4.3 Alternative to SP for IPTp 
Although results for western Africa look reassuring, a worrying lack of effectiveness on 
birth parameters has been observed in parts of eastern and southern Africa (Kalilani et 
al., 2011, Harrington et al., 2011). Presently, SP is the only antimalarial recommended for 
IPTp (WHO/AFRO, 2004). It has ideal properties for intermittent use; it can be given as a 
single stated dose as directly observed therapy in the clinics, it is cheap, widely available, 
has good reputation among health care workers and end users and is well tolerated and 
safe in the second and third trimesters of pregnancy. With all these qualities, it is a big 
challenge to replace this valuable drug for IPTp. Potential alternative drugs in the pipeline 
include 1) Mefloquine (effective but poor safety and tolerability profile (Briand et al., 
2009, Chico and Chandramohan, 2011b, Nosten et al., 2007)), 2) chloroquine-
azithromycine combination (good safety but weak tolerability profile of high-dose 
azithromycin), 3) dihydroartemisinin-piperaquine (good efficacy profile, but more data 
needed on its safety and tolerability profile in pregnancy (Davis et al., 2010)). 
Investigations of these drugs for IPTp are almost completed, most of them under the 
umbrella of the malaria in pregnancy consortium (http://www.mip-consortium.org/ P: 
https://portal.mip-consortium.org). In addition, under the sponsorship of the National 
Institute of Allergy and Infectious Diseases (NIAID), a randomized, controlled trial is being 
conducted in Malawi on chloroquine (CQ) as chemoprophylaxis versus IPTp (SP or CQ) to 
prevent malaria in pregnancy (NCT01443130, ClinicalTrials.gov). Even though this trial 
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may result in CQ being considered for IPTp,  the previous non-compliance with CQ 
prophylaxis (Denoeud et al., 2007) and pruritus induced by CQ (Onyeji and Ogunbona, 
2001) might be important programmatic barriers towards the reintroduction of CQ in 
malaria prevention during pregnancy.  
7.4.4 Intermittent screening and treatment strategy 
The concept of this strategy is to provide scheduled RDT-based screening as part of 
focused antenatal care (FANC) and treatment of those with positive results with an 
effective and long acting ACT during the second and third trimesters. Screening periods 
must be at least one month apart (4-8 weeks) with the aim of treating existing infection 
and providing post-treatment prophylaxis for up to six weeks (White, 2005). Recent 
randomized controlled trials conducted in Ghana (Tagbor et al., 2010) and other western 
African countries (http://www.mip-consortium.org/ P: https://portal.mip-
consortium.org) suggested the non –inferiority of this strategy to the standard IPTp-SP 
on birth parameters (Tagbor et al, unpublished). Although another advantage of this 
strategy is to reduce the exposure to unnecessary drug pressure in non-infected women, 
especially in areas with low malaria endemicity or under seasonal transmission, its 
success as a viable alternative to IPTp-SP relies also on the use of RDTs and their 
sensitivity to detect low-level, chronic placental infections. A combined HRP2 and pLDH 
based antigen, prequalified by WHO should be recommended (WHO-FIND, 2009), as it 
has the advantage to increase the test sensitivity to detect P. falciparum infections and 
other pan-species. Other important issues related to this strategy are: 1) the non-
adherence of health care providers, 2) lack of procurement and good storage of RDT kits, 
3) non-availability of adequate drug for treatments.  
In the absence of an alternative drugs to replace SP, this ISTp strategy can be a good 
alternative in areas with high SP resistance, especially in eastern and southern Africa, and 
also in areas with significant decline of malaria incidence such as Zanzibar (Bhattarai et 
al., 2007) and the Gambia (Ceesay et al., 2012, Ceesay et al., 2010). In the mid or long 
term, it can be an attractive strategy in other countries of Africa in the context of 
continuing global decline of malaria incidence when countries are moving towards pre-
elimination (van Eijk et al., 2013). However, whether this strategy is operationally 
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feasible and will be a cost effective alternative to IPTp-SP where SP resistance is high, or 
in areas where malaria is declining remains to be determined. 
Furthermore a better understanding of the clinical implications is required of low 
densities infections that are potentially missed by microscopy or RDTs during the 
screening for malaria in pregnant women (Fried et al., 2012). Research is also needed to 
improve diagnostic test options that have greater sensitivity (without affecting 
specificity) and can be used at point of care.  Nonetheless, because of the current lack of 
a suitable replacement drug to SP for IPTp, and based on the current evidence of the 
efficacy of ISTp despite the limited sensitivity of the existing RDTs, ISTp is currently the 
most attractive and promising strategy that could potentially replace IPTp-SP in areas of 
high SP resistance or low malaria transmission intensity. Further studies of its feasibility 
and analysis of the cost effectiveness of ISTp are therefore urgently needed. 
7.4.5 Monitoring of SP resistance 
In the presence of the alarming levels of high-grade SP resistance in parts of eastern and 
southern Africa and evidence for the decreased effectiveness of SP associated with an 
increased prevalence of DHPS A437G in West Africa, even in the absence of the 
additional DHPS K540E mutation (Figure 9. 2 & Figure 9. 3 in annex)  there is a clear need 
to continue monitoring of SP resistance and to assess its impact on birth parameters. This 
is especially important with the recent introduction of seasonal malaria 
chemoprevention with AQ-SP combination in the Sahel countries. In countries with low 
levels of the DHPS K540E mutation, DHPS A437G can be used as a good molecular marker 
of SP resistance in the population to correlate with clinical markers of IPTp-SP 
effectiveness on birth parameters. A simple standardized protocol is being developed by 
the malaria in pregnancy consortium in collaboration with WHO to direct the monitoring 
of IPTp-SP in Arica. 
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9. Annexes 
9.1 Meta-analysis of the risk of low birth weight with the receipt of IPTp-
SP in 11 observational studies in 5 countries of West Africa. 
The results gathered in chapter 6 were combined with those from similar studies conducted 
in 4 countries of West Africa. Using a meta-analysis approach, we looked at the prevalence 
ratio of LBW in women with at least two doses of SP versus those not receiving SP. This 
showed a pool relative risk reduction of 36% (95% CI, 22-48) in women taking 2 or more 
doses of SP (Figure 9.1). When plotting the estimates of the relative risk reduction on LBW 
against the population prevalence of DHPS A437G using meta-regression, a statistically 
significant linear trend was apparent (Figure 9. 2 and Figure 9. 3) and a greater impact of 
IPTp-SP was evident in areas with <50% DHPS A437G (RR, 0.50; 95% CI, 50-64) (I2 =0%, 8 
surveys, 3 countries) compared to areas with >50% DHPS A437G (RR, 0.87; 95% CI, 0.71-
1.07) (I2=0%, 3 surveys, 3 countries). Thus, in the presence of very low prevalence of DHPS 
K540E in West Africa, a high level of the DHPS 437 mutation is a good predictor of waning 
IPTp-SP effectiveness. This is potentially important observation that illustrates the potential 
value of regular molecular monitoring of SP resistance in West African countries along with 
clinical surveys that assess the association between IPTp-SP use and birth parameters. 
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Figure 9. 1: Meta-analysis of the risk of low birth weight associated with the receipt of IPTp-SP in 
11 observational studies in 5 countries of west Africa 
 
Notes: LBW, low birth weight; CI, confidence interval; D+L, Dersimonian-Laid methods for random 
effects models; M-H, Mantel-Haenszel methods for fixed effects models; Unp., unpublished studies. 
Data marker sizes indicate the weight applied to each study using random-effects meta-analysis. 
Diamonds represent summary effect of studies. P-values following the I2 statistics represent the Chi-
square test for heterogeneity. Subgroup difference was significant (Chi2 =12.21; P=0.02; l2=67.2%) 
HF* Health facilities 
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Figure 9. 2: Meta-regression of the relationship between the prevalence of  DHPS A437G and log 
risk ratio of LBW in 11 observational studies in 5 countries of west Africa 
 
Notes: LBW, low birth weight; DHPS, dihydropteroate synthase; Study specific estimates are 
depicted as circles proportional to their precision. The solid line indicates fitted values by random-
effects meta-regression.  P-value for linear trend: P=0.016 
Figure 9. 3:Meta-analysis of the risk of low birth weight associated with the receipt of  IPTp-SP by 
DHPS A437G strata in 11 observational studies in 5 countries of west Africa 
 
Notes:  DHPS, dihydropteroate synthase; LBW, low birth weight; CI, confidence interval; D+L, 
Dersimonian-Laid methods for random effects models; M-H, Mantel-Haenszel methods for fixed 
effects models; Unp., unpublished studies. Data marker sizes indicate the weight applied to each 
study using random-effects meta-analysis. Diamonds represent summary effect of studies. P-values 
following the I2 statistics represent the Chi-square test for heterogeneity. 
HF* Health facilities 
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9.2 Published papers of chapter 3, chapter 4, and chapter 5 
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sulphadoxine-pyrimethamine for intermittent
preventive treatment in Burkina-Faso and Mali:
42-day in vivo follow-up study
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Background: Intermittent Preventive Treatment in pregnancy (IPTp) with sulphadoxine-pyrimethamine (SP) is
widely used for the control of malaria in pregnancy in Africa. The emergence of resistance to SP is a concern
requiring monitoring the effectiveness of SP for IPTp.
Methods: This was an in-vivo efficacy study to determine the parasitological treatment response and the duration
of post-treatment prophylaxis among asymptomatic pregnant women receiving SP as part of IPTp in Mali and
Burkina-Faso. The primary outcome was the PCR-unadjusted % of patients with parasites recurrence by day 42
defined as a positive diagnostic test by malaria smear at any visit between days 4 and 42. Treatment failure was
based on the standard World Health Organization criteria. The therapeutic response was estimated using the
Kaplan-Meier curve.
Results: A total of 580 women were enrolled in Mali (N=268) and Burkina-Faso (N=312) and followed weekly for 42
days. Among these, 94.3% completed the follow-up. The PCR-unadjusted cumulative risk of recurrence by day 42
was 4.9% overall, and 3.2% and 6.5% in Mali and Burkina Faso respectively (Hazard Ratio [HR] =2.14, 95%, CI [0.93-4.90];
P=0.070), and higher among the primi– and secundigravida (6.4%) than multigravida (2.2%, HR=3.01 [1.04-8.69];
P=0.042). The PCR-adjusted failure risk was 1.1% overall (Mali 0.8%, Burkina-Faso 1.4%). The frequencies (95% CI) of the
dhfr double and triple mutant and dhps 437 and 540 alleles mutant genotype at enrolment were 24.2% (23.7-25.0),
4.7% (4.4-5.0), and 21.4% (20.8-22.0) and 0.37% (0.29-0.44) in Mali, and 7.1% (6.5-7.7), 44.9% (43.8-46.0) and 75.3%
(74.5-76.2) and 0% in Burkina-Faso, respectively. There were no dhfr 164L or dhps 581G mutations.
Conclusion: SP remains effective at clearing existing infections when provided as IPTp to asymptomatic pregnant
women in Mali and Burkina. Continued monitoring of IPTp-SP effectiveness, including of the impact on birth
parameters in this region is essential.
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http://www.malariajournal.com/content/13/1/41Background
In sub-Saharan Africa, malaria places 31 million pregnan-
cies at risk of maternal anaemia and intrauterine growth
retardation resulting in low birth weight (LBW) annually
[1-3]. In this region, the World Health Organization (WHO)
recommends Intermittent Preventive Treatment in preg-
nancy (IPTp) with at least two doses of sulphadoxine-
pyrimethamine (SP) for the control of malaria in pregnancy
[4]. The two-dose IPTp-SP regimen has been shown to be
very effective and is associated with an average reduction
in the risk of LBW of 29% [2]. More recent meta-analysis
has shown that this can be enhanced further by providing
three or more doses of SP at monthly intervals during
pregnancy [5].
However, the emergence of SP resistance is potentially
reducing the effectiveness of SP. In the early 2000s, SP
was abandoned as first line treatment for symptomatic
malaria in the general population in sub-Saharan Africa
in favour of more effective artemisinin-based combination
therapy (ACT). Because IPTp with SP continued to pro-
vide significant protection in areas with moderate to high
parasite resistance [2], SP continues to be recommended
by WHO for IPTp, and is currently the only anti-malarial
used for this indication [6]. The degree of SP resistance
correlates with the frequency of single nucleotide poly-
morphisms (SNPs) that encode amino acid substitutions
in the dihydrofolate reductase (dhfr) and dihydropteroate
synthetase (dhps) genes of Plasmodium falciparum. High
grade resistance is a particular concern in eastern and
southern Africa [7], where high frequencies of parasites
bearing haplotypes with three mutations in dhfr (encoding
the N51I, C59R, and S108N) and two in dhps (encoding
the A437G and K540E substitutions) exist, especially if the
additional dhfr164L or dhps581G mutations occur [8,9].
The latter has recently been associated with poor birth
outcomes in IPTp-SP recipients [10], although this as-
sociation has not yet been confirmed in other studies
in eastern and southern Africa [11-13].
In contrast, the parasite populations in western Africa
seem to be mostly sensitive to SP [7,14-16], and IPTp-SP
has proven to be highly effective and efficacious in clinical
trials and observational studies [5,15]. However, spread of
SP resistance from eastern and southern Africa, or the de
novo development of high-level SP resistance may occur
and monitoring of the effectiveness of SP when employed
as IPTp is essential.
Despite this need, there are no internationally stan-
dardized methods to evaluate the in vivo effectiveness
of IPTp-SP. Furthermore, the relationship between the
level of SP resistance as measured by molecular markers
and impact of IPTp-SP on birth parameters, or the
treatment response in asymptomatic women receiving
SP for IPTp is not known. Hitherto, monitoring SP re-
sistance was predominantly based on in vivo treatmentresponses among symptomatic children with acute malaria.
However, extrapolation from children to asymptomatic
pregnant women is not appropriate as protective immunity
against P. falciparum malaria is acquired progressively with
cumulative exposure and age. As a result pregnant women
in endemic areas remain typically asymptomatic when
infected and have lower parasites densities than sick
children and as a results have better treatment responses
to anti-malarials, including SP [17,18]. A single arm 42
days in vivo efficacy study of SP was conducted to deter-
mine the parasitological treatment response to SP and the
duration of post-treatment prophylaxis among asymptom-
atic parasitaemic women receiving SP for IPTp in, Mali
and Burkina Faso. The prevalence of molecular markers
for SP resistance was also assessed to explore the relation-
ship between the level of resistance and the treatment
responses.
Methods
Study sites and study period
In Mali, the study was conducted from July 2009 to
March 2010 in 2 district health centres located in the
towns of Kita in the Kayes region in western Mali and in
San in the Segou region situated approximately 500 kilo-
metres east of Kita (Figure 1). Malaria transmission in
the two sites is typical for most of the Sahel region with
highly seasonal transmission restricted to a single period
of three to five months during and shortly after the rainy
season, with peak transmission in October. The degree
of SP resistance is low in these areas and the quintuple
dhfr/dhps haplotype has not been found yet [15], al-
though the dhps581G mutation has been described in
isolation of other mutations in other settings [19,20]. No
previous in-vivo studies among pregnant women were
conducted in Mali.
In Burkina Faso, the study was conducted from January
2010 to December 2011 in five recruitment centres in
Ziniaré town, Oubritenga Province, located 400 km South-
East of the town of San (one of the study sites in Mali).
Malaria transmission is seasonal peaking in September-
October. In 2003, the polymerase chain reaction (PCR)-
adjusted parasitological failure rate by day-28 was 13%
among symptomatic primi- and secundigravida with acute
falciparum malaria in Ouagadougou, located 50 kilometers
from the study site [16].
Participants and procedures
In both countries, pregnant women of all parities with a
gestational age between 16–30 weeks attending for ante-
natal care for their first dose of IPT-SP were included.
Women were screened for malaria infection using HRP2
and pLDH-based combo Rapid Diagnostic Tests (RDTs,
CareStart™Malaria HRP-2/pLDH[Pf/pan] Combo Test)
[21,22]. Women with a positive RDT were then screened
Figure 1 Study sites in Mali (Kita and San) and Burkina Faso (Ziniaré).
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enrolment if they had a positive blood smear, were asymp-
tomatic, were willing to participate in the six-week follow-
up and provided written individual informed consent.
Women were excluded if they had a history of hypersensi-
tivity to SP or its components, a history of prior use of
IPTp-SP during this pregnancy, or a history of receipt of
other anti-malarials or antibiotics with anti-malarial activ-
ity in the previous month.
On enrolment, clinical, obstetric and demographic data
were obtained and information on bed net type and use
recorded. A finger-prick blood sample was taken for
malaria smears, haemoglobin assessment, and dried
blood spots (DBSs) for parasite DNA.
Three tablets of SP containing a total dose of 1,500 mg
sulphadoxine and 75 mg of pyrimethamine were admin-
istered as a single dose on day 0 by the study staff. If
vomiting occurred within 30 minutes after administra-
tion, the full dose was re-administered. Women were
scheduled to be seen again weekly from day 7 onwards
for 42 days for a brief clinical exam, assessment of the
axillary temperature and collection of blood by finger
prick for malaria smears, RDT, and DBSs for PCR. Par-
ticipants were asked to return to the study clinic any
time they felt ill in between the scheduled visits.
Women with positive smear or severe malaria at anytime on or after day 4 were treated according to national
guidelines.
In Mali, the study drug used was manufactured by
Kinapharma limited Ltd, Ghana and in Burkina Faso
this was also from Kinapharma limited Ltd, Ghana and
Medreich limited, India. A sample of 50 tablets from each
batch was assessed for quality using high-performance
liquid chromatography (HPLC) conducted in Atlanta,
GA, USA by the US Centers for Disease Control and
Prevention (CDC) to determine the amount of the ac-
tive ingredient and the dissolution profile. Both brands
passed the dissolution and content analyses criteria set
by the United States Pharmacopeia (USP).Laboratory methods
Haemoglobin concentrations were measured using HemoCue®
(301 System) on days 0, 14, 28 and 42, and on the day of
parasite recurrence. Giemsa-stained blood smears were
assessed in duplicate and if a discrepancy was found
(positive vs negative) the smear was read by a third expert
microscopist. Asexual parasites were counted against 300
leukocytes and densities expressed per mm3 of blood
assuming a leucocyte count of 7,500/mm3. Smears were
declared negative if no parasites were detected in 100
high-power fields.
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Gillings School of Global Public Health, University of
North Carolina, Chapel Hill, NC, USA using genomic
DNA (gDNA) extracted from dried blood spots (DBSs)
stored on Whatman 3 MM filter papers to differentiate
between recrudescence and new infection in follow-up
specimens with parasite recurrence. A standard method
was employed to genotype parasites using polymor-
phisms of the merozoite surface protein-1 (msp-1), mer-
ozoite surface protein-2 (msp-2), and glutamate rich
protein (glurp) genes [23]. The prevalence of genomic
markers of parasite SP resistance, genomic DNA from
all parasitaemic women was pooled by study site (2 in
Mali and 1 in Burkina Faso). Fragments of the dhfr and
dhps genes containing the SNPs of interest were PCR-
amplified from the pooled gDNA from each site to pro-
duce a mixture of gene fragments [24], and these PCR
products were sequenced on a Roche GS Junior next-
generation sequencing system.Figure 2 Study flow chart.Study endpoints classification
The primary outcome was the PCR-unadjusted % of pa-
tients with parasites recurrence by day 42, defined as a
positive diagnostic test (by microscopy) for malaria at any
visit between days 4 and 42. To define treatment failure,
the standard WHO criteria [25] were used.Statistical analysis
Data were analysed using STATA v12 and SPSS version
20. The treatment responses are summarized by weeks
of follow-up. The therapeutic response was estimated
using the Kaplan-Meier product limit formula [26]. In
the PCR-unadjusted analysis, recurrences were treated
as treatment failures and all other events (e.g. with-
drawal or protocol deviations) resulted in censoring at
the time of that event, or at the time of their last
follow-up visit in case of loss to follow-up. A similar strat-
egy was used for the PCR-adjusted analysis except that
Table 1 Baseline characteristics of women enrolled in SP
in vivo efficacy study, Burkina-Faso and Mali
Burkina-Faso Mali All
N=312 N =268 N=580
Age, years,
Mean (SD) 23.6 (5.4) 21.1 (5.1) 22.5 (5.4)
Residing in rural area, n (%) 81 (30.2) 146 (45.2) 222 (38.3)
Knows the date of LMP, n (%) 44 (16.4) 61 (19.6) 105 (18.1)
Pregnancy number
Median (range) 2 (1–8) 2 (1–9) 2 (1–9)
First or second pregnancy, n (%) 204 (65.4) 185 (69.0) 389 (67.1)
Use of a bed net last nighta
Any net, n (%) 187 (60.1) 207 (77.2) 394 (68.1)
ITN, n (%) 171 (55.0) 180 (67.2) 351 (60.6)
Use medicine in first trimester
Any medicine, n (%) 6 (1.9) 25 (9.3) 31(5.3)
Antimalarial, n (%) 2 (0.6) 15 (5.6) 17 (2.9)
Fundal height, cm
Mean (SD) 21.5 (2.9) 21.8 (3.2) 21.7 (3.1)
Gestational age, weeks
Mean (SD) 25.3 (3.1) 25.4 (3.2) 25.3 (3.1)
Maternal height, cm
Mean (SD) 162.7 (6.2) 162.2 (6.3) 162.4 (6.2)
Maternal weight, kgs
Mean (SD) 57.8 (7.5) 56.4 (8.5) 57.2 (8.0)
Haemoglobin, g/dLb
Mean (SD) 10.1 (1.4) 9.6 (1.6) 9.9 (1.5)
Anaemia (Hb <11 /dL), n (%) 225 (72.4) 198 (80.5) 423 (75.9)
Moderate-Severe anaemia
(Hb <8g/dL),
22 (7.1) 40 (16.3) 62 (11.1)
n (%)
Peripheral parasitaemia 623 716 664
GMPD/μl (95% CI) (537–723) (598–859) (592–746)
Notes: Data are n0. (%), unless otherwise indicated.
N, sample size; n, number of events; SD, Standard deviation; LMP, Last
Menstrual Period; ITN, Insecticide Treated Net; cm, centimeters; kgs, kilograms;
g/dL, Gram per deci-Litre; Hb, Haemoglobin; GMPD/μl, Geometric Mean
Parasite Density per microlitre.
aBed net use was not evaluated in 1 subject from Burkina-Faso.
bHaemoglobin was not measured for 1 subject in Burkina-Faso and 22 subjects
in Mali.
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were censored at the time of parasite reappearance [26].
Ethical considerations
The protocol was approved by the Faculty of Medicine,
Pharmacy and Dentistry, University of Bamako, Mali, In-
stitutional Ethical Review Committee, the National Ethical
Review Committee and Ministry of Health, Burkina-Faso,
the University of North Carolina, USA, and the Liverpool
School of Tropical Medicine, UK.
Results
Treatment responses
Overall 580 of 584 women who fulfilled all enrollment cri-
teria were enrolled (99.3%, Figure 2 and Table 1), and 572
of the 580 contributed to the survival analysis. Eight of the
33 women lost to follow-up were not seen after day 0; 3
from Mali and 5 from Burkina-Faso. The remaining 25
were censored on the day they were last seen.
PCR-unadjusted efficacy: Based on microscopy, overall
27 of the 572 women had a recurrence of parasitaemia
by the end of follow-up (Mali 8; Burkina Faso 19). The
cumulative recurrence risks by day 42 estimated by sur-
vival analysis were 4.9% overall, and 3.2% and 6.5% in
Mali and Burkina Faso respectively (Hazard Ratio [HR]
Burkina vs Mali=2.14, 95% CI 0.93-4.90; P=0.070, Table 2
and Figure 3). The recurrence risk was higher among
primi- and secundigravidae (6.4%) than multi-gravidae
(2.2%), HR=3.01 (1.04-8.69; P=0.042) (Figure 4).
PCR-adjusted efficacy: From 26 of the 27 recurrences,
DNA could be extracted and 24 were genotyped success-
fully. This suggested that only 6 of the 24 were recrudes-
cences. The PCR-adjusted cumulative failure rate obtained
by survival analysis was 1.1% overall, and 0.8% in Mali and
1.4% in Burkina-Faso (Figure 3). Overall, median (range)
time to PCR-adjusted failure and to reinfection was 21 (7–35)
and 35 (7–43) days, respectively.
Haematological response: There was a significant in-
crease in the mean haemoglobin concentrations compared
to enrolment at all-time points measured in both coun-
tries and both among primi-, secundi- and multigravida
(Figure 5 and Table 3).
Prevalence of molecular markers for SP resistance at
booking
No dhfr 164L or dhps581G mutations were found in any
of the three sites; the dhps 540E mutation was found in
one site of the two sites Mali, but at a very low prevalence
(Figure 6).
Discussion
SP when given as IPTp to asymptomatic parasitaemic
pregnant women was associated with a high cure rate
and marked increases in haemoglobin concentrations byday 42 in the 3 study sites in Mali and Burkina-Faso.
Overall, only 4.9% of women had a recurrence of parasites
by day 42, and genotyping suggested that the vast majority
of these were reinfections. Overall only 1.1% of treatments
resulted in true treatment failures (recrudescence) and all
of these were asymptomatic. The study shows that SP re-
mains very effective at clearing existing infections when
used as IPTp for malaria prevention in Mali and Burkina-
Faso. This study also showed the potential value of using
in-vivo follow-up to assess the parasitological cure rates
Table 2 Parasitological efficacy of SP among women enrolled in Burkina-Faso and Mali
Characteristics Burkina-Faso Mali All
N=312 N =268 N =580
PCR Days Non- adjusted Adjusted Non- adjusted Adjusted Non- adjusted Adjusted
Day 7:
Number at risk 307 307 265 265 572 572
Failures, n (%)
ETF 0 0 0 0 0 0
LCF 0 0 0 0 0 0
LPF 2 (0.5) 1 (0.3) 1 (0.4) 1 (0.4) 3 (0.5) 2 (0.3)
ACPR n (%) 305 (99.5) 306 (99.7 264 (99.6) 264 (99.6) 569 (99.5) 570 (99.7)
Day 14:
Number at risk 306 306 260 260 566 566
Failures n (%)
ETF 0 0 0 0 0 0
LCF 0 0 0 0 0 0
LPF 3 (1.0) 2 (0.7) 1 (0.4) 1 (0.4) 4 (0.7) 3 (0.5)
ACPR n (%) 303 (99.0) 304 (99.3 259 (99.6) 259 (99.6 562 (99.3) 563 (99.5)
Day 21:
Number at risk 300 300 259 259 559 559
Failures n (%)
ETF 0 0 0 0 0 0
LCF 0 0 0 0 0 0
LPF 3 (1.0) 2 (0.7) 1 (0.4) 1 (0.4) 4 (0.7) 3 (0.5)
ACPR n (%) 297 (99.0) 298 (99.3) 258 (99.6) 258 (99.6) 542 (99.5) 556 (99.5)
Day 28:
Number at risk 297 297 259 259 556 556
Failures n (%)
ETF 0 0 0 0 0 0
LCF 0 0 0 0 0 0
LPF 7 (2.4) 3 (1.0) 2 (0.8) 2 (0.8) 9 (1.6) 5 (0.9)
ACPR n (%) 290 (97.6) 294 (99.0) 257 (99.2) 257 (99.2) 547 (98.4) 551 (99.1)
Day 35:
Number at risk 295 294a 253 254 548 547a
Failures n (%)
ETF 0 0 0 0 0 0
LCF 0 0 0 0 0
LPF 14 (4.8) 4 (1.4) 2 (0.8) 2 (0.8) 16 (2.9) 6 (1.1)
ACPR n (%) 281 (95.2) 290 (98.6) 251 (99.2) 252 (99.2) 532 (97.1) 541 (98.9)
Day 42:
Number at risk 293 292a 253 251a,b 546 544c
Failures n (%)
ETF 0 0 0 0 0 0
LCF 0 0 0 0 0 0
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Table 2 Parasitological efficacy of SP among women enrolled in Burkina-Faso and Mali (Continued)
LPF 19 (6.5) 4 (1.4) 8 (3.2) 2 (0.8) 27 (4.9) 6 (1.1)
ACPR n (%) 274 (93.5) 288 (98.6) 245 (96.8) 249 (99.2) 519 (95.1) 538 (98.9)
Median (range) time in days 35 (7–43)d 21 (7–35)e 42 (7–42)d 18 (7–29)e 35 (7–43)d 21 (7–35)e
Notes: PCR, Polymerase Chain Reaction; ETF, Early Treatment Failure; LCF, Late Treatment Failure; LPF, Late parasitological Failure; ACPR, Adequate Clinical and
Parasitological Response.
aOne PCR inconclusive.
bPCR analysis not conducted for 1 woman with recurrent parasitaemia in Mali.
cPCR inconclusive (1 from Mali, 1 from Burkina) and no PCR analysis available (1 from Mali). These three cases were censored in the survival analysis.
dMedian (range) time to reinfection.
eMedian (range) time to PCR-adjusted failure.
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are due for their first dose of SP for IPTp.
The pooled molecular assays for the surveillance of SP
resistance showed that almost 50% of the parasite popula-
tion in Burkina Faso, but only 9% in San and <1% in Kita,Figure 3 Probability of parasitological failure by microscopy in Burkin
adjusted risk of parasitological failure in Mali and Burkina-Faso. Treatment f
cumulative risk of recurrence was determined using Kaplan-Meier survival a
and panel B represent survival analysis for crude and PCR adjusted analysiscarried the dhfr triple mutations. The pooled deep sequen-
cing of P. falciparum parasitaemia can provide estimates
of the mutant allele frequencies, but does not provide esti-
mates of the quadruple and quintuple dhfr/dhps haplo-
types. Nevertheless, the dhps 540E mutation, which is aa-Faso and Mali. Notes: This graph shows the crude and PCR
ailure was defined according to the standard WHO criteria and the
nalysis. Blue lines represent Mali and red lines Burkina-Faso. Panel A
, respectively.
Figure 4 Probability of parasitological failure by microscopy by gravida group. Notes: (Gravidae 1&2, primi-secundigravida; Gravidae>=3,
multigravida): PCR unadjusted (Panel A) and PCR adjusted (Panel B). This graph shows the crude and PCR adjusted risk of parasitological failure
in both primi-secundigravida and multigravida using Kaplan-Meier survival analysis. Blue lines represents multigravida (gravidae>=3) and the red
lines represent primi-secundigravida (gravidae 1&2), respectively.
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resistance to SP, was present in only one of the two sites
of Mali and at very low frequency (0.73%, 95% CI 0.58-
0.87). The mutation at dhfr codon 164L and dhps codon
581G conferring very high-level resistance to SP were
absent. In addition, there were several novel mutations
in dhps, which were limited to a very low frequency.
Their clinical and biological significance is unknown,
but their quantification underscores the ability of the
pooled genotyping approach to uncover low-level sub-
populations of parasites.
The 1.4% failure rate in Burkina Faso among asymp-
tomatic women in this study is in contrast to the 13%
PCR-adjusted failure rate by day-28 observed in the previ-
ous in-vivo study among symptomatic pregnant women
conducted in 2003 in an area located ≈32 miles south
from the current site [16]. The average parasite densitiesin the previous study were 10 fold higher than in the
current study, illustrating the differences in treatment
responses when SP is used as IPTp in asymptomatic
women with predominantly low-grade parasitaemia vs.
acutely ill women requiring case-management drugs.
This may in part explain the earlier findings from ran-
domized controlled trials that IPTp-SP remained sur-
prisingly effective in areas with moderate to high levels
of SP resistance [2,5].
The study provides an important contribution to the
understanding of the predictive value of the frequency of
population estimates of the different dhfr and dhps mu-
tations on the efficacy of SP in clearing malaria infection
among asymptomatic pregnant women, especially when
our results are compared against day 42 failure rates in
areas with higher resistance. For example, the dhfr triple
mutation (Ile51+Arg59+Asn108) was present in almost
Figure 5 Increase in haemoglobin concentrations by country in all gravida. Notes: (top panel) and by gravidae group (bottom panel).
Analysis was done with repeated measures Generalized Estimating Equation (GEE), adjusted for the baseline hemoglobin levels on Day-0. Black
squares or diamonds represent the point estimates and vertical lines the corresponding 95% confidence intervals.
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1.4% of the treatments recrudesced by day 42. The dhfr
triple mutation is known to confer intense pyrimethamine
resistance in vitro [27] and is associated with an approxi-
mate 1,000-fold reduction in pyrimethamine susceptibility
[28] and with an increased risk of SP treatment failure in
children with acute malaria [29-31]. These combined data
suggests that parasite densities and immunity contribute
importantly to parasite clearance, which in turn influences
the association of treatment outcome with dhfr and dhps
alleles.
It is likely that the results of this study are representative
for large parts of West and Central Africa that have a
similar low geographic prevalence of the dhfr/dhps quad-
ruple or quintuple mutations reflecting low and mid-levelresistance to SP [7]. A key question is whether this situ-
ation can be sustained or whether further development of
SP drug resistance is inevitable in this region. Mutations
arise under antifolate pressure in a stepwise fashion, with
successive mutations conferring higher levels of resistance
[32]. Previous studies from Ghana showed a rapid increase
in the prevalence of the triple-mutant dhfr alleles among
falciparum isolated from pregnant women in an area
where pyrimethamine prophylaxis (as mono-therapy) was
used 6 to 8 years previously for the prevention of malaria
[33]. Some fitness-reducing mutations, such as the dhfr
I164L can only be sustained under conditions of sustained
drug pressure. The switch from SP as first-line treatment
for symptomatic malaria in the general population to an
ACT will have hada marked impact on reducing SP drug
Table 3 Haemoglobin concentration and anaemia among women enrolled in Burkina-Faso and Mali
Characteristics Burkina-Faso Mali All
Day 0
N 311 246 557
Mean haemoglobin (SD), g/dl 10.1 (1.4) 9.6 (1.6) 9.9 (1.5)
Anaemia (<11 g/dl), n (%) 225 (72.4) 198 (80.5) 423 (75.9)
Day 14
N 301 237 538
Mean haemoglobin (SD), g/dl 10.2 (1.3) 10.1 (1.4) 10.2 (1.3)
Anaemia (<11 g/dl), n (%) 208 (69.1) 177 (74.7) 385 (71.6)
Mean difference, 95% CIa 0.13 (0.004, 0.26) 0.44 (0.28, 0.59) 0.26 (0.16, 0.36)
Risk ratio, 95% CIb 0.96 (0.86, 1.06) 0.93 (0.84, 1.02) 0.94 (0.88, 1.01)
Day 28
N 290 244 534
Mean haemoglobin (SD), g/dl 10.7 (1.2) 10.6 (1.2) 10.6 (1.2)
Anaemia (<11 g/dl), n (%) 171 (59.0) 153 (62.7) 325 (60.7)
Mean difference, 95% CIa 0.60 (0.46,0.74) 0.87 (0.69, 1.06) 0.72 (0.61, 0.83)
Risk ratio, 95% CIb 0.82 (0.72, 0.92) 0.78 (0.70, 0.87) 0.80 (0.74, 0.87
Day 42
N 265 249 514
Mean haemoglobin (SD), g/dl 11.0 (1.2) 10.9 (1.3) 10.9 (1.3)
Anaemia (<11g/dl), n (%) 127 (47.9) 120 (48.2) 247 (48.1)
Mean difference, 95% CIa 0.87 (0.65, 1.09) 1.30 (1.11, 1.49) 1.06 (0.93, 1.18)
Risk ratio, 95% CIb 0.66 (0.57, 0.77) 0.60 (0.52, 0.69) 0.63 (0.57, 0.70)
Notes:
N, sample size; n, number of events; SD, standard deviation; g/dl, gram per decilitre; CI, confidence interval.
aMean difference and 95% confidence interval for each time that haemoglobin was measured using day 0 as reference category.
bRisk ratio and 95% confidence interval for each time that haemoglobin was measured using day 0 as reference category, adjusted for gravida and site (all), and
for gravida (in each country).
Coulibaly et al. Malaria Journal 2014, 13:41 Page 10 of 13
http://www.malariajournal.com/content/13/1/41pressure in the population [34]. However, the effect of
continued use of cotrimoxazole in the treatment of diar-
rheal and respiratory infectious diseases in children should
also be considered, although this drug did not appear to
select for SP-resistance parasites [19]. Modelling of the
impact of the introduction of IPTi in infants suggest that
use of SP in small target populations such as infants or
pregnant women may not sustain sufficient drug pressure
to impact on the spread of drug resistance. This was also
suggested in field studies in Mali [35]. However, many
West African countries including Mali and Burkina are
seeking to implement Seasonal Malaria Chemoprevention
(SMC) [36] in children which would provide presumptive
treatment over the course of the transmission season to
a much larger fraction of the population. Although, the
combination of amodiaquine (AQ) and SP is one of the
main candidate anti-malarials for SMC, it is unclear if
the introduction of this strategy will indeed increase SP
drug pressure. The effect of SMC on drug pressure may
be minimal if implemented on a large enough scale to
impact on malaria transmission and the total parasitebiomass in the SMC population, especially if an ACT is
used as case-management for clinical episodes caused
by any SP resistant parasites that may have escaped the
drug action of SMC. It will be clearly important to
monitor the prevalence of molecular markers of parasite
resistance to SP, especially in areas where SP is used for
both IPTp and SMC.
This investigation found a high prevalence of anaemia
and showed that SP treatment was associated with a
marked increase in mean haemoglobin levels by day 42.
The fact that the impact was most pronounced in the
primi,- and secundigravidae, the group most susceptible
to adverse effect of malaria, may indicate that even
these asymptomatic infections are an important cause
of maternal anaemia in this subgroup. These findings
are consistent with previous findings that showed IPTp
has a marked beneficial impact on moderate-to-severe
anaemia in Mali [15,37].
The study was limited by the lack of genotyping of para-
sites from individual women for molecular markers of SP
resistance, and the genomic DNA from pooled sequencing
Figure 6 Prevalence of SP resistance molecular makers in Burkina-Faso and Mali among parasitaemic women at their antenatal
booking visit (pre-SP). Notes: dhfr /dhps alleles (Top panel) and dhfr haplotypes (Bottom panel). Mutant allele frequencies are represented in the
top panel graph by horizontal bars. Lines depict the 95% confidence intervals. The presence of “0” represents the absence of point mutations for
a designed codon. The bottom panel represents the frequency of dhfr haplotypes (N51I, C59R, and S108N) per country.
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tween treatment efficacy or the haematological response
in individual women and SP resistance molecular markers.Conclusion
This is among the first studies to examine the 42-day
in vivo response of IPTp-SP in asymptomatic women in
areas with low level of SP resistance in West Africa.
Despite growing concerns about the impact of SP resist-
ance in east and southern Africa, this study shows that
SP remains effective at clearing existing infections and
improving haemoglobin concentration when provided as
IPTp to asymptomatic pregnant women in Mali and
Burkina-Faso. SP has many attributes that makes it anexcellent candidate for IPTp, and it is thus likely that it
could remain the drug of choice for IPTp in this region
for the foreseeable future. However continued monitor-
ing of SP resistance over the next years in this region
coupled with monitoring of IPTp-SP effectiveness on
birth parameters is essential.
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